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Summary 
The growing age and multimorbidity of today’s society are driving factors for polypharmacy. 
Polypharmacy is commonly defined as the concurrent use of over five prescribed medications. The 
prevalence of patients with polypharmacy rises in parallel to the demographic development and occurs 
in around 20% of the primary and secondary care population in Switzerland. Whereas in secondary 
care medications are delivered by health-care professionals, the correct and safe medication 
administration relies on the patient’s capabilities in primary care. The patient’s capabilities often do 
not meet the demands of a complex therapy regimen, and especially within the population of older 
patients with polypharmacy, impaired medication self-management leads to medication errors, non-
adherence, and adverse health outcomes. 
Adherence is defined as ‘the extent to which a person’s behavior – taking medication, following a diet, 
and/or executing lifestyle changes, corresponds with agreed recommendations from a health care 
provider’. Typical adherence rates to oral medication range from 50-76%. Two types of non-adherent 
behavior are distinguished: intentional non-adherence is the patient’s active decision to alter the 
treatment plan without feedback to the prescriber, and unintentional non-adherence is the inability 
of the patient to follow the prescribed treatment plan. Non-adherence has been associated with 
various adverse health outcomes such as medication resistance, adverse drug events, and impaired 
quality of life, leading to increased morbidity and mortality. The overall productivity loss, increased 
healthcare utilization, and increased medication waste result in a huge economic burden for 
healthcare systems all over the world. Globally, estimations of health related expenditures that could 
be avoided by improved adherence range from U$172 billion to U$371 billion. This problem also affects 
European countries including Switzerland. Effective adherence-enhancing interventions were 
suggested to have a far greater impact on the health of the population than any improvement in 
specific medical treatment and the costs generated through increased medication use and adherence-
enhancing intervention programs are suggested to outweigh the expenses. Manifold interventions 
have been investigated to enhance adherence, though the evidence remains scarce and the effect on 
adherence and economic, clinical and humanistic outcomes moderate. Persistent criticism concerns 
the poor methodological quality, the large heterogeneity of the results, the missing of long-term 
outcomes, the small size of the study populations and the short study durations of the studies 
investigating adherence-enhancing interventions. Most promising interventions contained behavioral 
and repetitive elements and were usually complex. However, complex interventions are doubted to 
be implementable in daily clinical practice. 
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Dose-dispensing aids are plastic boxes containing a number of compartments filled with solid, oral 
medication for specific dosing times, which have been widely distributed to primary care patients to 
support medication self-management, i.e., the independent correct and safe administration of 
medication. They can be easily implemented in daily practice and their use is simple and cheap. Various 
authors have suggested dose-dispensing aids to enhance adherence in unintentionally non-adherent 
patients with polypharmacy by optimizing medication self-management. Previous reviews attributed 
a moderate effect of dose-dispensing aids in improving adherence and clinical outcomes, but declared 
the evidence insufficient to state firm conclusions. Multidrug punch cards constitute a special kind of 
dose-dispensing aids consisting of disposable frame cards with plastic compartments, sealed with a 
foil backing and typically providing 28 compartments for all oral solid medications of a patient 
according to a prescribed dosing regimen. In Switzerland, community pharmacies fill and distribute 
multidrug punch cards with the support of a specific software. Dose-dispensing service (i.e., the 
repackaging of solid oral medication by a health-care provider) is reimbursed by the health insurances 
with CHF 21.60 per week, if the patient has a prescription for over three different medications per 
week and for a dose-dispensing aid. 
Adherence measures encompass subjective methods, such as patient self-report, and objective 
methods, such as pill count and electronic measurement. Measurement of adherence to polypharmacy 
has long been difficult due to several limitations. For example, the most commonly used electronic 
adherence measurement method, the Medication Event Monitoring System (MEMS®), can only 
package and monitor one single medication. With the availability of POlypharmacy Electronic 
Monitoring System (POEMS), the situation changed: POEMS is an adhesive polymer film with printed 
electric circuitries and a RFID chip collecting real time data, which can be flexibly adjusted to fit the 
back of a multidrug punch card. Affixed like this, POEMS records date, time and location of the 
medication removal of a whole therapy regimen and thus is able to electronically monitor adherence 
to polypharmacy. 
The goal of this thesis was to investigate the effect of the multidrug punch card use on adherence and 
patient-relevant outcomes in primary care. We approached this goal through the mapping of the 
existing evidence on dose-dispensing aids, exploring the status quo of community pharmacy practice 
and multidrug punch card use by primary care patients, and by developing a randomized controlled 
trial testing the intervention of electronic multidrug punch card use and feedback on electronic dosing 
histories. 
PROJECT A1 was designated to outline the evidence of dose-dispensing aids in adherence-enhancing 
interventions and to identify research gaps. For this purpose, we chose the methodology of evidence 
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mapping, including all prospective controlled trials with an intervention using dose-dispensing aids for 
patients independently administering medication, and reporting adherence or economic, clinical, or 
humanistic outcomes. Ten randomized controlled trials, nineteen controlled clinical trials, and one 
cohort study were included in the analysis. Overall, dose-dispensing aids had a positive but moderate 
effect, significantly improving adherence in 17 (57%) and clinical outcomes in 10 (33%) studies. The 
methodological quality was strong in five studies and two studies provided complete information of 
intervention elements, which limited the evidence and the replicability in clinical practice. Evidence 
gaps concerned economic and humanistic outcomes, safety issues, long-term, disease-unspecific, and 
generalizable clinical outcomes, and clinical effects on multimorbid populations with polypharmacy. 
These results provided a rationale for our research. 
In the next step of the thesis, PROJECT B1, we explored the daily practice of community pharmacies in 
the nature and extent of adherence counseling. One master student in Pharmacy observed patient 
contacts at 20 community pharmacies and manually recorded counseling on a checklist. At the end of 
the observation, pharmacists were interviewed on triggers, topics, and barriers of adherence 
counseling. During the 1’476 observed patient contacts including the dispensing of more than one 
medications, counseling was provided to 799 (54.1%) patients, predominantly about administration, 
dose, and effect. Adherence counseling was provided to only 99 (6.7%) patients and mainly by 
pharmacists. However, all except one of 33 pharmacists stated to approach patients actively for 
adherence counseling. This discrepancy could be explained by the discordant definition of adherence 
counseling: while pharmacists mostly named implicit topics (e.g., administration, dose), our definition 
was more explicit (e.g. direct addressing of adherence, providing adherence support). The pharmacists 
stated structural (e.g., lack of education, rejection by patients) and procedural (e.g., time constraints, 
a lack of privacy area) barriers to adherence counseling indicating an implementation problem of 
research into daily practice. 
The following evaluation of the status quo concerned the multidrug punch card production and 
distribution in the community pharmacy and their use by primary care patients. In PROJECT B2, we 
mailed a survey to all 51 community pharmacies providing multidrug punch cards of the most common 
brand in Switzerland. At a response rate of 76%, pharmacies reported to provide 1’869 patients with 
multidrug punch cards, predominantly nursing home patients (1’402, 75%) and in 14% of the cases 
primary care patients. Thirty (75%) pharmacies recommended multidrug punch cards actively to 
primary care patients with a success rate of 31%. Triggers for recommendation encompassed 
polypharmacy, suspected non-adherence, increased age, inability of medication self-management, 
and hospital discharge. The dose-dispensing service fitted well in the community pharmacies’ daily 
practice, being cost-covering and acquiring additional value. Pharmacists estimated an adherence rate 
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of 93% for their primary care patients using the multidrug punch card, and assumed them to be 
satisfied with the device. 
We confirmed this view by a mixed methods study with primary care patients using multidrug punch 
cards in daily life in PROJECT B3. We combined quantitative and qualitative interviews in an explanatory 
way to investigate the acceptability, ease of use, preferences, and impact on adherence. Twenty-one 
community pharmacies in the region of north-western Switzerland recruited primary care patients 
using multidrug punch cards from a total of 149 patients, of which 22 and 11 patients participated in 
the quantitative (per telephone) and in the qualitative interviews (face-to-face), respectively. We were 
able to describe the characteristics of an independent primary care patient accepting to use multidrug 
punch cards as age over 70 years; low education grade; being retired; living alone; preference for 
tidiness, rituals, and daily routines; inability or reluctance to leave home; and motivation to lead a 
healthy life. All 33 patients considered adherence as very important and reported a median score of 
10 on a visual analog scale ranging from 0 (= no intake) to 10 (= perfect adherence). Emerging key 
variables for adherent behavior were personal experience (i.e. either negative clinical experience in 
case of non-adherence or clinical benefits in case of adherence) and trust in health-care professionals. 
The absence of package inserts and handling difficulties, reported as risk of dose-dispensing aid use 
for impaired medication safety, were not perceived as problems by the patients in our study. Rather, 
our results support the assumption that unintentionally non-adherent patients might substantially 
benefit from the packaging of their polypharmacy into multidrug punch cards. 
Finally, including the experiences and results of the preceding projects, we developed a randomized 
controlled trial to investigate the effectiveness of electronic multidrug punch cards in connection with 
feedback on electronic dosing histories to improve adherence and patient-relevant outcomes in a 
primary care population of various ages and different clinical conditions after hospital discharge. In 
PROJECT C1, we conducted a pilot study to assess and optimize the feasibility, efficiency, and quality of 
the study structures and procedures. 
At the University Hospital Basel, we screened the patient records of an internal medicine’s ward for 
eligible patients. Recruitment and assessment of baseline parameters were performed at bedside. All 
patients received medication counseling and an individualized medication plan prior to hospital 
discharge. Patients randomized to the intervention group received their oral solid medication 
packaged in an electronic multidrug punch card and regular feedback on their electronic dosing 
histories by a study pharmacist at the study pharmacy. Patients allocated to the control group received 
their medication from the community pharmacy of their choice. Follow-up visits were carried out at 
the study pharmacy at three, six, and twelve months after discharge. Primary outcomes were time to 
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hospital readmission and major adjustment of drug therapy and adherence calculated from pharmacy 
claims (medication possession ratio). Secondary outcomes were adherence according to patient self-
report and POlypharmacy Electronic Monitoring System data, quality of life, and patient satisfaction. 
The evaluation of the pilot study was developed according to the ‘Planning-Evaluation-Cycle 20’ and 
was based on Donabedian’s evaluation model of quality of care. 
Within nine months of the pilot study, we recruited ten patients and only one patient accepted the 
use of multidrug punch cards. No patient was readmitted to hospital during the follow-up period. One 
major adjustment of drug therapy occurred in the intervention patient, but could not be explained 
with an adherence problem. According to POEMS data and self-reported adherence, he was perfectly 
adherent. The control patients showed maximal adherence rates as well, by patient self-report and 
medication possession ratio. Quality of life remained relatively stable at an average value compared 
to a general population in both treatment groups. In the control group, all patients reported to use a 
system or strategy to manage their polypharmacy, with which they were very satisfied. However, one 
younger patient integrated fully in work life and dealing with polypharmacy for the first time after 
index hospitalization was interested in adopting a multidrug punch card after the completion of the 
study.  
The results of the intervention patient were further explored in PROJECT C2. This was to our knowledge 
the first case of long-term adherence monitoring of polypharmacy integrated in a pharmaceutical care 
service. The patient maintained perfect adherence according to all adherence measures and was 
clinically stable through the whole study period. The stability in quality of life and the gain of 
confidence with medication self-management might have been the result of successful disease 
management by the intervention. The patient was very satisfied with the multidrug punch card use, 
wishing to continue the service after completion of the study. No harms or adverse event could be 
associated with the intervention. 
The evaluation of the pilot study showed that the study design was feasible, but lacked efficiency and 
quality. The university hospital and the study pharmacy provided excellent infrastructure and working 
atmosphere. Patient satisfaction with the study procedures was high. Major inadequate points were 
the high exclusion and rejection rates, the inadequate time management, the vague task assignment 
within the study team, and the poor communication within the study team. The internal medicines’ 
ward turned out not to accommodate the target population for multidrug punch card service, since 
recruitment of an adequate number of patients predominantly failed because of the characteristics 
and preferences of the eligible patients. The poor quality of the study in the hospital phase was 
basically technical in nature and could be adjusted easily. In the primary care phase, the poor 
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communication with the community pharmacies, the induction of a potential bias by medication 
counseling at the follow-up assessments, and technical difficulties with the POEMS diminished the 
study quality. The evaluation of the pilot study pointed out important barriers for successful study 
performance and hence proved beneficial.  
In conclusion, this thesis showed the following: 
 Research gaps and poor methodological and reporting quality precluded a firm conclusion about 
the evidence of dose-dispensing aids in improving adherence and economic, clinical, and 
humanistic outcomes, and provided a rationale for future research. 
 Structural and procedural barriers (e.g. lack of public acknowledgement of the pharmacists’ 
competences, time mismanagement) hinder pharmacists to adequately deliver explicit adherence 
counseling. 
 Multidrug punch card service is well integrated in daily practice of Swiss community pharmacies, 
however, its provision for primary care patients is limited. 
 A specific group of primary care patients reports to benefit from multidrug punch card use, i.e., 
patients of the age of over 70 years, low education grade, living alone, appreciation for tidiness 
and daily routines, trust in health-care professionals, fidelity to pharmacy, and motivation for a 
healthy lifestyle and medication adherence. Emerging key variables for accepting multidrug punch 
card use and for perfect medication adherence were trust in health-care professionals and the 
patient’s experiences.  
 A pilot study investigating the effectiveness of electronic multidrug punch cards in primary care 
patients failed in recruitment of an adequate number of patients because of poor efficiency and 
quality of the study structures and procedures.  
 Six patients discharged from the internal medicine’s ward without any further intervention than a 
discharge counseling maintained perfect adherence, stability of clinical condition, and quality of 
life over one year. 
 One patient receiving the intervention of the electronic multidrug punch card combined with 
recurrent feedback on his adherence behavior showed maintenance of perfect adherence, stability 
of clinical condition and quality of life, gain in confidence of medication self-management, and 
satisfaction with the device. No harms could be associated with the use of electronic multidrug 
punch cards. 
 Prototypes of the POlypharmacy Electronic Monitoring System (POEMS) were easy to apply and 
well accepted by the intervention patient. However, drawbacks in the technology’s functionality 
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and specificity weakened the quality of our results and have to be addressed in future 
development. 
 Our recommendations for practice are: 
o To overcome structural and procedural barriers for patient-centered counseling e.g., by 
promotion of the pharmacist’s role by public information and advertisement, intensification 
of clinical pharmacy education, and reorganization of pharmacy accommodations and staffing. 
o To actively address medication self-management and non-adherence at patient contacts and 
to include the patient’s experiences, believes, and habits into counseling, respecting the 
patient’s preferences and life-style. 
o To establish trust of the patient to the health-care provider and to promote the patient’s active 
involvement in decision making. 
o To actively recommend multidrug punch cards to primary care patients with polypharmacy 
with regard to their capabilities, needs, and necessities, emphasizing the advantages of 
facilitation of medication self-management and increased medication safety.  
o To ensure continuous care by embedding dose-dispensing service in a pharmaceutical care 
framework. 
o To tailor interventions for non-adherent patients by e.g. a. screening of adherence pattern; b. 
selection of an appropriate intervention; and c. monitoring of outcomes. 
o To introduce the POEMS technologies to clinical practice for, e.g. diagnosis or pharmaco-
vigilance questions. 
 Our recommendations for future research encompass: 
o To identify further patient groups who accept multidrug punch cards and benefit from their 
use. 
o To develop guidelines for the delivery of tailored adherence support. 
o To reconsider the exclusion of adherent patients for clinical trials investigating the effect of an 
adherence-enhancing intervention. 
o A subsequent randomized controlled study on the effectiveness of multidrug punch cards 
could be optimized by  
 A well-instructed, adequately sized study team 
 Sufficient communication between all collaborators 
 Integration into clinical practice (e.g. physicians assisting recruitment at the ward and 
community pharmacies assisting in delivering the intervention) 
 Availability of sufficient, functioning electronic measurement material 
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 Locations enabling the recruitment of an adequate number of the target population (e.g., 
a rehabilitation center, community pharmacies). 
o To develop studies focusing on adherence-enhancing strategies with larger, multimorbid 
populations, measuring patient-relevant outcomes, and use of standardized adherence 
measures to enable comparison and generalization. 
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General introduction 
 
Polypharmacy and medication self-management 
“What constitutes ‘too many’ drugs is a prescribing dilemma, and choosing the best interventions 
aimed at ensuring appropriate polypharmacy is a challenge for all prescribers and health care 
organizations but particularly in general practice.“ 1 
Polypharmacy constitutes both, a blessing and a curse for the well-being of our society. Accordingly, it 
can be categorized into appropriate polypharmacy and problematic polypharmacy 1. The term 
polypharmacy refers to the ‘concurrent use of multiple medication items by one individual’ 1 and is 
defined either by the number of medications prescribed to an individual patient (usually over 5 or over 
10 different medications), or by appropriateness of prescribing 1-3.  
The beneficial effect of polypharmacy is acknowledged through the evidence of successful treatment 
of several clinical conditions, e.g., hypertension, diabetes mellitus, and human immunodeficiency virus 
(HIV) infection. The co-existence of multiple conditions makes it even indispensable. Appropriate 
polypharmacy occurs, when medication is prescribed according to best evidence and when its use has 
been optimized. Problematic polypharmacy occurs when the prescription is inappropriate and the 
benefit is outbalanced by risks. Polypharmacy has been associated with a substantial number of 
adverse outcomes including prescribing errors, high-risk prescribing, medication errors, adverse drug 
reactions, drug-drug interactions, non-adherence, increased geriatric syndromes (falls, unhealthy 
nutrition, urinary incontinence etc.), increased use of health care services, increased hospitalization 
rates, and increased morbidity and mortality 4-11. A Dutch study found that among 5.6% of patients 
experiencing medication related hospitalization, non-adherence and polypharmacy belonged to the 
major determinants of preventable hospital admissions 12, whereas both factors are known to be 
strongly interrelated 13,14. Incorporating the patient’s perspective reveals the pill burden, which 
strongly affects their quality of life, by interfering with daily activities and social life 15-17.  
Today, we find ourselves in a society of increasing age and multimorbidity, which are driving factors 
for polypharmacy. In Switzerland, the proportion of the over 65 year-old population increased from 
5.8% in 1900 to 17.4% in 2012 (Figure 1) 18 and the overall proportion of multimorbid patients was 
14.5% in 2012. The prevalence of multimorbidity rises with age (CH: 60-69 years: 25.8%, 70-79 years: 
33.6; 80-89 years: 37.7%) 19 and occurs in most patients with a long-term condition 20. However, the 
absolute number of multimorbid patients appears to be substantially higher in younger patients under 
65 years old 20, reflecting a highly multimorbid society.  
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Figure 1. Demographic change from 1900 to 2012 in Switzerland according to the federal office for statistics 
(men: left; women: right) 18. 
 
Due to these demographic changes, polypharmacy affects a vast proportion of the population in many 
countries, and is common in primary and secondary care 1,21-23. The proportion of the Swiss primary 
care population over 18 years with zero, one to four, and over five different medications filled in a 
quarter year were 52.2%, 31.1%, and 16.7%, respectively 24. In the age group of over 65 years, this 
distribution altered considerably with 21.5% filling zero, 37.4% filling one to four, and 41.2% filling over 
five medications 24. Twenty-one percent of these medications were determined inappropriate 
according to the PRISCUS list 25 and the Beers criteria 26. In a European comparison of the prevalence 
of polypharmacy in secondary care, Switzerland scored highest with a proportion of 21% elderly 
patients taking ten or more prescribed medications at hospital admission 23. Further, the number of 
medications usually again increases from hospital admission to discharge 27,28 with the consequences 
of confusion and non-adherence in discharged patients 29.  
Society more and more depends on the autonomous living of old and multimorbid patients and health 
policy increasingly encourages a development towards early hospital discharges in many countries, 
including Switzerland 1,30. This corresponds to the preferences of elderly patients with polypharmacy 
to maintain control and independency 31,32. Therefore, the primary care sector is especially charged, 
relying on the appropriate medication self-management of the patients. In this thesis, medication self-
management refers to the cognitive and physical ability of the patient to self-administrate medication 
according to a prescribed regimen 31,33. Studies showed that medication self-management was 
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remarkably impaired in older patients, leading to medication errors and thereby constituting 
problematic polypharmacy 34,35. 
Medicines optimization is an approach to ensure appropriate polypharmacy, setting medication use 
into a broad field from medication selection until the actual use 1. Evidence-based decision-making, 
active patient engagement, and professional collaboration are central elements of this approach and 
coincide with the concept of patient-centered care. Under these aspects, strategies for optimizing 
polypharmacy can be delivered by the community pharmacy and may comprise the assessment of the 
patient’s expectations and resources, the careful review of medications for appropriateness, the 
reduction of the number of inappropriately prescribed medication, as well as the support of the 
patient’s medication self-management 36. A comprehensive World Health Organization (WHO) report 
on adherence to long-term therapies asserts that there is ‘ […] strong evidence that suggests that self-
management programs offered to patients with chronic diseases improve health status and reduce 
utilization and costs’ 37.  
This thesis aimed at the optimization of medication use to reach appropriate polypharmacy through 
effective support of the patient’s medication self-management by pharmaceutical care services. 
Pharmaceutical care 
Medication management services are understood as the multidisciplinary support of the patient’s 
medication use by in ensuring its appropriateness, effectiveness, safety, and the ability and willingness 
of the patient to execute the medication plan as intended 38. Pharmaceutical care constitutes the 
professional practice of the pharmacist delivering patient-centered medication management services 
and thereby assuming responsibility for clinical decision-making. The current definition published by 
the Pharmaceutical Care Network Europe is: 
“Pharmaceutical care is the pharmacist’s contribution to the care of individuals in order to optimize 
medicines use and improve health outcomes.” 39 
The activities of pharmaceutical care involve the detection, resolution, and monitoring of actual and 
potential drug-related problems (Figure 2). A drug related problem is ‘an event or circumstance 
involving drug treatment that actually or potentially interferes with the patient’s experiencing an 
optimum outcome of medical care’ 40. This includes non-adherence, which can be evaluated at the 
community pharmacy during medication review, out of the refill history, in direct conversation with 
the patient or by monitoring of clinical outcome parameters, e.g., blood pressure, LDL-cholesterol. Part 
of the goal of pharmaceutical care is an optimal medication adherence, and the intervention to support 
it falls into the professional responsibility of the pharmacist. 
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Figure 2. The pharmaceutical care process adapted from Cipolle et al. 38 and Hersberger et al. 41. 
 
In 2011, the WHO and the Fédération Internationale Pharmaceutique (FIP) updated a joint publication 
on guidelines for Good Pharmaceutical Practice (GPP) specifically requiring the pharmacist to take an 
active role in patient-centered care and defining the core of GPP as ‘to help patients to make the best 
use of their medicines’ 42. The FIP further highlighted the important role of the pharmacist in assessing, 
addressing and improving medication adherence 43. Pharmaceutical care services delivered by 
community pharmacies were shown to significantly improve adherence 44-50. Recent Cochrane reviews 
even confirmed the pharmacists’ cognitive services to contribute beneficially to safe an effective 
medication use 51,52. 
Medication adherence 
The rational use of medication includes appropriate prescribing AND full adherence to prescriptions 37. 
Various models have tried to describe the patients’ behavior of medication taking, e.g., the Health 
Belief Model 53 , the Theory of Planned Behavior 54, and the Transtheoretical Model of behavior change 
55. The WHO defines adherence as follows: 
Adherence is “the extent to which a person’s behavior – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a health care provider.” 37 
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This definition embraces the whole process of therapeutic actions, from the seeking of medical advice 
to the actual intake of medication. An important point within this definition is the term agreed because 
it highlights the active participation of the patient in the prescribing process. The concept of adherence 
awards the patient’s own will and capability to initiate and implement a prescribed medication plan. 
In fact, it is now widely acknowledged that a therapeutic intervention will only be successful if the 
patient is involved in the clinical decision making 37.  
This definition also coincides with optimization of medicine taking and the model of patient-centered 
care discussed above, where a partnership between the patient and the health care professional draws 
on the capabilities of both to assess barriers, find solutions and plan follow-up on adherence. Despite 
adherence being the subject of a vast number of publications, this patient behavior is still poorly 
understood. The focus of this thesis lies in adding a contribution to the knowledge of medication 
adherence of primary care patients to polypharmacy. 
Factors and models of adherence 
“Despite evidence to the contrary, there continues to be a tendency to focus on patient-related factors 
as the causes of problems with adherence, to the relative neglect of provider and health system-related 
determinants.“ 37 
Adherence is a complex behavior requiring many of the patient’s resources, i.e. physical and cognitive 
ability, organizational skills, mobility etc., but also is dependent on four further dimensions. These 
dimensions group social/economic, health system / healthcare team, condition related, and therapy 
related factors (Figure 3). Frequently the patient related factors are made responsible for non-
adherent behavior, which accounts only insufficiently for the overall problem. A comprehensive review 
of reviews compiled 771 factors and grouped them according to their effect on adherence, i.e. 
beneficial, deteriorative, and neutral 13. Interplay of all sets of factors again lead to multiple 
interactions and makes adherence an even more complex multidimensional phenomenon. We can 
assume that the factors negatively affecting adherence represent targets for adherence-enhancing 
interventions. For example, if a patient is non-adherent because she/he forgets the medication intake, 
a memory support may be provided. Due to the many factors that can be influenced it seems obvious 
that adherence is a challenge for every patient and therefore merits special attention in consultations 
and during dispensing of medication at the community pharmacy. 
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Figure 3. The five dimensions influencing adherence according to the World Health Organization report 37 and 
examples of factors negatively associated with adherence. Hct, healthcare team. 
 
Based on these factors, various models were developed to describe the patients’ behavior of 
medication taking. In the Health Belief Model 53, the patient weighs her/his believes about necessity 
against concerns, resulting in a skeptical, ambivalent, indifferent, or accepting attitude towards 
medication taking. The Theory of Planned Behavior 54 proposes behavior to be guided by attitude, 
subjective norms, perceived behavioral control, and behavioral intention, were the latter is the 
immediate precursor of the actual behavior. In the model of Interpersonal Behavior 56, apart from 
cognitive, social, and personal factors, habits take a dominant role in affecting behavior change. In fact, 
habit has been described as a major determinant influencing adherence 57,58. The Transtheoretical 
Model of behavior change 55 describes the different stages that a patient has to pass through to reach 
effective behavior change, namely precontemplation, contemplation, preparation, action, and 
maintenance. Lately, Marcum et al. proposed a conceptual model of the effect of polypharmacy on 
adherence 14. In this model, polypharmacy can directly affect adherence, by the greater number of 
medications that can be missed on a daily basis and the close relation to regimen complexity, which 
has been associated with poor adherence. The effect of polypharmacy can also be mediated by various 
patient, health-system, or provider factors to lead to non-adherence 14. 
Despite of efforts made to group patients into ‘adherent’ and ‘non-adherent’, such prototype patients 
do not exist. There are rather several patterns of non-adherence, which might make sense (e.g., 
reducing the dose at experience of toxicity) or not. Types of non-adherent behaviors include, e.g., 
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stockpiling, drug holiday, white coat adherence, taking the wrong medication, overdosing, 
underdosing, erratic dosing, wrong dosing frequency, and wrong duration of treatment. These timely 
patterns can be revealed by electronic adherence monitoring 59. 
Adherence taxonomy 
“[A transparent taxonomy] should provide researchers and clinicians with a common language for 
describing different experimental investigations.” 60 
Compliance – Adherence –Concordance. Compliance describes the passive following of the physician’s 
order. It indicates that the patient did not actively take part in the decision process about the 
treatment. In contrary, the term adherence implies the patient’s active participation in and agreement 
with the treatment. However, adherence and compliance are frequently used interchangeably, also in 
this thesis 61. Concordance describes the agreement of the patient and physician on the clinical 
condition, the therapy goals and the choice of therapy 62.  
Intentional non-adherence – unintentional non-adherence. These terms describe the behavior of the 
patient and relate to the reason of non-adherence. Intentional non-adherence applies when the 
patient willingly alternates the prescribed treatment without feedback to the physician. This is an 
active decision, occurring when patients, e.g., do not trust health-care professionals, fear adverse 
reactions or feel stigmatized by medication taking. In contrary, unintentional non-adherence is 
characterized through the patient’s prevention of medication intake against his/her actual intent, 
typically because of physical or cognitive barriers to medication self-management, but also because of 
language barriers, inability to pay for the treatment or not recalling treatment instructions. It is a 
passive process and the patient’s ability to memorize and polypharmacy are related to it. To distinguish 
these two behaviors at the assessment of non-adherence might be crucial for picking the right 
intervention for a patient. For example, unintentionally non-adherent patient may benefit from dose-
dispensing aids, whereas intentionally non-adherent patients will persist with this kind of adherence 
support 33,62,63. 
Primary non-adherence – secondary non-adherence. These terms distinguish the behavior of 
medication filling and the actual intake, where primary non-adherence constitutes the lack of filling a 
first prescription and secondary non-adherence represents the non-execution of the treatment plan 
after filling the prescription 64. 
Initiation – Implementation – Discontinuation – Persistence. In order to describe the secondary 
adherence process, the Ascertaining Barriers to Compliance (ABC) project team defined adherence to 
medication as a process containing several steps: initiation is the intake of the first dose of a prescribed 
treatment; implementation is the extent of the patient’s dosing corresponding to the prescribed 
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treatment; discontinuation is the stop of intake. The time period between initiation and 
discontinuation is defined as persistence. Whereas adherence relates to the intensity of medication 
intake, persistence describes the duration of intake. Persistence and implementation are continuous 
variables, while initiations and discontinuation are two discontinuous actions (Figure 4) 60. 
 
 
Figure 4. Illustration of terminology of the single steps of the adherence process according to the Ascertaining 
Barriers to Compliance (ABC) project team 60. Light blue: process of adherence to medication; dark blue: 
process of management of adherence. 
 
Taking adherence – timing adherence. To further characterize the patients intake behavior, these 
terms express the proportion of the medication taken as prescribed per day and the proportion of 
medication taken at the right time, i.e. prescribed time per day 65. 
In order to understand, report, and describe adherence, the terms defined above enable to convert 
the abstract health related behavior ‘medication adherence’ into a measureable entity. Several 
measurement methods have been developed to quantify this complex behavior. 
  
27: GENERAL INTRODUCTION Medication adherence 
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
Adherence Measurement 
“In order to compare and reproduce medication adherence results, researchers and healthcare 
providers have to consider, firstly, using an internationally accepted operational, standardized 
definition of medication adherence; secondly, accurately describing medication adherence methods 
used; and thirdly ensuring the quality, validity and reliability of the methods and data analysis 
employed.” 66 
Adherence measurement methods 
Direct and indirect methods constitute two groups of adherence measurement methods (Table 1). 
Thereon, they can further be divided into subjective and objective methods. Whereas objective 
measurement methods are usually deemed more reliable, subjective methods allow deeper insight in 
the patients’ behavior with the possibility to ascertain the reasons for it. 
 
Table 1. Direct and indirect methods of adherence measurement, adapted from Osterberg et al. 65. 
Indirect Direct 
Self-report Directly observed therapy 
Clinical response / physical marker Therapeutic drug monitoring 
Medication refill frequency  Biomarker monitoring 
Pill count  
Electronic medication monitoring  
 
Patient self-report is a subjective measurement method and is applied by interviews, questionnaires, 
and diaries. Many different instruments exist for different clinical conditions, with different scales, and 
for different patient populations. Valid instruments are, e.g., the Morisky Medication Adherence Scale 
8 67, the Believes about Medicines Questionnaire 53, and the Adherence Estimator 68. The advantages 
of the self-report measurement methods, namely their practicability, flexibility in use, low cost, low 
time expenditure, have made them a common tool used in clinical and research settings. They can 
assess social, situational and behavioral aspects and allow the differentiation between intentional and 
unintentional adherence. Patient self-report, however, has been criticized to overestimate 
adherence 66. 
Objective adherence measurement methods can be viewed as a camera capturing momentous 
pictures with different zoom levels. For example, pharmacy refill and prescription claims data would 
represent a wide-angle lens, capturing large community samples, thereby representing the 
community. Their use is non-invasive, of strong statistical power, economic and show the real-world 
picture apart from clinical trials. Data are comparable to electronically measured adherence. However, 
pharmacy refill and prescription claims are afflicted with a certain level of blur, because 
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implementation and discontinuation cannot be observed. Factors limiting the validity are patients 
receiving medication samples from the physician, stock-piling their medication at home without using 
them, collecting their medication at different pharmacies, or claims registered at different health 
insurance databases 66. 
If we zoom further in, pill count gives information on if and how much the patients took from 
medication they (re-)filled at the pharmacy. Pill count is easy to perform in any setting, inexpensive 
and therefore a globally used measurement method. The opponents argue that it provides no 
information on the actual taking, that the patients have to bring back the pill containers at each visit, 
that there is a risk of the patients discarding the medication before a visit, and that does not represent 
an accurate measure for detecting poor adherers, i.e., patient persisting but not implementing 
correctly the treatment plan 66. 
The highest resolution to date is provided by electronic monitoring. Electronic monitoring was first 
reported in 1984 69 and records when the medication was taken additionally to the amount of taken 
medication. A continual real time monitoring is feasible, recording treatment initiation, 
implementation, taking adherence, timing adherence, discontinuation, and persistence. Through this 
method, adherence patters like drug holidays and white coat adherence can be uncovered, and 
conclusions can be drawn about the clinical outcomes of the treatment 59. Nevertheless, electronic 
medication monitoring has its limits. The high cost of the devices precludes their widespread use. 
Further, despite capturing intake patterns, it still does not capture the actual swallowing of the pill. 
The patients might take a pill out of the device at the right time and then discard it or take pocket 
doses and so produce false-negative registrations. Not all patients are comfortable with electronic 
monitoring devices and it does not suit all galenic formulations 66. Electronic monitoring and pill count 
were concluded to complement each other 70,71. 
Direct adherence measurement methods are usually costly, invasive and obtrusive and are not used 
routinely in clinical practice or research. They are not relevant for this thesis. 
In summary, every method has its strengths and limits and there has not been agreement on a ‘gold 
standard’. Despite the progress in the field of adherence measurement, the patient’s action after 
removal of the medication from the container remains hidden and the number is only a surrogate for 
the patient’s actual behavior. Whenever adherence is to be measured, the setting, resources, goals of 
the measurement and the accuracy requirement have to be considered for the choice of the 
appropriate method. The current state-of-art of adherence measurement is concordantly considered 
as the combining two or more methods, to benefit from all their strengths 37,65,66.  
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Electronic measurement devices 
The Medication Event Monitoring System (MEMS®; AARDEX Group Ltd., Sion, Switzerland) is the most 
commonly used electronic measurement device for oral solid dosage forms (Figure 5). The medication 
is placed in a pill bottle with a microprocessor chip embedded in its cap. At every opening of the bottle, 
the chip records time and duration of the ‘medication taking event’. The major drawback of MEMS® is 
its limitation to the monitoring of one lead drug, and thus it is not suitable to monitor polypharmacy. 
Further, it remains unknown if and how many pills are removed with each opening. The high costs of 
these containers do not allow their use in routine clinical practice. 
The POlypharmacy Electronic Monitoring System (POEMS; Confrérie Clinique S.A., Lausanne, 
Switzerland) consists of an adhesive polymer film with printed electric circuitries. It can be fixed on the 
back of a regular blister pack to record date, time and location of medication removal. Transmission 
to an electronic database yields numeric and visual data (Figure 6). Acceptance and internal validity 
were reported to be similar and data quality to be higher compared to MEMS® 72. The advantage of 
POEMS is the flexible adjustment to multidrug punch cards (i.e. cards with several plastic 
compartments to pack oral solid medication according to dosing times) (Figure 5). This allows the 
electronic measurement of adherence to a whole medication regimen and thereby restores the 
allocation of single dose-units to a specific signal. Knowing the adherence pattern of the entire 
medication regimen provides the possibility to explain unreached clinical outcome, drug–drug 
interactions, and drug resistance.  
 
 
Figure 5. Medication Event Monitoring System (MEMS®, left) 73; multidrug punch card, front (middle); 
multidrug punch card, back with affixed POlypharmacy Electronic Monitoring System (POEMS, right). 
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Figure 6. Example of output graph of the POlypharmacy Electronic Monitoring System (POEMS) measuring 
adherence to a four-times daily regimen over one week. 
 
POEMS was used so far in a study on primary care patients with polypharmacy over one week to rule 
out adherence as a determinant for drug resistance to aspirin and clopidogrel 74. The technology could 
demonstrate that a smaller intake time variability of the lipid lowering drug was significantly associated 
with better levels of LDL-cholesterol 75. In a case study, it discovered a distorted adherence pattern 
which allowed the conduction and monitoring of a personalized intervention 76. 
Several other electronic measurement devices exist, most of them are connected with automatic dose 
dispensing, they come with or without acoustic alarm, and apply to different dosage forms e.g., DO-
Pill SecuR™, Electronic Medication Management Assistant (EMMA®), Medido® Pill Pouch Dispenser, 
Wisepill™, Neb Nebulizer™, eye-drop monitor, IDAS®, and Helping Hand® 66,77. 
Adherence measures 
Several measures have been proposed to calculate and present adherence out of measured data. The 
two most commonly used measures are the medication possession ratio (MPR) and the proportion of 
days covered (PDC). The MPR describes the proportion of supply to fulfil a treatment plan over a 
distinct period of time and is calculated as the total days’ supply of medication dispensed divided by 
duration of prescribed therapy in the period of interest. The PDC describes the proportion of days on 
which the medication is available for the patient divided by the total days of the analysis period. Both 
measures are usually ranging between 0 and 1, with 1 signifying perfect adherence. Although 
thresholds separating good adherers from bad adherers have been widely used, their validity is 
controversially discussed. Thresholds of 0.8-0.9 have been associated with fewer hospitalizations in 
schizophrenia, hypertension, diabetes mellitus and hyperlipidemia 78,79. For HIV, adherence rates 
between 50-80% were associated with increased drug resistance, whereas a threshold of > 95% was 
31: GENERAL INTRODUCTION Medication adherence 
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
considered evident for successful viral suppression 80. However, these values are not above doubt, and 
for many clinical conditions the question of how much adherence is necessary remains unanswered. 
An approach to this question was proposed by the concept of forgiveness, which sets the medication’s 
duration of beneficial action in relation to its prescribed dosing frequency and hence describes how 
long the therapeutic effect will prevail in case of non-adherence 59,81. 
Whereas MPR and PDC suffice the requirements of monotherapy regimens, a new method for 
calculating adherence to polypharmacy was introduced recently. The daily polypharmacy possession 
ratio (DPPR) calculates the days covered with polypharmacy day by day. First results of validation 
showed that various characteristics of polypharmacy, e.g., medication switching, duplication, and 
overlapping, which could not be included in the above named methods, could be accounted for by the 
DPPR 82. 
Due to the many different adherence measurement methods and measure calculation methods, the 
congregation of studies about adherence and adherence-enhancing interventions has been difficult 
83,84. In this thesis, we used patient self-report, pharmacy refill claims, and electronic measurement 
methods (POEMS), and calculated adherence measures by MPR. 
Dimensions and consequences of non-adherence 
“Prescribed medications help to control symptoms and slow disease progression, enabling the person 
to maintain their health and live independently for as long as possible with an optimal quality of life.” 85 
Non-adherence starts at filling a prescription: Within 15’961 patients receiving a first-time 
prescription, primary non-adherence was 31.3% 86. New users had a lower filling rate (34.3%) than 
patients switching treatment within a pharmacologic class (11.6%) 86. After the first filling, persistence 
subsequently decreases with rates varying for different conditions, e.g., with 60% for bisphosphonates, 
61% for statins, 66% for angiotensin-receptor blockers, and 72% for oral antidiabetics 87 (measured by 
pharmacy refill claims). This is consistent to a review, which compiled electronic adherence data over 
95 studies on different conditions reporting a persistence of 60% at one year 59. Persistence rates can 
be associated with execution rates: the poorer the execution the lower the persistence 59,88. Non-
execution ranged around 10% in patients on antihypertensive treatment, with 42% of omissions of a 
single day’s dose, 15% up to two days, and 43% of three or more days, defined as drug “holidays”) 88. 
Almost half of the patients had at least one drug holiday a year. There were particular weekdays on 
which dosing omissions occurred more frequently for a third of patients, mostly weekend days. 
Patients who took their medication in the morning executed their treatment more correctly than 
patients with evening or variable doses 88. Similarly, taking adherence and timing adherence were 
more correct for once-daily regimens than for 2-times, 3-times, and 4-times daily regimens within rates 
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of 93.0%, 85.6%, 80.1%, and 84.4% for taking adherence and 76.9%, 59.3%, 35.9%, and 18.8% for 
timing adherence, respectively 89. Higher time variability existed in midday and evening doses 
compared to morning doses and in weekend doses compared to weekday doses in patients with 100% 
taking adherence to polypharmacy 75. 
Non-adherence occurs in all situations where medication self-administration is required, 
independently of medical condition, severity, and accessibility to health resources 37. A review 
summarizing adherence rates for several conditions over 50 years showed mean adherence rated for 
HIV of 88.3%, for arthritis of 81.2%, for cancer of 79.1%, for seizures/brain disorders of 78.4%, for 
cardio-vascular diseases of 76.6%, and for diabetes of 67.5%, among others 90. In phase I to III clinical 
trials, non-adherence results in inaccurately adjusted dosing and an underestimation of adverse 
reactions. Still, patients participating in clinical trials usually adhere better to treatment than in real-
life 59,91. Non-adherence represents the missing link between effective therapy and effective disease 
management. 
Non-adherence has been associated with impaired effectiveness and safety of treatments leading to a 
variety of adverse health outcomes. Inability to reach treatment goals lead to drug resistance in HIV 
and tuberculosis 80,92. Treatment failure has also been described in elderly patients with chronic 
conditions 93 and in transplantation, constituting a major risk factor for transplant rejection in the latter 
94. In statin treatment, non-adherence leads to inappropriate dose escalation 95. Disease progression 
due to treatment failure leads to increased hospitalization 96 and mortality 97 in HIV. Non-adherence 
to antihypertensive medications constitutes an independent risk factor for stroke related hospital 
admissions and deaths 98. Furthermore, evidence has accumulated that patients with cardiovascular 
diseases who are poorly adherent to cardio-protective therapy had a higher risk of vascular events, 
hospitalization and mortality 99-103. Even in secondary prevention of myocardial infarction, these 
observations persisted 104. Corresponding results could be shown for patients with diabetes mellitus 
type 2, and asthma 105,106. Additionally, non-adherence was associated with adverse drug events 107,108 
and was found as one of the largest determinants of hospitalization due to preventable drug related 
problems 12,109. Further risks are more intense relapses, medication dependence, rebound effect, 
toxicity, and accidents (e.g. with antidiabetics, antieplieptics) 37. 
Impaired health outcomes may be the consequence but also the cause of non-adherence. Quality of 
life, for example, has been reported to be influenced from two sides. On one hand regular medication 
intake guarantees the attenuation of first dose effects and leads to adequate symptom control in 
epilepsy 110, HIV 96,111,112, and chronic obstructive pulmonary disease 113. In these cases, higher 
adherence led to increased quality of life. On the other hand, the high pill burden, missing flexibility in 
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daily life and increased adverse reactions with high adherence decreased quality of life 15,114. Patients 
with diabetes mellitus type 2 experiencing low tolerability with the treatment reported low quality of 
life as a reason for low satisfaction and adherence 115 and several factors associated with the 
maintenance of adherence were identified, e.g., treatment fatigue and burnout, social support 
problems, and emotional and self-efficacy problems, which in the end motivated the patients for non-
adherence.  
Finally, due to intensified treatment, increased healthcare utilization, medication waste, and loss of 
productivity, substantial economic costs arise 96,116-121. The global impact of non-adherence in 186 
countries was estimated to range between U$172 and 371 billion 117. In the United States of America, 
non-adherence accounts for up to U$100 billion in health care and productivity costs which constitutes 
approximately 10% of the total annual healthcare budget 116 and the English National Health Service 
(NHS England) reported losses of £900 per year because of non-adherence within five clinical 
conditions 122. Across five European countries, increasing the percentage of patients being adherent to 
antihypertensive treatment to 70% was estimated to lead to a reduction of cardiovascular related 
healthcare costs by €332 million 123. In Switzerland, antihypertensive treatment costs were 
disproportionately high because of non-adherence 124. In studies on diabetes mellitus type 2 and HIV 
patients, adherence was shown to reduce costs due to decreased healthcare utilization 96,118 and 
hospitalization rates 119. These savings outweigh the costs generated through increased medication 
use and adherence-enhancing intervention programs 125. 
The collective burden of non-adherence allows the assumption that an effective adherence-enhancing 
intervention ’may have a far greater impact on the health of the population than any improvement in 
specific medical treatment’ 126. 
Adherence-enhancing interventions 
“Current methods of improving medication adherence for chronic health problems are mostly 
complex, labor-intensive, and not predictably effective”. 127 
Manifold interventions have been explored, specifically for single clinical conditions, e.g., HIV, 
depression, diabetes mellitus, and hypertension 50,128-131 or focusing on the delivery of the intervention 
by specific health-care professionals 51,84,128,129.  
Kripalani et al. 132 proposed a taxonomy for types of adherence interventions in a literature review 
investigating interventions for patients on chronic conditions, including: 
 Informational: Education and instruction about disease and/or medication, e.g., oral, telephone, 
written, or audiovisual education; didactic group class; instructional material. 
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 Behavioral: Strategies to influence behavior, e.g., skill building by a health care professional; 
pillboxes, calendars, a change in packaging, other reminders; simplifying/tailoring the medication 
regimen; rewards and reinforcement. 
 Social/family: Social support strategies, e.g., support groups and family counseling. 
 Combined: Combination of the groups described above. 
The review included 37 studies on 13 informational, 10 behavioral, and 15 combined interventions. A 
significant improvement of at least one adherence measure was reported in 20, and of corresponding 
clinical outcomes in 11 studies. Successful interventions were behavioral, with or without combined 
elements (simplifying medication regimen, feedback and monitoring), contained multiple of the same 
elements delivered over time, or were combined including elements from different types.  
An extensive Cochrane review 126 analyzed 78 trials on the effectiveness of adherence-enhancing 
interventions. The review presented a vast variety of applied interventions with 19 categories. Only 36 
of 87 reported interventions in long-term treatments significantly improved adherence and 26 also 
had an effect on improving clinical outcomes. Combined complex interventions were mostly successful 
comprising combinations of comprehensive patient instructions and counseling, reminders, close 
follow-up, supervised self-monitoring, rewards for success, family therapy, couple-focused therapy, 
psychological therapy, crisis intervention, and manual telephone follow-up. A common characteristic 
was the more frequent interaction of healthcare professionals with patients. Two studies on patients 
with complex regimens, i.e. polypharmacy did not show improved outcomes (i.e. adherence, re-
hospitalization rates).  
The literature on interventions specifically designed to improve adherence to polypharmacy is scarce. 
Independently living patients with polypharmacy were reported to benefit from dose-dispensing aids 
with regular follow-up 133 and from engaging in self-management, mainly delivered by pharmacists 85. 
The modes of delivery of adherence-enhancing interventions were more beneficial if they were 
performed personally at hospital discharge and by a pharmacist at the pharmacy 134.  
The effect of electronic medication packaging, i.e., adherence recorder, audiovisual alarm, liquid 
crystal display, and/or real-time monitoring, ranged from a decrease of 2.9% to an increase of 34.0% 
in adherence 135. Electronic devices embedded in complex interventions and the combination of digital 
displays with alarms were most frequently associated with improved adherence 135. Electronic 
packaging devices combined with feedback on the patient’s adherence performance was assumed 
beneficial. This was particularly observed by a meta-analysis including 79 studies on adherence-
enhancing interventions measured by electronically compiled dosing histories 136. They observed 
increased adherence of 14.1% in the intervention groups compared to the control groups. 
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Interventions with a cognitive-educational or a feedback element showed significant effects of 
improved adherence.  
Some interventions targeting adherence through medication optimization improved patient 
satisfaction and health related quality of life 46,113,115. Usually intensive, complex interventions were 
estimated to be more effective, but simple interventions were more cost-effective 137,138. Quality of 
pharmaco-economic studies and reported economic outcomes in studies on adherence-enhancing 
interventions were insufficient to make a clear statement on the cost-effectiveness of adherence-
enhancing interventions 83,139,140. Compared to the enormous costs caused by non-adherence, 
adherence-enhancing interventions are generally thought to be cost-effective 37. 
Overall, the evidence of adherence-enhancing intervention remains scarce and their effect on 
adherence and economic, clinical and humanistic outcomes, if assessable, is moderate. Persistent 
criticism concerns the poor methodological quality, the large heterogeneity of the results, the small 
sized study population and the short study duration. Many studies did not suffice the ethical standards 
for adherence research proposed by the National Heart Lung and Blood Institute 141, which demand 
the report of benefits for the patients through the measurement of patient-relevant outcomes (i.e. 
clinical and humanistic outcomes) in trials investigating adherence-enhancing interventions. Often, 
promising interventions were too complex and diverse to attribute the only moderate effect sizes to a 
single element. To date, it is suggested that the effect of the interventions might be augmented by 
tailoring the elements of the intervention to the patients’ individual necessities and needs 62,142. To 
enable such interventions, patient individual factors of non-adherence have to be assessed before 
delivering it. 
Although complex interventions were usually suggested to yield larger effects, the reviewers doubted 
their integration into daily practice because of poorly described intervention details and unavailable 
resources. To be implementable in clinical practice, adherence interventions have claimed to be 
simple, easy to use, continuous and cheap 37,143. These requirements are fulfilled by interventions 
supporting medication self-management e.g. dose-dispensing aids. In a meta-analysis, dose-dispensing 
aids were one among three intervention elements showing positive moderation on the overall effect 
size of adherence 144. Various authors have suggested dose-dispensing aids to enhance adherence in 
unintentionally non-adherent patients with polypharmacy by optimizing medication self-management 
1,62,65,145,146. 
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Dose-dispensing aids 
“Calendar packaging of medications for long-term use is intuitively attractive as a simple adherence 
strategy, but only a paucity of clinical trials have assessed its adherence benefits systematically, and 
essentially none has evaluated its potential for harm.” 147 
Dose-dispensing aids represent a simple technical option and require little resources on the patient’s 
as well as on the provider’s side. They are easy to use, cheap, support medication self-management 
through adherence (self-) monitoring and constituting a reminder for medication intake, and thus 
might prolong independent living , save time, costs, healthcare resources (e.g., home care nursing), 
and medication waste 1,126,145,148,149. Due to the missing of a Medical Subject Heading, there is a variety 
of synonyms used in the literature (Table 2).  
 
Table 2. Synonyms used for dose-dispensing aids in alphabetical order.  
Of note: This list makes no claim to be complete. 
Blister packaging 
Calendar (blister) packaging  
Drug packaging  
Drug reminder packaging 
Pillbox 
Pill calendar  
Pill container  
Pill organizer 
Pill packaging  
Special medication packaging 
Unit dose packaging 
Unit of use packaging  
Brand names 
Dosett® 
Easyblist® 
Medidos® 
Nomad® 
Pharmis® 
Webster® pack 
Venalink® 
MTS® 
 
Dose-dispensing aids consist of a certain number of compartments, containing solid, oral medication 
for specific dosing times. They can roughly be divided into three groups 77: 
 Multicompartment adherence aids are reusable plastic boxes, which come in many different 
shapes and colors. Usually, they provide compartments for seven days with or without sub-
compartments for additional dosing times per day. They are filled either by the pharmacy or 
by the patient (Figure 7). 
 Multidrug punch cards are disposable frame cards with plastic compartments, sealed with a 
foil backing. Typically, they provide 28 compartments, but other models from 4-35 
compartments exist too enabling the individualized packaging of polypharmacy according to 
a prescribed dosing regimen. On the front side, the medication is visibly packaged and 
labelled with patient and pharmacy information and marked with the dosing times (morning, 
lunch, evening, night; Monday-Friday). The adhesive medication plan at the backside labels 
brand name, dose, administration number, dosing frequency, size, color, imprint, batch 
number, and expiration date of each packaged medication. Multidrug punch cards are filled 
by pharmacy staff, by a specialized company, or an automated system (Figure 8). 
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 Blister pouches are little sealed unit-dose bags containing one or multiple medication and 
usually coming in a sequential line of pouches with perforated limits. They are produced by 
an automated system, often by a specialized company and sometimes at the pharmacy. 
Unlimited dosing times per day can be packaged for a requested time of use (Figure 9). 
 
 
Figure 7: Multicompartment adherence aids (top left: Dosett®; top right: Medi-7®). 
 
 
Figure 8: Multidrug punch cards front (left) and back (right). 
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Figure 9: Blister pouches (Medifilm®). 
 
Advantaged and disadvantages of the specific groups are illustrated in Table 3. 
Table 3. Advantages and disadvantages of dose-dispensing aids. 
Multicompartment 
adherence aid 
Advantages  Independent filling by the patient 
 Reusability 
 Medication self-monitoring possible 
 Visual intake reminder 
Disadvantages  Lack of hygiene 
 Restricted number of dosing times  
 Risk of deteriorated stability and compatibility of deblistered 
medication 
 Risk of inaccurate filling by the patient 
Multidrug punch card Advantages  Hygiene 
 Medication self-monitoring possible 
 Visual intake reminder 
 Electronic monitoring possible 
 Not open to manipulation 
Disadvantages  Not reusable / waste 
 Restricted number of dosing times per day 
 Risk of deteriorated stability and compatibility of deblistered 
medication 
 Risk of handling difficulties by the patients 
 Risk of fewer contact to health care professionals 
 Risk of fading knowledge about packaged medication 
Blister pouch Advantages  Hygiene 
 Unrestricted dosing times per day 
 Separable unit-doses 
 Electronic monitoring possible 
 Can be integrated in an automated dosing system 
 Not open to manipulation 
Disadvantages  Not reusable / waste 
 Risk of deteriorated stability and compatibility of deblistered 
medication 
 Risk of fewer contact to health care professionals 
 Risk of fading knowledge about packaged medication 
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The dose-dispensing service is defined as ‘the repackaging of solid oral medication by a health-care 
provider, mostly in a community pharmacy or hospital pharmacy, to assist patients in the management 
of their polypharmacy’ 77. It ideally should be integrated in a pharmaceutical care service, with 
instruction and counseling of the patient, information for his/her caregiver(s), and regular follow-up, 
i.e. medication review of the packaged and unpackaged medication 77,150 (Figure 10). 
 
 
Figure 10: Workflow of dose-dispensing service from Hersberger et al. 77. 
 
Dose-dispensing aids are widely used in practice. Although acknowledged for facilitating medication 
self-management, their use is not without risks (Table 3, disadvantages) and their widely spread use 
has been criticized. Difficulties with handling were described in several studies, leading to the 
dangerous action of emptying the content of the dose-dispensing aid into regular pill bottles 32,146,151,152. 
The other concern was about the patients loosing contact to health-care professionals and a fading 
knowledge of medication. The authors feared a loss of skills and autonomy of the patients, which could 
limit the safe administration of their medication 152-154. However, despite declined knowledge of 
patients using pre-packed dose-dispensing aids, their adherence appeared to be better than patients 
self-managing their medication 154. In fact, adverse events of dose-dispensing aids resulting in harm for 
the patients have never been studied in randomized controlled trials 147, representing a security gap.  
Prior systematic literature reviews have investigated the impact of dose-dispensing aids on adherence 
and economic, clinical and humanistic outcomes. They univocally stated a moderate effect of dose-
dispensing aids on adherence and clinical outcomes, but declared the evidence to be insufficient to 
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draw firm conclusions 147,155,156 (detailed information is provided in Chapter 2). One retrospective 
propensity score matched study including 9’266 patients in the ‘real-world’ setting reported 
significantly improved adherence and persistence rates with a single-pill combination in reminder 
packaging.  
In this thesis, we focused on multidrug punch cards to optimize medication use by support of the 
patient’s medication self-management and thus to reach appropriate polypharmacy. 
Multidrug punch cards 
In Switzerland, multidrug punch cards represent one possibility for a dose-dispensing service. The 
devices are filled and dispensed at the community pharmacy. A specific software assists the production 
by archiving patient data, documenting prescriptions, verifying the medication filled through barcode 
scanning, and by composing data from the database to a label that is fixed on the card (Figure 8) 157. 
Health insurances are obliged to reimburse this dose-dispensing service with CHF 21.60 per week, if 
the patient has a prescription for over three different medications per week and for a dose-dispensing 
aid (according to the collective agreement LOA IV 158). Multidrug punch cards as a single or as an 
element of a composite intervention significantly improved adherence 49,159,160 and clinical outcomes 
49,160,161. Additionally, they are assumed to promote interdisciplinary collaboration, since the 
medication plan is actively managed by the pharmacist and drug related problems can be solved 
instantly. Continuity of care, which is known to improve medication safety and adherence, is given by 
the provision of the all medication through the same community pharmacy 37,162. To date, studies on 
multidrug punch cards used mainly pill count for adherence measurement. With the availability of 
POEMS, which can be affixed on the back of a multidrug punch card, it becomes possible to measure 
adherence to polypharmacy electronically.  
In this thesis, we focused on (electronic) multidrug punch cards as an adherence-enhancing 
intervention to improve patient-relevant outcomes in primary care patients with polypharmacy. 
Rationale and approach 
The global health situation demands polypharmacy for many clinical conditions, especially in 
multimorbid patients. Within the momentary demographic changes, many patients are concerned 
with polypharmacy, which constitutes a considerable risk factor for non-adherence. Non-adherence 
has been of increasing concern because it impairs clinical conditions and quality of life, and it generates 
exceeding healthcare costs. Despite numerous tested interventions, evidence has been limited 
through methodological flaws, heterogeneity of outcome measures, and lack of patient-relevant 
outcomes. Dose-dispensing aids, like multidrug punch cards, were designated elements of successful 
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adherence interventions. They aim at enhancing adherence through optimization of medication self-
management in unintentionally non-adherent patients with polypharmacy.  
The goal of this thesis was to investigate the effect of multidrug punch card use on adherence to 
polypharmacy and patient-relevant outcomes in primary care patients. We approached this goal in 
three steps. 
In a first step (A), we used the methodology of evidence mapping to provide an overview on a whole 
topic area and to identify evidence gaps. We used a tool 163 appraising methodological quality 
specifically designed for public health studies of various study designs. Further, we aimed at extending 
the information of the evidence by assessing the completeness of reporting of intervention details 
(PROJECT A1). 
In a second step (B), a real life picture of current pharmacy practice in adherence support and of 
primary care patients using multidrug punch cards in daily life was aspired. Pharmaceutical care 
interventions delivered at community pharmacies have been successful in improvement of adherence. 
PROJECT B1 aimed at quantifying and qualifying patient-centered counseling, especially explicit 
adherence counseling, in daily pharmacy practice. Adherence-enhancing interventions were claimed 
to be simple, easy to use, continuous, inexpensive, and implementable in clinical practice. Multidrug 
punch cards are suggested to suffice these requirements. They were introduced in Switzerland in 2002 
as a dose-dispensing service provided by community pharmacies. With PROJECT B2, we intended to 
evaluate integration of multidrug punch cards into community pharmacy practice. Multidrug punch 
cards are suggested to optimize medication self-management in unintentionally non-adherent 
patients. Little is known about the characteristics, preferences, and experiences of primary patients 
using multidrug punch cards in daily life. Lately, concerns about handling difficulties and fading 
medication knowledge have been expressed and warn from a wide spread distribution of such aids. 
Hence, PROJECT B3 aimed at the exploration of current multidrug punch card user in Swiss primary care. 
In a third step (C), we affixed POlypharmacy Electronic Monitoring System foils on multidrug punch 
cards to measure adherence to polypharmacy and to give feedback on adherence behavior. Having the 
research gaps identified in PROJECT A1 and the results of PROJECTS B1, B2 and B3 in mind, we aimed at 
developing and piloting a randomized controlled trial investigating the intervention of electronic 
multidrug punch card use for all oral solid medication and individualized feedback sessions on 
electronic dosing histories on adherence and patient-relevant outcomes (PROJECTS C1 and C2). The 
described steps and projects with corresponding objectives are listed below. 
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A EVIDENCE MAP OF DOSE-DISPENSING AIDS 
PROJECT A1: EFFECT OF DRUG REMINDER PACKAGING ON MEDICATION ADHERENCE: A SYSTEMATIC REVIEW 
REVEALING RESEARCH GAPS 
To review and map the evidence of dose-dispensing aids in improving adherence and 
economic, clinical, and humanist outcomes; to identify research gaps providing a 
rationale for future research. 
B ADHERENCE SUPPORT IN CURRENT PHARMACY PRACTICE AND MULTIDRUG PUNCH CARD USE BY PRIMARY CARE PATIENTS 
PROJECT B1: ADHERENCE COUNSELING DURING PATIENT CONTACTS IN SWISS COMMUNITY PHARMACIES 
To determine the degree and nature of counseling delivered at community 
pharmacies, focusing on adherence counseling; to assess the community pharmacists’ 
opinions about adherence counseling. 
PROJECT B2:  FIRST EVALUATION OF PHARMIS® BLISTER PACKAGING PROVIDED BY PHARMACIES IN SWITZERLAND 
To explore the integration of multidrug punch card service in contemporary 
community pharmacy practice, assessing experiences, benefits, and expenditures. 
PROJECT B3: MULTIDRUG PUNCH CARDS IN PRIMARY CARE: A MIXED METHODS STUDY ON PATIENTS’ PREFERENCES 
AND IMPACT ON ADHERENCE 
To assess the acceptance, preferences, and experiences of multidrug punch card users 
in primary care and the device’s impact on adherence; to profile the primary care 
patient benefitting most of multidrug punch card use and thus to facilitate targeted 
adherence interventions. 
C EFFECTIVENESS OF MULTIDRUG PUNCH CARD USE IN PRIMARY CARE PATIENTS – A PILOT STUDY 
PROJECT C1:  ELECTRONIC MULTIDRUG PUNCH CARDS TO IMPROVE CLINICAL AND HUMANISTIC OUTCOMES IN 
PATIENTS AFTER HOSPITAL DISCHARGE 
To develop and pilot a randomized controlled trial investigating the effectiveness of 
electronic multidrug punch cards and feedback on electronic dosing histories in 
improving adherence and in extending time to hospital readmission and major therapy 
adjustment in primary care patients after hospital discharge. 
PROJECT C2:  SUCCESS OF A SUSTAINED PHARMACEUTICAL CARE SERVICE WITH ELECTRONIC ADHERENCE 
MONITORING IN A DIABETIC PATIENT OVER 12 MONTHS 
To report in detail of the first long-term electronic monitoring of adherence to 
polypharmacy. 
 
Clarification of terms: Due to the absence of generally accepted terms, different synonyms were used in: 
 PROJECT A1: ‘drug reminder packaging’ was used instead of ‘dose-dispensing aids’. The term ‘humanistic 
outcomes’ refers to the definition given by Kozma et al. 174: “Consequences of disease or treatment on 
patient functional status or quality of life measured along several dimensions”, e.g., physical function. 
 PROJECT B2: ‘Pharmis® blister’ was used instead of ‘multidrug punch card’. ‘Ambulatory patient(s)’ was used 
instead of ‘primary care patient(s)’. 
 PROJECT C2: ‘electronic records‘ was used for the electronic dosing history generated by POlypharmacy 
Electronic Monitoring System (POEMS). 
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Abstract 
Background: This was a systematic review of the literature in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Evidence mapping was used to 
reveal the effect of drug reminder packaging on medication adherence, to identify research gaps and 
to make suggestions for future research. 
Methods: PubMed, Embase, CINAHL and PsycINFO were searched with an end date of September 2013 
using the Medical Subject Headings (MeSH) term ‘medication adherence’ and 20 different search 
terms for ‘drug reminder packaging’, limited to the English and German languages. Additional 
references were identified through cross-referencing. All prospective controlled trials with an 
intervention using drug reminder packaging for patients taking at least one medication without the 
assistance of a health-care professional were included in the evidence mapping of the effect of drug 
reminder packaging on adherence and outcomes according to the Economic, Clinical and Humanistic 
Outcomes (ECHO) model. 
Results: A total of 30 studies met the inclusion criteria: 10 randomized controlled trials, 19 controlled 
clinical trials and 1 cohort study. Drug reminder packaging had a significant effect on at least one 
adherence parameter in 17 studies (57%). The methodological quality was strong in five studies. Two 
studies provided complete information. Clear research gaps emerged. 
Conclusions: Overall, the studies showed a positive effect of drug reminder packaging on adherence 
and clinical outcomes. However, poor reporting and important gaps like missing humanistic and 
economic outcomes and neglected safety issues limit the drawing of firm conclusions. Suggestions are 
made for future research. 
 
Keywords: medication adherence, patient compliance, polypharmacy, drug reminder packaging, 
multicompartment adherence aid, pillbox, multidrug punch card, blister pouch, dose-dispensing service. 
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Background 
Adherence is defined as the extent to which a patient’s behavior matches the agreed 
recommendations from the prescriber 37. Reported rates vary from 4.6% to 100% of patients of all age 
classes with different medical conditions and on long- or short-term treatments 37,90. Mean adherence 
rates for specific diseases are 88.3% for HIV infection, 76.6% for cardiovascular disease, 67.5% for 
diabetes mellitus and 58% for psychosis patients 90,164. Adherence depends on patients’ capability (e.g., 
physical, cognitive and economic) and willingness to initiate and execute their treatment plan: if either 
is insufficient, unintentional or intentional non-adherence will be the consequence 65,165. Non-
adherence is known to impair clinical, economic and humanistic  outcomes 12,83,103,105,125,166,167 (the 
meaning of ‘humanistic outcomes’ is declared in ‘clarification of terms’, p. 42). In a study across five 
European countries, increasing the percentage of patients adhering to antihypertensive treatment to 
70% was estimated to lead to a reduction of cardiovascular related health-care costs by €332 million 
($461 million) 123. Reasons for non-adherence are highly individual and complex. Therefore, individual 
needs and necessities have to be assessed to find the optimal aid for each patient.  
Drug reminder packaging, such as weekly pillboxes or multidrug punch cards, is widely used in everyday 
practice. It usually consists of a certain number of compartments containing solid oral medication for 
specific dosing times. Compared to other adherence-enhancing programs, such as patient counseling, 
education or motivation 126, drug reminder packaging is a simple technical option and requires little 
resources on the patient’s as well as on the provider’s side. The provision of drug reminder packaging 
aims at enhancing adherence by facilitating medication organization and intake, by decreasing 
medication errors and by (self-) monitoring medication intake. Various authors suggest that drug 
reminder packaging supports mainly unintentionally non-adherent patients, e.g., geriatric patients and 
patients with complex drug regimens 62,65,145,146. Previous reviews with restrictive inclusion criteria 
investigated the effect of reminder packaging on adherence and were inconclusive 147,155,156. This 
review uses evidence mapping 168,169 to analyze data from a different perspective, highlighting 
methodological strength and completeness of information as well as research gaps, to identify areas 
for future research. 
Methods 
A systematic review was conducted, complying with the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) statement. We proceeded by following the evidence mapping 
methodology in four steps: question development, question prioritization, evidence search and 
selection, and data extraction 168. 
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Question development and prioritization 
The study question was deduced from previous reviews. An evidence report was composed after a 
preliminary literature search. Keywords were defined based on the results of this search. Experts were 
consulted to prioritize the question. 
Literature search 
PubMed, Embase, CINAHL and PsycINFO were searched for articles published up until September 2013. 
The keywords used in the search strategy were the Medical Subject Headings (MeSH) term ‘medication 
adherence’ and 20 different terms for ‘drug reminder packaging’: unit dose*, reminder pack*, unit of 
use pack*, pill organiser, pill organizer, medication packaging, medication container, pill container, pill 
box, pillbox, pill calendar, calendar pack*, calendar blister pack*, doset*, dosset*, blister pack*, pill 
pack*, special packaging AND medication, drug pack*, webster pack. The search was restricted to the 
English and German languages. Abstracts were screened and full text articles of potential hits were 
retrieved. References of retrieved articles were screened for relevant cross-referenced articles. 
Study selection and data extraction 
The full text of potentially relevant articles was reviewed. Inclusion criteria were any prospective 
controlled study design, with at least one outcome being adherence, economic, clinical or humanistic, 
with drug reminder packaging as an intervention in any adherence-enhancing program, for patients 
taking one or more oral medication (prescribed or over-the-counter) without the help of a health-care 
professional. Trials were excluded if they were performed in developing countries or if they used drug 
reminder packaging with incorporated electronic features (e.g., the Medical Event Monitoring System). 
Drug reminder packaging included reusable multicompartment adherence aids (plastic pillboxes with 
several compartments per day or per week filled by the patient or pharmacy staff ), non-reusable 
multidrug punch cards (frame cards with plastic cavities, sealed with a foil backing, with typically 28 
compartments, filled by pharmacy staff, by a specialized company or an automated system) and non-
reusable unit-of-use packaging (e.g., blister pouches attached to form flexible chains, with an 
unrestricted number of separated daily dosing times, filled by automated systems) 77. 
Data extracted included the author, publication year, study design, duration of the intervention and 
follow-up, description of the participants (e.g., age, clinical conditions and number of medications), 
outcomes, method of adherence measurement, type of drug reminder packaging and additional 
interventions. The literature selection and analysis of methodological issues were performed 
independently by two reviewers. Consensus regarding the results was reached by discussion. 
Methodological quality and completeness of information  
The methodological quality of the studies was assessed using the tool for quantitative studies 
developed for public health topics by the Effective Public Health Practice Project (EPHPP) group 163. In 
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brief, the tool is applicable to a variety of study designs other than randomized controlled trials (RCTs), 
such as pre- and post-cohort studies and case-control studies, and it has been validated 170. It assesses 
eight components: (1) selection bias, (2) study design, (3) confounders, (4) blinding, (5) data collection 
method, (6) withdrawals and dropouts, (7) intervention integrity and (8) analysis. Components 1 to 6 
were rated as strong, moderate or weak. Based on the rating of the components, studies were 
described as of weak, moderate or strong methodological quality 163,171. The tool was adapted to the 
review question. The component ‘(4) blinding’ was not assessed because it is not applicable in studies 
investigating adherence with drug reminder packaging. The rating of criterion ‘(5) data collection 
method’ focused on adherence outcomes 65. Data collection was considered ‘valid and reliable’: (a) if 
the calculation of the medication possession ratio, the calculation of the medication refill frequency, 
therapeutic drug monitoring or a validated questionnaire were applied as a single method; (b) if pill 
count or clinical parameters were combined with at least one additional adherence measurement 
method (e.g., therapeutic drug monitoring) and (c) if appointment keeping was combined with at least 
two additional adherence measurement methods. 
Following the recommendations of the CONSORT (Consolidated Standards of Reporting Trials) 
statements for non-pharmacological treatment 172 and the Cochrane Handbook 173, eight additional 
criteria were selected to assess completeness of information (Table 1). One point was accredited per 
reported criterion. ‘Completeness of information’ was defined as the sum of the points divided by 
eight, resulting in rates from 0 (no item on completeness of information available) to 1 (all items on 
completeness of information available). The packaging was defined as ‘described’ if the design (daily, 
weekly or monthly) and the number of cavities were reported. Criteria 7 and 8, concerning medication 
not packed in the drug reminder packaging, were not applicable if it was stated that all medication was 
packed into a drug reminder packaging device. Results were calculated according to the adjusted 
denominator. 
 
Table 1. List of additional criteria for completeness of information. 
Each available criterion is accredited with 1 point; completeness of information is calculated as the sum of the points 
divided by the number of all applicable criteria. 
1 Description of drug reminder packaging 
2 Description of medication packaging of the control group 
3 Description of intervention conditions 
4 Description of control conditions 
5 Description of all medication used in both groups 
6 Specification of all medication packed in the drug reminder packaging  
7 Specification of medication not packed in the drug reminder packaging 
8 Handling of medication not packed in the drug reminder packaging 
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Outcomes 
Any measurement estimating taking adherence (i.e., an indicator of taken medication) was extracted 
as an adherence outcome. The Economic, Clinical and Humanistic Outcomes (ECHO) model 174 was 
used to classify further study outcomes. Therapeutic drug monitoring, biomarker and physiological 
measurements were categorized as clinical outcomes, unless they were part of a composite adherence 
outcome. A listing of costs was considered as an economic intermediary outcome if compared between 
groups. Patient surveys on handling, opinion or satisfaction with drug reminder packaging were 
considered as humanistic intermediary outcomes if comparison between groups was given. 
Results 
Of the total 855 identified references, 30 fulfilled the inclusion criteria. The PRISMA flow diagram of 
study inclusion and the PRISMA checklist are provided in Additional files 1 and 2, respectively 
(supplementary material). According to the EPHPP assessment tool for study design, 10 studies were 
RCTs, 19 controlled clinical trials and 1 was a cohort study (one group with a pre- and post-intervention 
comparison). Compared to the previously published reviews 147,155,156, a total of 13 studies were 
additionally included, from which 7 were controlled clinical trials, 5 RCTs and 1 was a cohort study.  
Overall, the mean number of participants was 191 (range 14 to 2,081 participants). They were on 
average 62 years old (range 38 to 87 years, not described (n.d.) in five studies), took an average of 3.9 
medications (range 1 to 9 medications, n.d. in 12 studies) and were treated for hypertension (7), 
diabetes mellitus type 2 (3), geriatric conditions (3), Helicobacter pylori infection (2), HIV (2), vitamin 
supplementation (2), chronic mental illness (2), hypercholesterolemia (1), epilepsy (1), pain relief in 
cancer patients (1), anticoagulation (1), and Chlamydia infection (1). Medical conditions were not 
described in six studies of mainly elderly multimorbid patients. The mean study duration was 5.4 
months (range 7 days to 14 months, n.d. in three studies). Table 2 is a summary of the studies (attached 
at the end of the article). 
Effect on adherence 
Considerable variation exists between studies regarding definitions, measures and calculations of 
adherence. Taking adherence was estimated in 27 studies (90%). Pill count (15 studies) and patient 
self-report (12 of which 1 was electronic) were the most used measures. Other methods included refill 
data (6), therapeutic drug monitoring (5), appointment keeping (2) and clinical measures (2). Eleven 
studies used composite adherence measures. The calculation of adherence was unclear in three 
studies 151,175,176.  
A significant effect of drug reminder packaging was reported in 17 studies and concerned at least one 
of the measured adherence parameters. Six of these 17 studies were not incorporated in the previous 
reviews (Table 2).  
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Twelve studies reported significant adherence improvement in the group with drug reminder 
packaging as part of a multiple intervention strategy 49,159,176-185. The effect on adherence was also 
significant when drug reminder packaging was a single intervention 160,182-189; however, it was less 
pronounced in direct comparison with multiple interventions 182-185. 
Methodological quality and completeness of information  
Methodological quality was rated as strong for 5 studies, moderate for 12 and weak for 13. Overall, 
weaknesses were in the methods used for data collection (mostly not valid and not reliable) and the 
report of confounders and their comparison between groups (insufficient or missing). The most 
accurate standard in statistical analysis, the intention-to-treat analysis, was applied by seven studies. 
The number of studies with strong and moderate methodological quality doubled after 1996, the year 
of the first publication of the CONSORT statements 190, while the number of weak methodological 
quality studies diminished by a factor of 3. 
Completeness of information ranged from 0 to 1.0 with a mean score of 0.3. Two studies 49,185 gave 
complete information for all required details. Reported criteria for the completeness of information 
are depicted in Figure 1. Criteria 7 and 8 were not applicable for 5 studies 49,159,183-185 and practically 
non-existent in all 25 remaining studies (criterion 7: 0; criterion 8: 1). Information on the person in 
charge and place of intervention were often missing from the description of the intervention and 
control conditions. Figure 2 shows the included studies according to their methodological quality, 
completeness of information and outcome measures. 
 
Figure 1: Distribution of the eight criteria defined for the completeness of information (n = 30 studies). 
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Figure 2: Consolidation of results of outcomes, methodological quality and completeness of information. Each 
box represents one study numbered as in Table 2, plotted in a segment of reported outcome(s) and at a height 
based on its methodological quality. Completeness of information is indicated by the size of the box, with 
values between 0 (e.g., study no. 21) and 1 (e.g., study no. 12). Bold frames are for the additionally included 
studies compared to previously published reviews 147,155,156. No filling indicates at least one outcome was 
statistically significant and shading indicates none of the outcomes were statistically significant. A, adherence; 
C, clinical outcome; E, economic outcome; H, humanistic outcome. 
 
Outcomes 
Two studies assessed direct costs as intermediary economic outcomes 183,184 and there was a significant 
increase in prescription costs. However, a cost-effectiveness analysis that would qualify as an 
economic outcome according to the ECHO model was not reported. 
Clinical outcomes were measured in 16 studies using one or several parameters: blood pressure (6), 
glycosylated hemoglobin (HbA1C) (2), psychiatric symptoms (2), low-density lipoprotein cholesterol 
(LDL-C) levels (1), pain reduction (1), number of seizures (1), plasma levels of anticonvulsant drugs (1), 
viral load (1), CD4 cell count (1), number of opportunistic infections (1), hospitalizations (1), 
percentages of sub-therapeutic international normalized ratio (INR) values (1), time within the 
therapeutic INR range (1) and 13C-urea breath test (1). 
Of these 16 studies, 7 were not incorporated in the previous reviews. Five of the seven additional 
studies showed a statistically significant effect 49,175,188,191,192. In one study, LDL-C levels and blood 
pressure were significantly reduced after eight months compared to the baseline for patients using 
drug reminder packaging (LDL-C: −4.8 mg/dl, P = 0.001; systolic blood pressure: −6.9 mmHg, P = 0.005; 
diastolic blood pressure: −2.5 mmHg, P = 0.04) 49. In a study with diabetes mellitus type 2 patients, 
HbA1C was significantly reduced (−0.74%, P < 0.0001) and patients who took ≥5 tablets/day, ≥3 
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hypoglycemic drugs/day and were <55 years old had the largest benefit from drug reminder packaging 
191. In other studies, pain reduction was effective in cancer patients (P < 0.0001) 192, the number of 
opportunistic infections and hospitalizations decreased significantly in HIV patients (P < 0.05) 188, the 
percentages of sub-therapeutic INR values with oral anticoagulation (warfarin) decreased (P = 0.04) 
and time within the therapeutic INR range increased significantly (P = 0.03) 175. Of the ten studies with 
multiple adherence-enhancing strategies in the intervention group, six showed significantly improved 
clinical outcomes 49,175,181,182,192,193. The clinical outcomes of all studies are presented in Table 2. 
Two studies reported humanistic outcomes 159,161. The usability of drug reminder packaging was rated 
significantly higher than the usability of usual packaging 161. Safety issues related to the intervention 
were addressed by two studies 159,181. 
Clear gaps emerged from the overall results. Aside from methodological weaknesses (under-reporting 
of quality issues) and incomplete information (under-reporting of control settings and specification of 
medication), economic outcomes (cost-effectiveness), humanistic outcomes and safety issues are 
lacking. 
Discussion 
Although more than half of the studies included in this review reported significant effects, only three 
studies were graded as methodologically strong. Drug reminder packaging had a significant effect on 
adherence in a geriatric population 177, for chronic mental illness 178 and for cardiovascular disease 49. 
The overall effect of drug reminder packaging on adherence parameters remains inconclusive, as 
reported by previous reviews with more restrictive selection criteria 147,155,156. Three studies reported 
a significant effect on adherence but not on clinical outcomes 159,178,182. Thus, the question of how much 
adherence is necessary for altering treatment success is raised and there is a requirement to present 
the clinical benefits for the patients 194. We observed that drug reminder packaging offers a broad field 
of application and is mostly used for polypharmacy. As a consequence, disease-unspecific, 
generalizable clinical outcomes like morbidity or re-hospitalization rates would provide viable and 
comparable results rather than measures of disease-specific clinical parameters. Only two trials 
investigated such outcomes 188,195, with one showing that drug reminder packaging significantly 
reduced the mean hospitalization rate. 
We included five RCTs in the evidence map that were excluded by three previous reviews 147,155,156 
because of their multiple intervention design. In a direct comparison (factorial trials), the effect was 
higher with multiple interventions, which is consistent with previous findings 126,155. Yet, the evidence 
is limited, for these trials were graded as weak in methodological quality. 
53: PROJECT A1 | Effect of drug reminder packaging on medication adherence: a systematic review revealing research gaps Discussion 
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
The overall methodological quality of the studies included is poor and thus evidence for the effect of 
drug reminder packaging on adherence is low. We used a quality assessment tool that is applicable to 
a variety of study designs and was specifically developed to provide research evidence for studies on 
public health services with a focus on behavior change education 163. In comparison to previous 
reviews, we were able to include four additional studies of strong methodological quality 49,177,191,196. 
However, information on intervention and control settings was incomplete in three of these additional 
studies (completeness scores: 0.13, n = 2; 0.25, n = 1). As a consequence, being graded as strong and 
complying with all the criteria for completeness of information was observed in one out of the 30 
studies included 49. It therefore represents a thin basis for informed clinical decision support. 
The increasing number of methodologically strong trials after 1996, the year when the CONSORT 
statements were released, is intriguing and probably follows from under-reporting in studies published 
before 1996. Various authors indeed stated that complete reporting of methodological quality 
according to the CONSORT criteria was inadequate, but that poor reporting did not necessarily 
correlate with the quality of how the trial was conducted 197-200. The CONSORT statements of non-
pharmacological treatment require ‘precise details of both, the experimental treatment and the 
comparator’ 172 and omission of trial details has been shown to lead to decreased uptake of trial results 
into clinical practice 201,202. Thus, to obtain valuable and reliable study results, high methodological 
quality and detailed information are crucial. 
Most studies were designed as RCTs, which provide the most reliable results through the minimization 
of confounding. However, RCTs might not be the appropriate design for all research questions and 
settings, especially in the field of behavior research. Alternative designs might be worth considering. 
Firstly, randomized allocation of study participants to a predefined intervention may not be practicable 
since tailored interventions, in respect of patients’ needs and abilities, are expected to be the most 
effective 126. Secondly, in studies on survival outcomes for HIV patients, investigating adherence-
enhancing strategies in a randomized controlled fashion has been declared to be ethically difficult 
203,204. The reason for this declaration was the assumption that allocation to the control condition 
equaled withholding a tool, which could possibly lead to higher survival rates through an optimal 
clinical response due to increased adherence 203,204. Thirdly, behavioral interventions are often complex 
and can only be controlled poorly under real-life conditions and therefore randomization might not be 
practical in a primary care setting 205. Consequently, confounding could even persist despite 
randomization. Alternatives to conventional randomization designs, i.e., randomization at the patient 
level, include pre- and post-cohort studies, historical control studies, pre-randomized designs and 
cluster randomization 206. 
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More studies could be included and research gaps identified using our approach of evidence mapping. 
Patient-relevant disease-unspecific long-term clinical outcomes, e.g., (re-)hospitalization, admission to 
a nursing home, etc., were neglected. Economic outcomes as defined by Kozma et al. 174 were not 
reported in any study on drug reminder packaging. This may be due to the fact that drug reminder 
packaging is generally supposed to be inexpensive, and thus cost-effective. Humanistic outcomes were 
measured in two studies 159,161, which is insufficient for judging whether a condition optimally treated 
through drug reminder packaging leads to increased quality of life. Improved adherence could lead to 
increased adverse events as well. However, safety issues were reported by two studies only 159,181. 
Patient satisfaction and other aspects of safety, such as opening medication packaging, confusion with 
new packaging and decreased ability to identify one’s own medication 148,153,207,208, were hardly 
mentioned by the studies. 
Our study has strengths. First, evidence mapping allows the inclusion of more studies and gives an 
overall view of the subject. Second, the tool used to assess methodological quality is independent of 
study design (EPHPP) and was developed specifically to assess studies within the scope of public health. 
Third, with completeness of information, a further element for judging quality is added. Fourth, the 
consolidation of adherence outcomes and economic, clinical and humanistic parameters allows an 
overall presentation and highlights research gaps. Our study has limitations also, such as the language 
restriction, which led to the exclusion of articles considered relevant. Information may also have been 
missed due to the exclusion of studies performed in developing countries. 
A suggestion for future research is to develop methodologically strong studies reporting complete 
information to clarify the effect of drug reminder packaging on medication adherence. 
Conclusions 
New information was extracted from the 30 studies included and several studies had statistically 
significant and relevant results for adherence and clinical outcomes with drug reminder packaging. 
However, firm conclusions cannot be given for the effect of drug reminder packaging on adherence, 
mainly because the studies lack methodological quality and the information was incomplete. The main 
research gaps concerned economic, disease-unspecific clinical outcomes and humanistic outcomes. 
Safety issues and satisfaction with the intervention were marginally reported. Researchers of 
behavioral interventions might consider alternative study designs for similar research questions, 
without neglecting methodological issues and reporting important details. Future research should aim 
at filling the observed gaps with a focus on patient safety and the benefit to patients as well as on 
implementable and valuable interventions. Drug reminder packaging should be distributed with 
respect to patient needs, requests and abilities. 
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Table 2 
 
Table 2. Summary of the 30 included studies. 
No Author Design n Duration Intervention 
Drug reminder 
packaging 
Outcomes Effect 
Methodologica
l Quality 
Compl. of 
Information 
1 Ascione 177 
(1984) 
cct 158 n.d. Drug reminder packaging, 
counseling 
n.d. A: Self-report*: Unclear Strong 0.13 
2 Azrin 178 (1998) cct 39 2m a. Drug reminder packaging, 
counseling with family 
member vs.  
b. Drug reminder packaging, 
counseling vs.  
c. Psychoeducational 
condition 
Multicompartment 
adherence aid 
A: Pill count*: 
 
a. vs. baseline: 95.03 vs. 76.24 
(p<0.05, Ø CI) 
b. vs. baseline : 92.01 vs. 69.52 
(p<0.01, Ø CI) 
c. vs. baseline: n.s. 
Strong 0.13 
C: Symptoms Checklist 90-R: n.s. 
3 Becker 209 
(1985) 
cct 180 12m Drug reminder packaging Multidrug punch 
card 
A: Pill count, self-report, 
self-report + bp: 
n.s. Moderate 0.38 
C: Bp: n.s. 
4 Binstock 193 
(1988) 
cct 112 12m a. Counseling vs.  
b. Drug reminder packaging, 
counseling vs. 
c. Drug reminder packaging, 
counseling, other aids vs.  
other interventions 
n.d. A: Self-report: a., b., c.: n.s. Weak 0.25 
C: sbp*, dbp*: b. vs. a.: 133/80mmHg vs. 
148/89mmHg (p<0.01, Ø CI) 
c. vs. a.: 134/84mmHg vs. 
148/89mm Hg (p<0.01, Ø CI) 
b. vs. c.: n.s. 
5 Crome 210 
(1980) 
cct 26 10d Drug reminder packaging Multicompartment 
adherence aid 
A: Pill count: n.s. Weak 0.25 
6 Crome 211 
(1982) 
cct 78 4w Drug reminder packaging Multidrug punch 
card 
A: Pill count: n.s. Weak 0.25 
7 Eshelman 
186(1976) 
cct 100 n.d. Drug reminder packaging n.d. A: TDM*: “Adherent” patients: 97% vs. 
69% (p<0.05, Ø CI) 
Moderate 0.13 
Pill count: n.s. 
Self-report: Unclear 
8 Fairley 179 
(2003) 
rct 43 5m Drug reminder packaging, 
counseling, other aids 
Multicompartment 
adherence aid 
A: Self-report*: Total Morisky-Score: 3.3 vs. 
2.9 (p=0.006, Ø CI) 
Moderate 0.13 
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Table 2. Summary of the 30 included studies. 
No Author Design n Duration Intervention 
Drug reminder 
packaging 
Outcomes Effect 
Methodologica
l Quality 
Compl. of 
Information 
Rate of patients with a 
Morisky-Score of 0: 29% vs. 
49% (p=0.04, Ø CI) 
C: CD4-cell count, viral load: n.s. 
9 Henry 196 
(1999) 
cct 119 10d Drug reminder packaging, 
counseling, other aids 
Multidrug punch 
card 
A: Pill count + self-report: n.s. Strong 0.25 
C: 13C-UBT: n.s. 
10 Huang (TRACE) 
187 (2000) 
rct 184 2m Drug reminder packaging Multicompartment 
adherence aid 
A: Pill count, self-report, 
TDM: 
n.s. Moderate 0.38 
11 Huang (VITAL) 
187 (2000) 
cct 297 Unclear Drug reminder packaging 
(multidrug punch card vs. 
multicompartment) 
 
Multidrug punch 
card, 
Multicompartment 
adherence aid  
A: Pill count*: Patients who took >90% of 
pills taken: 93% vs. 87% 
(p=0.05, Ø CI) 
Moderate 0.38 
Self-report*: 
 
Positive answer to question 
‘forgot to take pills’: 21% vs. 
31% (p=0.05, Ø CI);  
self-report total score n.s. 
TDM: n.s. 
12 Lee JK 49 (2006) rct 200 14m Drug reminder packaging, 
counseling, regular follow-
up 
Multidrug punch 
card 
A: Pill count*: 95.5 vs. 69.1 (p<0.001, Ø CI) Strong 1.0 
C: sbp*: Drug reminder packaging vs. 
baseline: -6.9mmHg (p=0.005, 
CI -10.7- (-3.1) mm Hg) 
dbp*: 
 
Drug reminder packaging vs. 
baseline: -2.5 mm Hg (p=0.04, 
CI -4.9-(-0.2) mm Hg) 
LDL-C*: Drug reminder packaging vs. 
baseline at 8m: - 4.8mg/dl 
(p=0.001, CI -7.8-(-1.9) mg/l) 
Drug reminder packaging vs. 
baseline at 14m: n.s. 
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Table 2. Summary of the 30 included studies. 
No Author Design n Duration Intervention 
Drug reminder 
packaging 
Outcomes Effect 
Methodologica
l Quality 
Compl. of 
Information 
13 Lee M 180 
(1999) 
rct 125 14d Drug reminder packaging, 
counseling, other aids 
Multicompartment 
adherence aid 
A: Pill count*: ITT1 (patients unavailable for 
follow-up took 100% [cg] resp. 
0% [ig] of drugs):  
No. of patients with >60% of 
pills taken: n.s. 
Patients with > 90% of pills 
taken: 87% vs. 71% (p<0.05, Ø 
CI) 
ITT2 (patients unavailable for 
follow-up took 0% [cg + ig] of 
drugs):  
Patients with >60% of pills 
taken: 94% vs. 78% (p<0.05, Ø 
CI) 
Patients with > 90% of pills 
taken: 87% vs. 59% (p<0.01, Ø 
CI) 
Weak 0.25 
14 MacDonald 151 
(1977) 
rct 165 3m Drug reminder packaging, 
counseling 
Multicompartment 
adherence aid 
A: Unclear - Weak 0.25 
15 Maier 191 
(2005) 
rct 2081 6m Drug reminder packaging Multicompartment 
adherence aid 
C: HbA1C*: - 0.74% vs. -0.53% (p<0.0001, 
Ø CI) 
Strong 0.13 
16 McPherson-
Baker 188 (2000) 
cct 42 5m Drug reminder packaging Multicompartment 
adherence aid 
A: MRC*: 75.8% vs. 39.3% (Ø p, CI) 
Drug reminder packaging vs. 
baseline: 75.8% vs. 46.8% 
(p<0.01, Ø CI) 
Weak 0.13 
Appointment keeping*: 
 
76.1% vs. 73.3% (Ø p, CI) 
Drug reminder packaging vs. 
baseline: 76.1% vs.56.7% 
(p<0.05, Ø CI) 
C: (here as proxies for 
adherence) 
 
Mean hospitalizations*: 0.33 vs. 1.04 (p<0.05, Ø CI) 
Opportunistic infections*: Reduction with increased 
medication intake (Ø numbers 
given, p<0.05, Ø CI) 
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Table 2. Summary of the 30 included studies. 
No Author Design n Duration Intervention 
Drug reminder 
packaging 
Outcomes Effect 
Methodologica
l Quality 
Compl. of 
Information 
17 Miaskowsky 192 
(2004) 
cct 174 6w Drug reminder packaging, 
counseling, other aids 
Multicompartment 
adherence aid 
C: Pain reduction*: Relieve in average, worst and 
least pain: Ø numbers given, 
(p<0.0001, Ø CI) 
Moderate 0.25 
Appropriate prescriptions*: 
 
Patients with appropriate 
opioid analgesic prescriptions 
vs. baseline: 37.0% vs. 28.3% 
(p=0.008, Ø CI) 
Change in total amount 
opioids prescribed and 
taken: 
Prescribed: Ø numbers given, 
(p<0.0001, Ø CI) 
Taken: Ø numbers given, 
(p<0.001, Ø CI) 
18 Murray 189 
(1993) 
cct 36 6m Drug reminder packaging Unit-of-use 
packaging 
A: Pill count*: 
Self-report: 
92.6 vs. 79 (p<0.0001, Ø CI) 
No. of pat reporting all 
medication taken: 9 vs. 8 (Ø p, 
CI) 
Weak 0.38 
19 Nochowitz 175 
(2009) 
pre-, 
post-
cohort 
14 3m Drug reminder packaging, 
other aids 
Multicompartment 
adherence aid 
A: Pill count (+/- self-report 
if pills were not available): 
n.s. Moderate 0.38 
C: INR*: Sub-therapeutic INR values 
(<2) vs. baseline: 35% vs. 60% 
(p=0.04, Ø CI) 
Time spent in therapeutic 
range vs. baseline: 56% vs. 
32% (p=0.03, Ø CI) 
20 Park 212 (1992) cct 61 2w Drug reminder packaging ± 
organizing chart, factorial 
Multicompartment 
adherence aid 
A: Electronic self-report: Unclear Weak 0.13 
21 Peterson 181 
(1984) 
rct 53 4m Drug reminder packaging, 
counseling, other aids 
Multicompartment 
adherence aid 
A: MRF*:  “Adherent” patients: 88% vs. 
50% (p<0.01, Ø CI) 
Moderate 0 
TDM*: 
 
Patients within therapeutic 
range vs. baseline: 88% vs. 
48% (p<0.005, Ø CI) 
Appointment keeping: n.s. 
C: Seizure frequency*: Frequency of seizures vs. 
baseline: 2.5 vs. 6 (p<0.01, Ø 
CI) 
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Table 2. Summary of the 30 included studies. 
No Author Design n Duration Intervention 
Drug reminder 
packaging 
Outcomes Effect 
Methodologica
l Quality 
Compl. of 
Information 
22 Rheder 182 
(1980) 
cct 100 3m Drug reminder packaging ± 
counseling, factorial 
Multicompartment 
adherence aid 
A: Pill count*:  No. of pat who took ≥95% of 
pills: Drug reminder packaging 
± mi > mi, Ø numbers given 
(p<0.01, Ø CI) 
Weak 0.63 
C: bp*:  
 
Drug reminder packaging + mi 
vs. baseline: Ø numbers given 
(p<0.02, Ø CI) 
Drug reminder packaging vs. 
baseline: n.s. 
23 Schneider 160 
(2008) 
rct 85 12m Drug reminder packaging Multidrug punch 
card 
A: MPR *:  0.93 vs. 0.87 (p=0.039, Ø CI) 
Patients with their 
prescription refilled on-time (± 
5d): 80.4% vs. 66.1% (p=0.012, 
Ø CI) 
Moderate 0.5 
C: dbp*: No. of patients with decreased 
dbp at 12m: 12 vs. 4 (p=0.031, 
Ø CI) 
sbp: n.s. 
Absolute change in bp: n.s. 
Long-term outcome 
measures: 
n.s. 
24 Simmons 161 
(2000) 
rct 68 8m Drug reminder packaging (Multi-) drug punch 
card 
C: dbp*: 
 
- 5.8mmHg vs. 0.1mmHg 
(p=0.0041, Ø CI) 
Moderate 0.13 
sbp: n.s. 
HbA1C*:  - 0.95% vs. -0.15% (p=0.026, Ø 
CI) 
H: Usability*: 77% vs. 27% (p<0.001, Ø CI) 
25 Skaer (NIDDM) 
183 (1993) 
cct 258 12m Drug reminder packaging ± 
refill reminder (rr), factorial 
Unit-of-use 
packaging 
A: MPR*  
 
Drug reminder packaging vs. 
cg: 0.71 vs. 0.58 (p ≤ 0.05, Ø 
CI) 
rr+drug reminder packaging 
vs. cg: 0.87 vs. 0.58 (p ≤ 0.05, 
Ø CI) 
rr+drug reminder packaging 
vs. drug reminder packaging: 
0.87 vs. 0.71 (p ≤ 0.05, Ø CI) 
Weak 0.33 
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Table 2. Summary of the 30 included studies. 
No Author Design n Duration Intervention 
Drug reminder 
packaging 
Outcomes Effect 
Methodologica
l Quality 
Compl. of 
Information 
E:  Drug reminder packaging vs. 
cg: 
Prescription expend.* : +$74.09 (p ≤ 0.05, Ø CI) 
All other expend.: n.s. 
 rr+drug reminder packaging 
vs. cg: 
Prescription expend.* : +$124.86 (p ≤ 0.05, Ø CI) 
Physician expend.* : -$66.79 (p ≤ 0.05, Ø CI) 
Laboratory expend.*: -$18.05 (p ≤ 0.05, Ø CI) 
Hospital expend.*: -$107.69 (p ≤ 0.05, Ø CI) 
Total expend.*: -$67.67 (p ≤ 0.05, Ø CI) 
(per capita) 
26 Skaer (BP) 184 
(1993) 
cct 304 12m Drug reminder packaging ± 
refill reminder (rr), factorial 
Unit-of-use 
packaging 
A: MPR* Drug reminder packaging vs. 
cg: 0.67 vs. 0.56 (p ≤ 0.05, Ø 
CI) 
rr+drug reminder packaging 
vs. cg: 0.79 vs. 0.56 (p ≤ 0.05, 
Ø CI) 
rr+drug reminder packaging 
vs. drug reminder packaging: 
0.79 vs. 0.67 (p ≤ 0.05, Ø CI) 
Weak 0.33 
E: Drug reminder packaging vs. 
cg: 
Prescription expend.*: +48.17$ (p ≤ 0.05, Ø CI) 
All other expend.: n.s. 
 rr+drug reminder packaging 
vs. cg: 
Prescription expend.*: +104.39$ (p ≤ 0.05, Ø CI) 
Physician expend.* : -78.41$ (p ≤ 0.05, Ø CI) 
Hospital expend.*: -89.54$ (p ≤ 0.05, Ø CI) 
Laboratory expend. : n.s. 
Total expend.* : -75.28$ (p ≤ 0.05, Ø CI) 
(per capita) 
62: PROJECT A1 | Effect of drug reminder packaging on medication adherence: a systematic review revealing research gaps Table 2 
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
Table 2. Summary of the 30 included studies. 
No Author Design n Duration Intervention 
Drug reminder 
packaging 
Outcomes Effect 
Methodologica
l Quality 
Compl. of 
Information 
27 Solomon 185 
(1988) 
cct 372 7d Drug reminder packaging ± 
videotape ± telephone 
interview, factorial 
 
Unit-of-use 
packaging 
A: Self-report (non-
compliance score)*: 
Drug reminder packaging vs. 
cg: 30.2 vs. 50.7 (p<0.001, Ø 
CI) 
Drug reminder packaging + 
video-tape vs. cg: 5.5 vs. 11.1 
(p<0.001, Ø CI) 
Moderate 1.0 
28 Valenstein 159 
(2009) 
rct 118 12m Drug reminder packaging, 
counseling, other aids 
Multidrug punch 
card 
A: MPR* : At 6m: 0.91 vs. 0.64 (p < 
0.0001, Ø CI) 
At 12m: 0.86 vs. 0.62 
(p<0.0001, Ø CI) 
Moderate 0.17 
CAM*: 
(MPR + self-report + TDM) 
 
At 6m: 26% vs. 9% (p=0.0003, 
Ø CI) 
At 12m: 17% vs. 9% (p=0.06, Ø 
CI) 
C: Psychiatric symptoms: n.s. 
H: Patient satisfaction, 
quality of life : 
n.s. 
29 Ware 176 (1991) cct 84 3m Drug reminder packaging, 
counseling 
Multidrug punch 
card 
A: Self-report + pill count*: 
 
Patients taking all prescribed 
doses: 
At discharge: 86.7% vs. 66.7% 
(p=0.03, Ø CI) 
At 10d: 69% vs. 41% (p=0.02, 
Ø CI) 
At 1m : 64.4% vs. 38.5% 
(p=0.03, Ø CI) 
At 2m : 57.8% vs. 28.2% 
(p=0.01, Ø CI) 
At 3m: 48.9% vs. 23.1% 
(p=0.03, Ø CI) 
Weak 0.38 
30 Winland-Brown 
195 (2000) 
cct 61 6m Drug reminder packaging Multicompartment 
adherence aid 
A: Pill count: n.s. Weak 0.13 
C: bp, INR, TDM, mood 
stabilization, HbA1C: 
Not reported 
Physician visits: Mean (per patient) vs. 
baseline: 1.5 vs. 1.5 (Ø p, CI) 
Hospital admission: No. of patients vs. baseline: 7 
vs. 4 (Ø p, CI) 
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Table 2. Summary of the 30 included studies. 
No Author Design n Duration Intervention 
Drug reminder 
packaging 
Outcomes Effect 
Methodologica
l Quality 
Compl. of 
Information 
Home visit: No. of patients vs. baseline: 0 
vs. 0 (Ø p, CI) 
Transition to a higher level 
of care: 
Not reported 
The 13 additionally included studies compared to previous reviews 147,155,156 are designated in bold. A, adherence outcomes; (s/d)bp, (systolic/diastolic) blood pressure; C, clinical outcomes; CAM, composite 
adherence measure; cct, controlled clinical trial; cg, control group; Compl., completeness; 13C-UBT, 13C-urea breath test; d, days; E, economic outcomes; expend., expenditures; H, humanistic outcomes; ig, 
intervention group; INR, international normalized ratio; m, months; mi, multiple interventions; no, number; n.s., not significant; rct, randomized controlled trial; TDM, therapeutic drug monitoring; vs., versus; w, 
weeks; *, significant change. 
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Abstract 
Purpose: Numerous studies showed the effectiveness of pharmaceutical care in improving medication 
adherence in primary care patients. However, in daily pharmacy practice, the provision of 
pharmaceutical care appears to be limited. We aimed at quantifying the content of counseling by 
community pharmacy staff during patient contacts, especially adherence counseling, and at 
investigating pharmacist views about their practice of adherence counseling. 
Patients and methods: A Master’s student in Pharmacy observed patient contacts at selected 
community pharmacies in the region of Basel, Switzerland. Content of counseling was manually ticked 
on a checklist with predefined themes (administration, dose, effect, and adherence). Pharmacists 
working in the pharmacy were interviewed on triggers, topics, and barriers in adherence counseling. 
Results: In 20 community pharmacies and during a total of 148.1 hours, 1,866 patient contacts were 
observed. During the 1,476 patient contacts including the dispensing of one or more medications, 
counseling was provided to 799 (54.1%) patients; with 735 (49.8%) patients counseled about 
administration, 362 (24.5%) about dose, 267 (18.1%) about effect, and 99 (6.7%) about adherence. 
Significantly more patients received counseling when they obtained prescribed versus over-the-
counter medication (P=0.002), a new prescription versus a repeat prescription (P<0.001), or when they 
were served by a pharmacist versus by another staff member (P<0.001). Of the 33 interviewed 
pharmacists, all except one reported actively approaching patients for adherence counseling. Triggers 
included medication-related and patient-related factors. The pharmacists named predominantly 
product-centered topics of adherence counseling. The most cited barriers were rejection of counseling 
by the patient and lack of time. 
Conclusion: Half of the patients receiving one or more medications were counseled, and only 6.7% of 
all contacts included explicit adherence topics. Future studies should clarify how barriers to adherence 
counseling at the community pharmacy can be overcome. 
Keywords: pharmaceutical care, community pharmacy, medication adherence 
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Introduction 
Pharmaceutical care has been defined as “…the pharmacist’s contribution to the care of individuals in 
order to optimize medicines use and improve health outcomes,”39 and the pharmacist has been 
designated as part of the health care team for added value in the health care system.42,52,213 
Pharmaceutical care activities practiced by community pharmacies have been shown effective in 
improving medication adherence.44-51  Face- to-face counseling during dispensing of medication is part 
of pharmaceutical care.42  Counseling can include providing education to patients (eg, about therapy, 
their condition), intervening in a patient’s drug therapy (eg, optimizing intake times), and ultimately, 
helping improve medication adherence.214  Previous studies reported significantly improved adherence 
and persistence through targeted counseling by community pharmacists.215-217 
Counseling practice in community pharmacies has been reported to be limited. In a pan-Europe 
comparison in 2009, the mean total score of pharmaceutical care provision, expressed as a percentage 
of the total score achievable, ranged from 31.6% to 52.2%.218  Patient counseling was reported to be 
only a minor task in every day practice in the community pharmacy,219-222  and communication was 
predominantly nonmedical or product-centered, instead of patient-centered.223-225 
At the dispensing of prescription medication, Swiss pharmacists are reimbursed for providing 
counseling on dose, frequency, administration, duration of use, storage, and potential adverse 
effects.226  Introduced in 2005, this was the first acknowledgment of cognitive services delivered by 
community pharmacists to improve the patients’ use of medication. Additionally, the provision of a 
dose-dispensing aid by the pharmacy is reimbursed.227 
To our knowledge, the current counseling practices in Swiss community pharmacies have not yet been 
addressed, especially the content of adherence counseling. The aim of this study was to quantify the 
content of counseling by community pharmacy staff during patient contacts, with a specific focus on 
adherence counseling, and to investigate the views of community pharmacists about their practice of 
adherence counseling. 
Materials and Methods 
Of 106 community pharmacies in the region of Basel, Switzerland, community pharmacies that had 
participated in previous studies228,229  were approached consecutively, according to a random number 
list, until the sample size of 20 was reached. This number was calculated to enable approximately 2,000 
patient contacts, assuming that counseling would take 5 minutes and one investigator could observe 
approximately 100 patients during 8 hours. We did not perform analysis of health communication 
between pharmacy staff and patients, but rather observed and quantified the content of counseling. 
A Master’s student in Pharmacy observed the patient contacts of the pharmacy staff in sequential 
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order during 1 day at each pharmacy. The observation began at the entrance of one patient into the 
pharmacy and lasted until the departure of this patient; thereupon, the student observed the next 
patient who entered the pharmacy. Information about the staff member serving the patient, the 
number of dispensed medications, and content of counseling were manually ticked on a checklist. The 
checklist enabled ad hoc coding of the patient contacts by allocation into two categories (“medication 
on prescription” and “medication over the counter”), as well as the coding of four themes 
(“administration”, “dose”, “effect”, and “adherence”) and 12 topics of adherence counseling. The 
latter were deduced from published recommendations (Table 1).230  Observation time and 
characteristics of the pharmacy and the team were simultaneously assessed. At the end of the 
observation time, an interview was performed with all present pharmacists, consisting of two closed-
ended questions (active approach to patients about adherence and frequency of active approach per 
month) and three open-ended questions (triggers, topics, and barriers in adherence counseling). 
We defined explicit adherence counseling as provision of patient-centered information that directly 
addresses the spectrum of adherence problems, including unintentional (ie, the patient is physically or 
cognitively unable to adhere) and intentional nonadherence (ie, the patient is not willing to adhere); 
this included the use of targeted questioning (“have you missed any pills in the past week”), offer of 
refill reminders and dose-dispensing aids, reinforcement, etc.230  We defined implicit adherence 
counseling as provision of product-centered information, eg, information on administration or dose. 
This information does not directly address adherence but might prevent unintentional nonadherence. 
Coded patient contacts were quantified and analyzed statistically within the sample of patients 
obtaining one or more medications. Answers from the interviews were categorized and analyzed 
quantitatively. We used SPSS V. 20 (IBM Corp., Armonk, NY, USA) for Windows for descriptive and 
comparative (χ2-test) calculations. A P-value of ≤0.05 was considered statistically significant. Missing 
data were excluded from analysis. 
Results 
During February and March 2010, 21 community pharmacies were approached, 20 took part in the 
study, and one pharmacy declined participation without specification of a reason. The pharmacies 
were located in the city center (eight), in residential districts (eight), and in shopping centers (four). Of 
a median of 9.25 opening hours (range 8.75–11.5), 7.5 hours (range 6.5–7.75) were observed per day 
and pharmacy. The observation day was equally distributed over the weekdays (Tuesday [five]; 
Monday, Wednesday, and Thursday [four]; and Friday [three]). The median number of working staff 
members was two pharmacists, three pharmacy technicians, and one apprentice, respectively. 
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During the total observation time of 148.1 hours, 1,866 patient contacts were observed, of which 21 
resulted in a referral to the physician, 18 in further inquiry by phone or fax with the physician, and 
eight in a refusal of dispensing. A total of 1,476 patient contacts included the dispensing of one or 
more medications, constituting the basis sample for statistical analysis (Figure 1). Of 2,789 products 
dispensed, 1,742 (62.5%) were on prescription and 1,047 (37.5%) were “over the counter” (OTC). 
Counseling was provided to 799 (54.1%) patients, with 735 (49.8%) patients counseled about 
administration, 362 (24.5%) about dose, 267 (18.1%) about effect, and 99 (6.7%) about adherence 
(Figure 2). The total number of observed counseling events was 1,800, with most patients receiving 
counseling on two (55.4%) or three (21.2%) themes. Explicit adherence counseling (n=130) mostly 
included comprehensive instruction (49 [37.7%]) and counseling on knowledge of disease and 
medication (36 [27.7%]) (Table 1). Significantly more patients solely obtaining prescription medication 
were provided with overall counseling compared with those solely obtaining OTC medication (57.3% 
vs 50.2%) (χ2=7.1, P=0.002; n=1,402). In the same groups, the single theme “effect” was observed 
significantly more often in patient contacts with the dispensing of OTC than in patients contacts with 
the dispensing of prescription medication (31.3% vs 6.3%) (χ2=148.3, P<0.001; n=1,402). There was no 
significant difference in frequency of adherence counseling for prescription vs OTC medication (7.1% 
vs 5.9%) (χ2=0.9, P=0.17; n=1,402). 
Focusing on the 757 patients solely receiving prescription medication, 421 (55.6%) had a new 
prescription, 293 (38.7%) requested a repeat prescription, 26 (3.4%) had both, and 17 (2.2%) were not 
specified (Figure 1). The pharmacy staff provided overall counseling to significantly more patients with 
new prescriptions compared with patients with repeat prescriptions (74.1% vs 33.8%) (χ2=115.0, 
P<0.001; n=714). There was no significant difference in frequency of adherence counseling in these 
two groups (new vs repeat prescriptions: 7.1% vs 4.4%, respectively) (χ2=2.2, P=0.14). 
Of all patients receiving one or more medications (n=1,476), 368 (24.9%) were served by a pharmacist, 
1,075 (72.8%) by another staff member (eg, pharmacy technician or apprentice), and 33 (2.2%) by a 
combination of both. Significantly more patients received counseling when they were served by a 
pharmacist compared with other staff members (62.1% vs 51.2%) (χ2=14.1, P<0.001). Adherence 
counseling was provided to twice as many patients when served by a pharmacist compared with other 
staff members (10.7% vs 5.2%) (χ2=14.2, P<0.001). 
Of 390 patients who did not receive a medication at the observed contact (eg, buying dose-dispensing 
aids, ordering out-of-stock medication), 42 (10.8%) received counseling. 
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Interview 
Among the 20 community pharmacies, 33 pharmacists participated in the interview (with median two 
and range of one to three pharmacists per pharmacy) and were mainly women (69.7%), with a median 
age of 41 (range 25–68) years and a median duration of 14 (range 1–43) years after university 
graduation. They worked with a median of 90% employment at the community pharmacy (range 40%–
100%). All pharmacists except one reported actively asking patients about their adherence, and 20 
(60.6%) did so on a daily basis. Figures 3 and 4 illustrate named triggers and topics of adherence 
counseling. Barriers included rejection by the patient (15 [45.5%]), lack of time (12 [36.4%]), lack of 
patient data (seven [21.2%]), lack of checklists and demo material (six [18.2%]), lack of confidential 
room (five [15.2%]), lack of remuneration (three [9.1%]), and “Other” (19 [57.6%]). 
Discussion 
Counseling was provided to half of the patients receiving one or more medications and occurred more 
frequently when the medication was on prescription, on a new prescription, or if patients were served 
by a pharmacist. The content of the counseling mostly included information on medication 
administration and dose. Only 6.7% of the patients obtaining medication received explicit adherence 
counseling, significantly more of them if the pharmacist was involved in the dispensing. However, most 
pharmacists seemed motivated to provide adherence counseling. They named a lot of triggers but also 
barriers to start adherence counseling and mostly named topics for adherence counseling, which only 
implicitly addressed the issue. 
Due to easy access, regular patient visits, the possibility to monitor medication refill frequency, and 
the competences of the pharmacist, the community pharmacy seems to be a predestined place for 
counseling about adherence. In our study, we showed that if pharmacy staff counseled, they counseled 
about more than one theme, indicating motivation and assumption of responsibility for safe and 
effective medication management. If only looking at prescription medication, unsurprisingly, 
dispensing of first prescriptions largely predominated in the number of patients provided with 
counseling. A considerable percentage (74.1%) of these patients were counseled. Apart from the need 
to ensure the patient’s knowledge at first use, the patient filling a first prescription also seems to 
expect more counseling, which might result in facilitating counseling.231  Still, explicit adherence 
counseling plays a very small part in both situations, dispensing of a new and of a repeat prescription. 
Because the pharmacist is able to detect nonadherence in patients with long-term therapy, eg, by 
analyzing medication refill frequency, we expected adherence counseling to occur more in patients 
with repeat prescriptions.  
Evidence that community pharmacy interventions have been successful in improving health outcomes 
and adherence have accumulated,44-50,232-235  and two Cochrane reviews concluded that the 
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pharmacists’ cognitive services were beneficial for safe and effective medication use.51,52  However, 
our study confirms results of earlier studies showing that community pharmacies provided limited 
pharmaceutical care services,218,220,236-238  indicating a problem of implementation in daily practice. 
Studies on counseling in community pharmacies were conducted using patient and pharmacist 
surveys, observation, and simulated patient visits.239,240  They mostly reported on pharmacists’ 
behavior only, with a total counseling rate of 8%–100%.240  Similar to our study, predominant 
categories of counseling were administration and dose, and hence were more product- than patient-
centered.223-225,240  A large proportion of communications (26%–40%) between pharmacists and 
patients was reported to be nonmedical.237,238  The only observational study specifically investigating 
adherence counseling was performed with pharmacy students, who had a lack of specific training in 
adherence management and of resources, and therefore reported not to address adherence in 
counseling sessions.241  A German study showed that pharmacists documented “evidence of 
nonadherence” in only 1.6% of all assessed drug-related problems during patient contacts in 
community pharmacies, indicating that the pharmacists had difficulties in identifying nonadherence.242 
We showed that pharmacists provided more counseling than pharmacy staff, which confirms the 
results of another study.236 Differences may arise from the more detailed knowledge about therapy 
and disease, more intense training, and from the assumption of the responsibility for safe and effective 
medication use by the patients. This knowledge and attitude, however, should be transferred to the 
whole pharmacy team. 
In our study, the comparison of observed counseling practice (observed adherence counseling of 6.7%) 
with pharmacists’ interview responses (60.6% indicated actively approaching patients with adherence 
issues every day) reveals a discrepancy between our definition and the pharmacists’ opinions about 
the topics of adherence counseling. We defined the topics more explicitly, whereas the most 
frequently named topics by the pharmacists were implicit. Several problems could arise from the 
implicit approach. First, the patients might not understand the purpose of the counseling and reject it. 
Second, while some unintentional nonadherence problems might be clarified with counseling on 
administration and dose, intentional nonadherence might be completely overlooked. Literature has 
described habits of pharmacists mainly asking standardized questions, eg, “Do you have any 
questions?”; at the same time, authors have suggested a more considerate and individualized 
approach according to patients’ needs, and the necessity of engaging patients in counseling.225,243,244  
Such an approach would include a more direct addressing of adherence. Further, almost all topics on 
our predefined list of explicit adherence counseling were named by the pharmacists, indicating that 
they were familiar with most of the topics, though less frequently addressed them during the observed 
patient contacts. 
72: PROJECT B1 | Adherence counseling during patient contacts in Swiss community pharmacies  Discussion 
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
The most frequently reported barrier was rejection of the offered counseling by the patients. This has 
also been shown in other studies, with 41%–63% of patients declining offered counseling.231,237  
Expectations of patients have been shown to not coincide with the recent development of the 
pharmacist’s role.244,245  Qualitative studies reported patient tendency to rely solely on the physicians, 
recommendations and to deny the pharmacists’ competences.246,247  This attitude persisted even in 
patient-centered consultations248  and was confirmed by a recent study that collected data over 15 
years.249 
It seems logical that patients with prescribed medications obtain more counseling, on one hand 
because the medication plan usually is more complex, including long- and short-term medication for 
serious diseases, hence counseling might be more relevant. On the other hand, the counseling about 
prescribed medication is remunerated by a medication tax of CHF 4.20 (= US$ 4.60) per prescribed 
item. Nevertheless, lack of adequate remuneration was only named by 9.1% of the pharmacists as 
barrier for adherence counseling. Remarkably, counseling was also given without product sale. 
Apart from the structural factors discussed above, several procedure-related factors were identified, 
which hinder pharmacists in counseling, and patients in asking questions. Time constraints pose such 
a barrier.241,249-251  However, surveys on pharmacists’ activities revealed that pharmacists were mainly 
occupied with traditional product-centered activities, such as business management, logistics, and 
product assembly, than with patient-centered activities, like counseling.219,221,222  In our study, we 
observed that pharmacists had fewer patient contacts in relation to their presence compared with the 
rest of the staff. Consequently, the problem could be designated as time mismanagement, and 
reconsiderations of staffing and of assignment of responsibilities might be a solution. 
Another barrier to patient-centered, individualized counseling is the lack of privacy, named by the 
pharmacists in our study and also reported elsewhere.236,246,251  Most people certainly are 
uncomfortable discussing their sensitive health problems next to a line of others at the counter. The 
traditional conceptualization of the pharmacy accommodations reminds patients more of a shop247  
than of a health care center and hence is not supportive in promoting counseling. 
The limitations of our study firstly include the restriction to one region in Switzerland. Secondly, the 
methodology of observation has been reported to yield variable results but a more holistic picture of 
counseling practice.240  We chose a minimally obtrusive method to observe the counseling, in order to 
prevent the introduction of biases. However, the open approach of the pharmacies and the presence 
of an observer could have triggered pharmacy staff to engage more in counseling practice than usual 
(Hawthorne effect).252  Thirdly, the ad hoc coding without review by second person could have limited 
the results’ reliability. Fourthly, due to the observational setting, we could not evaluate the rate of 
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overall offered counseling. With the most named barrier for adherence counseling being the rejection 
of counseling by the patients, we can assume higher counseling rates at higher acceptance of 
counseling. 
Conclusion 
The unique position of the community pharmacy in the health care chain and the competencies of 
pharmacists make the community pharmacy a predestined place for medication and adherence 
counseling. Pharmacists are motivated to provide counseling but experience several structural and 
procedural barriers in delivering it. In our study, half of patients collecting one or more medications 
received counseling, which was predominantly product-centered, and only 6.7% of the patients 
received adherence counseling. This study revealed insufficient knowledge and gaps in the provision 
of explicit adherence counseling by pharmacists. Future studies should explore the pharmacist–patient 
interaction in depth and clarify how barriers to adherence counseling in the community pharmacy can 
be overcome. 
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Table 1: Definitions and numbers of observed counseling events by counseling domains and topics of explicit adherence counseling 
Counseling domain Definition No. of observed counseling 
(Prescription / OTC)  
Administration Counseling on basic administration issues (e.g. with respect to meals) 435 / 317 
Dose Counseling on dosage, dosing times, intervals, and duration of medication therapy 418 / 226 
Effect Counseling about the effects of the medication 53 / 221 
Adherence Explicit adherence counseling according to the list of topics 73 / 57 
Topics of explicit adherence counseling 
Morisky question Asking the explicit question: “Do you ever forget to take your medication?” 0 / 0 
Adherence Directly addressing adherence, assessing the patients attitude towards adherence, and mentioning the 
importance of adherence 
8 / 2 
Positive reinforcement Acknowledging and encouraging the patients on efforts for adherent behavior 2 / 0 
Motivation Assessing motivation of patient to be adherent and, if necessary, providing support 2 / 2 
Organization Offering facilitation of medication management through stick-on labels, diaries, timers, dose-dispensing aids, 
phone reminders, organization of social support etc. 
9 / 2 
Appointment keeping Reminding the patient of appointments (with physician, refill, monitoring) 1 /1 
Psychological barriers Among others: Forgetfulness, fear of side effects 3 / 0 
Physical barriers Among others: Impaired vision and dexterity, difficulties with swallowing 4 / 0 
Instruction of product Providing comprehensive verbal information on use of the medication in the context of adherence 31 / 18 
Written Information Providing written information on the medication 2 / 5 
Knowledge about disease / therapy Explaining the relation between medication therapy and disease / necessity of therapeutic intervention 10 / 26 
(Self-) Monitoring Instructing the patient about how to perform (self-) monitoring, inclusive instruction on interpretation of 
monitored parameters 
1 /1 
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Figure 1: Patient numbers and allocations by category and domain. 
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Figure 2: Numbers of observed counseling events about administration, dose, effect, and adherence in total 
and according to dispensing category (prescription / OTC) (ntotal = 1’800). 
 
 
Figure 3: Triggers to start adherence counseling named by 31 pharmacists. 
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Figure 4: Topics of adherence counseling named by 33 pharmacists. The topics marked with asterisks 
correspond to the predefined topics of explicit adherence counseling in Table 1. 
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Background and Objective 
Multicompartment blister packaging is thought to facilitate drug intake and enhance compliance. To 
date, reviews could not state clear recommendation for their use 147,156,253. Pharmis® blisters (herein as 
synonym for multidrug punch cards; Figure 1) were introduced in 2002 as first weekly blister packaging 
in Switzerland. They are produced manually with the aid of a software program and have not yet been 
evaluated. Our aim was to assess experiences, benefits, and expenditures of pharmacies providing this 
service. 
Methods 
A national questionnaire based survey was performed including all pharmacies providing Pharmis® 
blister packaging for ≥ 6 months. Questionnaires were piloted and sent to all pharmacies. They had to 
be filled out by a pharmacist or a technical assistant. Pharmacies which did not answer in time were 
contacted by phone. Data was analyzed descriptively by SPSS Vers. 17 for Windows. 
Main Outcome Measures  
Benefits and experiences were measured on 4-point Likert scales and values like time, expenditures or 
compliance rate were numeric estimates. 
Results 
A total of 52 pharmacies provide Pharmis® blisters in Switzerland. The return rate of the questionnaires 
was 76% (n=40). Pharmacies were situated in the German speaking part of Switzerland (Figure 1), 
mostly in rural and peripheral areas (78%) and were mainly members of a grouping (60%). All were 
community pharmacies except for one hospital pharmacy. 
 
 
Figure 1: Pharmis blister (left); Distribution of Pharmis® distributing pharmacies in Switzerland;  = > 2 
pharmacies,  = 2 pharmacies,  = 1 pharmacy per city, village (right). 
 
80:  PROJECT B2 |First evaluation of Pharmis® blister packaging provided by pharmacies in Switzerland Results 
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
Patients 
Numbers and distribution of patients see Table 1/Figure 2. Thirty pharmacies recommended Pharmis® 
blisters actively to their patients and reported a success rate of 31% (± 26%, range 0-100%). They 
recommended Pharmis® blisters to: Patients with multiple medication (29%), patients with compliance 
problems (14%), elderly patients (11%), overstrained patients (9%), and patients after hospital 
discharge (6%). Twenty-nine pharmacies (73%) indicated that the patients were very satisfied with 
Pharmis® blisters. Of 33 pharmacies with ambulatory patients, 31 controlled compliance by pill count, 
if used Pharmis® blisters were brought back. Pharmacies estimated the taking compliance rate of the 
ambulatory patients at 93% ± 4%. 
 
Table 1. Number of patients provided with Pharmis® blisters. 
No., number; amb, ambulatory.. 
Total no. of patients  Mean no. of patients per 
pharmacy (range) 
Total no. of ambulatory 
patients 
Mean no. of amb patients 
per pharmacy;n=33 (range) 
1’869 48 ± 39 (1-135) 269 8 ± 8 (1-30) 
 
 
Figure 2: Number and distribution of patients provided with Pharmis® blisters (n=1’869). 
 
Expenditures 
Expenditures of time, material, and software for producing one Pharmis® blister was 15.70 CHF (Table 
2). Space requirements for the production were evaluated as appropriate by 72% of pharmacies. 
Difficulties in production were mainly due to the software and it was the main point of dissatisfaction, 
indicated by 32% of pharmacies. 
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Table 2. Estimation of expenditures per production of one Pharmis® blister. 
* neglected for calculation of costs. CHF, Swiss francs; min, minutes; tech. assist., technical assistant. 
Production steps Total 
duration 
(min) 
Proportion of production steps by staff 
member (%) 
Mean time per production step by staff 
member (min) 
Pharmacist Tech. assist. Other Pharmacist Tech. assist. Other 
Administration 6.8 ± 5.6 25.7 ± 2.9 74.2 ± 32.8 0.1 ± 0.8 1.7 5.0 0 
Filling 8.7 ± 4.6 15.1 ± 7.5 80.9 ± 30.4 4.0 ± 16.6 1.3 7.0 0.3 
Control 4.3 ± 3.1 94.5 ± 5.5 5.5 ± 15.5 0 4.0 0.2 0 
Total time required per staff member (min) 7.0 12.5 0.3 
Estimated salaries per hour 60.00 CHF 35.00 CHF -* 
Salary expenditures per blister by staff member 7.00 CHF 7.10 CHF  
Total salary expenditure  
14.10 CHF 
 
Material costs per blister 1.20 CHF  
Software costs per blister 0.40 CHF  
Total expenditures per Pharmis® blister 15.70 CHF  
 
Benefits 
The packaging service is remunerated 21.60 CHF per blister if the patient takes ≥ 3 different 
medications per week and if it is prescribed by a physician. Pharmacies agreed that other benefits 
arose as well from the introduction of Pharmis® blister service (Figure 3). But the gain of new 
customers, patients, and sales increase were mainly negatively valued. Generally the handling of the 
software, preparation, filling, and sealing of the Pharmis® blister was rated rather easy or very easy. 
 
 
Figure 3: Pharmacies’ ratings on benefits perceived after introduction of Pharmis® blisters. 
 
Discussion 
Pharmis® blister distributing pharmacies seem to stay regionally limited, grouped around Pharmis 
GmbH head office. In the French speaking part of Switzerland a French competitive product (Oréus®) 
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is used. The technology did not break through to the hospital setting because medication is seldom 
distributed to individual patients. The devices employed in the nursing home setting are thought to 
relieve the nursing home staff and are not operated by the patients themselves. Only 269 ambulatory 
patients are provided with Pharmis® blisters. Pharmacies perceived the patients as very satisfied. The 
pharmacies recommended blisters actively to a specific group of patients. When asked, they said that 
the acceptance was low in middle aged, mentally sound patients. Pharmis® software was a recurring 
issue and was described as user-unfriendly. However, benefits seem to outweigh expenditures. In the 
aspect of compliance enhancement, Pharmis® blisters seems to have an impact since pharmacies 
estimated remarkably high compliance rates for Pharmis® blister users (93.3%). 
Conclusions 
 The Pharmis® blister packaging service integrates well into daily work of a community pharmacy. 
 Pharmacies estimate high compliance rates for ambulant Pharmis® users. 
 Although benefits for pharmacies and patients overweigh expenditures, still few of the community 
pharmacies in Switzerland provide such service. 
 The full potential of Pharmis® blisters in ambulatory care is only little taped. 
Annex 
 A2.1 Pharmacy survey on multidrug punch card provision 
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Abstract 
Background: Multidrug punch cards are frame cards with 28 plastic cavities filled with a patient’s oral 
solid medication. They are used in primary care to facilitate medication management and to enhance 
adherence. Main criticism concerned handling difficulties and fading knowledge about medication of 
patients using them. This study aimed at exploring daily use, preferences and adherence of primary 
care patients using multidrug punch cards.  
Methods: Community pharmacies in Switzerland recruited primary care patients using multidrug 
punch cards. A mixed methods approach was applied with quantitative interviews performed by 
telephone and qualitative interviews face-to-face.  
Results: Of 149 eligible patients from 21 community pharmacies, 22 participated 2011 in the 
quantitative and 11 participated 2013/14 in the qualitative interview. Patients were very satisfied 
with the multidrug punch cards and stated increased medication safety. All considered adherence as 
very important. Self-reported adherence was 10 (median) on a visual analogue scale (0 = no intake, 
10 = perfect adherence). The absence of package inserts and predefined handling difficulties e.g., 
tablets spiking at removal were not perceived as problems.  
Conclusions: Patients are satisfied with the multidrug punch cards, feel safe, mostly have no handling 
problems and adhere to their treatment. Trust in health-care professionals and patients’ experiences 
emerged as key variables for initiating multidrug punch card use and for medication adherence. This 
mixed methods study invalidates previous concerns about disadvantages of multidrug punch cards. 
Health-care professionals should actively recommend them for primary care patients with 
polypharmacy and poor adherence. 
 
Keywords: pharmaceutical care, community pharmacy, medication adherence, primary care, dose-dispensing 
aids, multidrug punch card, polypharmacy, mixed methods. 
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Introduction 
Medication management i.e., the patient’s ability to self-administrate her/his medication constitutes 
a major preoccupation in a patient’s life 31,254,255. Physical and cognitive barriers hinder patients from 
removing medication from the primary and secondary packaging, from preparing it (e.g., handling a 
measuring cup, tablet-splitting, etc.) and from administering it the right way at the right time in the 
right dosage 35,207,256. Medication administration errors including non-adherence and incorrect use 
belong to the leading causes for adverse drug reactions and related hospitalizations 12,107-109. Elderly 
patients with polypharmacy for chronic diseases are at highest risk for such adverse drug reactions 257.  
The World Health Organization defined medication adherence as “the extent to which a person’s 
behavior - taking medication, following a diet and/or executing lifestyles - corresponds with agreed 
recommendations from a healthcare provider” 37. An average of 50% of patients does not take long-
term medication as prescribed 37, either intentionally (when the patient consciously decides not to 
take the medication) or unintentionally (when the patient is not able physically or cognitively to follow 
his own intent of taking medication as recommended). Non-adherence increases morbidity and 
mortality, decreases quality of life and raises healthcare costs 83,99,103,105,125,166,167. Strategies and aids to 
enhance adherence have been of major interest 143. Dose-dispensing aids such as multidrug punch 
cards and pillboxes have been suggested for unintentionally non-adherent elderly patients with 
complex medication regimen 62,77,145. Current literature reviews state an effect of dose-dispensing aids 
on adherence and clinical outcomes, but robust and reproducible studies are lacking 147,155,258.  
Several studies have described handling difficulties with the use of dose-dispensing aids 32,146,151,259. In 
one study, six out of fifteen patients put the loose tablets from a dose-dispensing aid back into a bottle 
because they could not handle the device 151. Another study reported that patients who elaborated 
their own medication management system tended to return to it after initiation of a prefilled dose-
dispensing aid 32. Such misuse is critical for patient safety. Medication knowledge has been advocated 
as essential for patient safety. Often, prepackaged dose-dispensing aids are delivered directly to the 
patient’s home and thus were observed to reduce contact between the pharmacist and the patient. In 
connection, knowledge about self-administered medication seemed to be poorer in patients with 
dose-dispensing aids than in patients who manage their medication on their own 153,154. A 
recommendation paper of the Royal Pharmaceutical Society criticizes the distribution of dose-
dispensing aids to all patients without assessing their capabilities and needs 152. In Switzerland, one 
single criterion (intake of >3 different medications) is required by the health insurance to supply 
reimbursed dose-dispensing service (repackaging of solid oral medication into dose-dispensing aids by 
a healthcare provider) by the community pharmacy to primary care patients.  
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Two qualitative studies explored the views of patients using various dose-dispensing aids 32,255. Findings 
of these studies indicated that one group of patients saw clear benefits in dose-dispensing aids, 
whereas the other group felt patronized and restricted in liberty. Some of the patients had handling 
problems with the devices and troubles with identifying their medication. Both studies concluded that 
future studies have to clarify which patients benefit most from dose-dispensing aids and how to 
recognize them in primary care. 
Multidrug punch cards are disposable frame cards with plastic cavities, sealed with a foil backing, with 
typically 28 compartments, filled by pharmacy staff, by a specialized company or an automated system 
(Figure 1). They provide a visual reminder for medication intake, the possibility of adherence self-
monitoring and the saving of time, costs, healthcare resources (e.g., home care nursing), and 
medication waste. Multidrug punch cards were introduced in Switzerland in 2002 together with a 
documentation software for community pharmacies 157.  
 
 
Figure 1: Multidrug punch card. Front side (left): 28 plastic cavities with visible packaged medication and 
labeling with patient and pharmacy information. Back side (right): 28 cavities sealed with foil and marked with 
indication of dosing time (morning, lunch, evening, night; Monday–Friday); the adhesive medication plan labels 
brand name, dose, administration number, dosing frequency, size, color, imprint, batch number, and expiration 
date of each packaged drug. All specifications are in German. 
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We conducted a mixed methods study to assess experiences, attitudes and adherence of primary care 
patients using multidrug punch cards in Switzerland. We aimed at investigating the preferences of 
primary care patients using multidrug punch cards in daily life, at compiling a profile of the primary 
care patient benefitting most of the multidrug punch cards’ use and thus at facilitating a targeted 
adherence interventions. The results should advance the rational distribution of multidrug punch cards 
and connected healthcare services. 
Materials and methods 
Quantitative interviews were performed in 2011 and qualitative interviews were conducted 
sequentially in 2013/2014 to clarify the results. A positive notification was obtained by the regional 
ethic boards. Good Reporting of A Mixed Methods Study (GRAMMS) guidelines were considered 260. 
Recruitment and inclusion criteria 
In 2011, all community pharmacies in the cantons of Basel-Stadt, Baselland, Aargau and Solothurn 
(Switzerland) delivering multidrug punch cards to primary care patients were asked to participate in 
the recruitment of patients for the quantitative interviews. Community pharmacies providing 
multidrug punch cards to primary care patients in the cantons of Basel-Stadt and Baselland were re-
invited in 2013/2014 to recruit patients for the qualitative interview. One pharmacist per pharmacy 
was instructed for recruitment. Patients were eligible if they had used multidrug punch cards for at 
least three months, lived independently, administering medications without external help, spoke 
German and were able to give informed consent. The pharmacists decided upon eligibility of the 
patients and recruited them by phone or face-to-face at their next visit at the pharmacy. The study 
team received the contact details of accepting patients and called them to fix a date for the interview. 
Patient information and the informed consent form were provided through the pharmacy or at the 
interview. For both interviews, patients were approached in the same manner, irrespective of 
participation in the first, quantitative interview. 
Instruments 
A quantitative questionnaire was developed containing five domains (living situation, general 
questions about the multidrug punch cards, handling, design and medication adherence). Answers 
were indicated as multiple choice, Lickert-scales, on visual analogue scales (VAS) or were open ended. 
The questionnaire was validated for feasibility, understandability and consistency of the scales. The 
questionnaire comprised 31 questions and took 30 minutes to conduct. Demographic parameters 
included age, sex, living situation, education, status of employment and number of medications. 
Adherence was measured through patient self-report on a VAS ranging from 0 (taking no medication) 
to 10 (taking all prescribed medication every day at the right time). The term ‘medication adherence’ 
is not colloquially used in Swiss German. We therefore replaced it with ‘fidelity to therapy’ 
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[Therapietreue], which we suggested to be more understandable. The term was explained to the 
patients before patient self-report of adherence by the VAS and discussion about importance of 
adherence was conducted. 
A qualitative topic guide was constructed upon the results of the quantitative questionnaire with 
themes that remained unclear or contradictory. The topic guide and the course of the interview were 
piloted with two patients who were not included into the final analysis. Adoption of the multidrug 
punch cards, acceptance, use in everyday life, design and medication adherence built the five domains. 
Subtopics were outlined with 19 pre-worded questions. Demographics and adherence were asked in 
the same manner as in the quantitative interview. Both, the quantitative questionnaire and the 
qualitative topic guide were applied as interviews. After interviews had been held, the current 
medication plan was obtained from the corresponding pharmacies. 
The quantitative interview was conducted by telephone after informed consent was received by post. 
One interviewer performed the interview, reading out the questions and the possible answers of the 
questionnaire. Immediate feedback was requested from the interviewed patient for assurance of 
ticking the right box. 
The qualitative interview was held face-to-face at the patient’s home or at the pharmacy in a separate 
room. FB led the interview and another researcher asked in-depth questions. Each domain was 
introduced to the patients by a general open-ended question to allow the patients to answer freely. 
Subtopics that remained untouched were then explored by further questions. The order of the 
domains and questions followed the patient’s answers. The interviews were held in Swiss German and 
were audiotaped. One research assistant (NR) orthographically transcribed the recordings in German 
language, preserving dialect expressions. All transcriptions were double-checked by FB.  
Analysis 
The quantitative interviews were analyzed descriptively by using Microsoft Excel 2013 for Windows 
(Microsoft Corporation, Redmond, WA, USA). Answers to open questions were categorized and 
analyzed quantitatively. Missing data were excluded from the analysis. Numbers of valid answers are 
given for each question. 
Transcriptions of qualitative interviews were transferred to MAXQDA V. 11 for Windows (VERBI GmbH, 
Berlin, Germany). Data were analyzed analogously to a five-stage ‘framework approach’ developed for 
applied qualitative research 255,261. A coding framework was constituted by preliminary coding of five 
interviews. Domains related to the original topics were structured as main codes and emergent themes 
formed sub-codes. After verification, the coding framework was applied to all interviews. Coding was 
performed manually line-by-line by FB. Codes of all interviews were grouped for detection of 
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associations and patterns. Quotations were selected to illustrate the analysis. They were translated 
into English by FB and checked by a native English speaker. Original German transcriptions of the 
quotations are listed in the supplementary material. 
Quantitative and qualitative data are presented in direct relation to each other in the Results’ section 
and were integrated by FB on the level of interpretation. Qualitative data were used to complete and 
explain findings from the quantitative interviews. 
Results 
Demographics 
In 2011, 33 of 266 community pharmacies in the cantons of Basel-Stadt, Baselland, Aargau and 
Solothurn delivered multidrug punch cards, mainly to nursing home patients. Of the 25 pharmacies 
supplying primary care patients, 21 participated in the recruitment of the patients for the quantitative 
interview. They supplied a total of nquant= 149 patients, of whom 25 (17%) were contacted by the study 
team and 22 (15%) consented to perform the quantitative interview.  
In 2013/2014, 13 of 124 community pharmacies in the cantons of Basel-Stadt and Baselland supplied 
primary care patients with multidrug punch cards and 6 participated in the recruitment of the patients 
for the qualitative interviews. Of a total of nqual=60 patients, 18 (30%) were recruited and 16 (27%) 
consented to perform the qualitative interviews. Five patients had to be excluded from the analysis, 
two because they participated in the pilot study, two because of language difficulties and one because 
of the use of a dose-dispensing aid other than multidrug punch cards. Reasons for exclusion by the 
pharmacist for the quantitative and qualitative interviews were (nquant/nqual): cognitive or psychological 
barrier 30/16; participation rejected 27/13; home care 25/4; language barrier 19/11; patient 
unreachable 6/6; multidrug punch card use for less than three months 6/3; terminal medical condition 
2/0; deceased 2/2; multidrug punch cards abandoned 1/0; reason unknown 6/3. Patient demographics 
are listed in Table 1. Mean durations of the quantitative and qualitative interviews were 28.5 (SD ± 
7.5) and 42.8 (SD ± 14.2) minutes, respectively.  
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Table 1. Demographics of patients participating in the quantitative and in the qualitative interviews. 
Patient demographics Quantitative interview Qualitative interview 
Participants, n 22 11 
Age, median (range) [years] 71 (37-96) 76 (27-91) 
Sex, n Female 14 5 
Male 8 6 
Living situation, n Alone 13 10 
With partner 9 1 
Education, n No school graduation 2 2 
Primary school 19 8 
University 1 1 
Status of employment, n Employed 1 0 
Retired / unemployed 21 11 
Number of medications, 
median (range) 
In multidrug punch cards 7 (4-13) 7 (4-12) 
Additional (outside 
multidrug punch cards) 
1 (0-4) 1 (0-3) 
 
Reason to recommend multidrug punch cards 
According to the quantitative interviews, multidrug punch cards were recommended by pharmacists 
in 54% of the cases, by physicians in 18%, by relatives in 14% and by others in 14%. Of the 16 patients 
who had the multidrug punch cards recommended by a pharmacist or a physician, 14 remembered 
one or several reasons: (new) prescription of numerous medications and / or complex regimen (n=7), 
facilitation of medication management (n=6), poor adherence (n=6), hospital discharge (n=3) and 
medication abuse (n=2). 
Qualitative interviews largely confirmed these reasons. The medical condition was named as principal 
reason which finally resulted in getting multidrug punch cards (n=4). The same four patients, who 
stated that they were confused with their medication or had difficulties in handling it, also declared 
that non-adherence was a reason for the recommendation of the multidrug punch cards. 
Difficulty/confusion: “I always have messy cupboards xxx. I’ve always had a box with one pill here, one 
pill there. Packaged like this [in regular packaging], right? Then I just did ‘tschak, tschak, tschak’ back 
and forth. And in time it seemed to me, it’s not the best solution, is it.” (P7) [xxx = garbled speech, 
unable to make an educated guess]. Non-adherence: “Sometimes it’s also happened that I’ve forgotten 
one [tablet] or so.” (P7). These patients mentioned their problems in the community pharmacy or to a 
relative, which led to the recommendation of multidrug punch cards. Four patients received the 
multidrug punch cards on prescription or by arrangement between the general physician (GP) and the 
pharmacist. Two of them did not remember having talked about it to the GP or the pharmacist prior 
to the initiation of the multidrug punch cards. One patient explained that it was his own idea to save 
money, because the size of packages often did not fit his needs. The packaging was proposed as 
solution by the GP. “[…] either they [the pharmacy] make packs with only 10 [tablets], and then this 
doesn’t really go far. Or they [the pharmacy] make a pack with 50 or 100 [tablets] and I don’t need 
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them either. And then, there’s a lot lost. And that way [with the multidrug punch cards], I really have 
only the medication that I need.” (P2). 
Advantages and disadvantages of multidrug punch cards 
In the quantitative interviews, all 22 patients felt well cared for by the pharmacy. All were satisfied 
with the multidrug punch cards, 20 of them very much. Facilitation of medication management and 
the reminding of medication intake were the main advantages mentioned. Overall, 67 advantages and 
12 disadvantages were named (Table 2). Twenty patients liked the design of the multidrug punch cards 
and agreed fully that it was clearly arranged. The orientation according to the written dosing times was 
judged as very easy by 21 patients and as easy by one. However, the patients stated uniformly that the 
functionality was more important than the design. The multidrug punch cards were rated as practical 
and very robust by all 22 patients. 
 
Table 2. Advantages and disadvantages named by all 22 patients of the quantitative interview in an open-ended 
question. 
Advantages Disadvantages 
Facilitation of medication management  22 Difficult medication removal 5 
Reminder for medication intake 14 Missing package insert 3 
Clear design 7 High refill frequency 2 
Control 6 Waste 1 
Medication safety 4 Missing confidentiality 1 
Organization  4   
Communication 2   
Facilitation of therapy adjustment 2   
Mentioned once: recycling of medication, 
space-saving, hygiene, documentation, home 
delivery, rationing 
6   
Total 67  12 
 
The satisfaction was also high in the qualitative interviews with 55 passages coded with positive 
expressions about the multidrug punch cards (e.g., “This is marvelous!” (P1)). There were no 
corresponding negative remarks. Most patients said that they much preferred the multidrug punch 
cards to their prior medication management system. It was a facilitation, not only for medication 
management, but also for their life: it was less time consuming, they did not have to reflect which ‘box’ 
to use at which dosing times and they did not have to store numerous medication boxes. “This 
[multidrug punch cards] really simplifies my life!” (P1). “Again, one concern less for me!“ (P5). Patients 
also highlighted the clarity and order of the multidrug punch cards. The layout helped them to 
orientate themselves. Interviewer: “And why do you like it, when it [the medication] is packaged like 
this [in the multidrug punch cards]?” - Patient: “You have an overview. […]” (P8). Few comments 
concerned the high-level hygiene and the suitability for old and / or forgetful people. Only four 
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negative comments were issued by three patients: the sound of the multidrug punch cards while 
handling was displeasing, a long sheet with the medication plan glued on the back was unpractical 
while removing medication, the assumption that the handling could be difficult for people with 
disabilities and the lack of package insert and information to identify the tablets. “The disadvantage, I 
find a bit is that you don’t have an overview of the tablets. Now, I really can’t…. Where there is a heart 
on it [the tablet], I know it is for the heart somehow, but on the whole, I do not know what I here 
[take]…. Well, everything is written in the back, isn’t it, for me. I don’t know if they do that in general 
or not?” (P4). This comment was stated by a patient who also criticized that he could not understand 
the information of the medication plan glued on the back, he thought it was written in Latin. On the 
other hand, the lack of package insert did not trouble other patients and was appreciated as an 
advantage by several patients. 
Handling of the multidrug punch cards 
In the quantitative interviews, 21 out of 22 patients were very satisfied with the handling of the 
multidrug punch cards. Nineteen patients pushed the medication out with their fingers. Of five patients 
cutting the foil on the backside, four seldom or never had trouble in pushing out the tablets. In total, 
14 (64%) patients indicated never having trouble with removing medication from the multidrug punch 
cards. Eight patients had technical or physical difficulties: tablets spiked at removal (n=5); tablets stuck 
in the cavity at removal (n=4); dexterity problems (n=3); cavity too fully loaded (n=1).  
During the qualitative interviews, patients were asked to demonstrate with a demo multidrug punch 
card how they removed their medication. All 11 patients removed the mock medication without 
trouble, but sometimes it spiked. Although some patients admitted that this happened from time to 
time with their own multidrug punch cards too, they mostly did not see it as a drawback. Some of the 
patients described problems with removing medications at the very beginning of multidrug punch card 
use, but they developed their own strategy to overcome these problems. Most patients had not been 
instructed how to use the multidrug punch cards or did not remember it. They negated the need for 
it, because they found the multidrug punch cards self-explaining. Four patients reported that they daily 
removed the content of the cavities in advance into a separate little box or bowl. This was practical to 
them because they kept the medication ready and could not mix it up, or they had it in their pocket in 
case they left home. One patient was sure that she would forget the intake in the morning, if she did 
not prepare the dose the evening before. “Because I have to prepare them, otherwise I would really…, 
I have to tell you honestly, I would forget them [the medication].” (P8). Two patients told that they 
manipulated the multidrug punch cards for their purpose. The main motivation was cutting the size 
for storage or transport. “[…]. If I know, of course, I will leave for three days, then I cut it [multidrug 
punch card] here.” (P2). One patient also pushed medication into the cavities or took some of the filled 
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medication out if there was a short-term change in medication therapy. She did not report these 
therapy changes to the pharmacy until she was sure it was fixed. “[…]. And after this, just once for this 
evening I did it, so that I don’t have to mess around for a long time, I took the two [tablets] that I have 
to take anyway, I pushed them in here and the blue one I already pushed out [of the multidrug punch 
card]. That’s how I work with the blister [= multidrug punch card].” (P1). 
Safety issues 
In the quantitative interviews, safety and control were named by four and six patients, respectively, as 
an advantage of the multidrug punch cards (Table 2). All 22 patients stated that they felt safer in 
medication management with the multidrug punch cards than without. All patients agreed fully that 
they could read the text with the information written and glued on the back of the multidrug punch 
cards without problems. Three patients admitted that they never read this text. Three patients named 
the missing package insert as a disadvantage. 
The topic safety was explored in-depth in the qualitative interviews. All 11 patients confirmed that the 
multidrug punch cards made them feel safe in managing medication. The main reasons were the 
overview of their medication and to be in control of medication intake. It was very important for them 
to be sure they had the right medication at the right time. “Yes, I would say there is a kind of safety in 
it [multidrug punch cards]. Then I’m sure I took the right one, here.” (P2). Some patients mentioned in 
that context that they believed the medication filling to be correct and that they could rely on the 
controls of the health-care professionals. Nevertheless, all 11 patients reported that they controlled 
the tablets immediately after removal by number, shape or color. Two patients felt safe because the 
medication was incorporated in a package that was hygienic and robust. In relation to medication 
knowledge, the patients could be divided in two groups (Figure 2). Group A was confident to know the 
name and indication of their medication, could more or less identify the tablets in the multidrug punch 
cards and stated that they did not need further information or a package insert. Group A/Knowledge: 
“I know exactly what I have to take, […].“ (P5). Group A/Package insert: “Because if I have to read the 
package insert, either I have to or I want to, I suffer from everything that is written there. And I don’t 
want that at all.” (P1). Group B did not know the name and indication of their medication and could 
mostly not identify the tablets. All patients of Group B except one did not want more information 
because they declared not to understand it. The package insert was refused quite fiercely by some 
patients and was named as a reason for denied medication intake. All patients of group B explained 
that they were faithful to the pharmacy for years and that they trusted health-care professionals. Trust 
and fidelity to the pharmacy also coincided with statements of perfect medication adherence. Group 
B/Knowledge: Interviewer: „How well do you know which tablet is which, for example?“ Patient: “I 
don’t know.” (P9). Group B/Package insert: Patient: “But what the other one is, I don’t know.” - 
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Interviewer: “You don’t know it. Would you like to know it then? So, do you mind not knowing it?” - 
Patient: “Well, I don’t know if I would actually like to know it or not.” - Interviewer: “That means this 
fits for you then?” - Patient: “You know, this would… if, if this was something that… This would concern 
me very much. […]” (P8). Group B/Package insert/trust and fidelity: „[…]. I trust you and the physicians. 
I’m not interested in this because I don’t understand it anyway. What’s in it and what’s written on it 
[in/on the multidrug punch card] and so. No, I never look at it.“ (P3). The medication plan glued on the 
backside of the multidrug punch cards was very much appreciated and was declared to contain enough 
information about the medication and the user. Some patients saw it as a major advantage in safety 
because they could give the correct names and dosages of their medication to physicians at first 
consultation or at admission to the hospital. Two patients told that they requested oral and written 
information on medication from the pharmacy if they had specific questions. All 11 patients described 
their contact to the pharmacy to be very good and the pharmacy team to be very friendly. 
 
 
Figure 2: Adherence elements emerging from qualitative interviews. Although all patient stressed perfect 
adherence, statements of Group A allowed margins for time of medication intake (= near to perfect 
adherence). ‘Medication knowledge’ relates to a patients’ confidence to appoint the name and/or the 
indication of the medication and/or to identify the tablets. ADRs, adverse drug reactions; hcp, health-care 
professionals. 
 
Adherence 
In the quantitative interviews, patients indicated that the multidrug punch cards were a tool to remind 
them of medication intake. Compared to their prior medication management system, 21 patients rated 
a relative improvement of +37% (SD ± 43%) for taking adherence and 19 patients rated a relative 
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improvement of +38% (SD ± 43%) for timing adherence after the initiation of multidrug punch cards. 
One patient estimated his timing adherence to be 13% worse with the multidrug punch cards than 
without. Median self-reported adherence of the 33 patients participating in quantitative and 
qualitative interviews was 10 on the VAS (range 3-10). 
In the qualitative interviews, all 11 patients stated that they did not know the term adherence [fidelity 
to therapy, Therapietreue], but three patients could imagine the rough sense of it. “Yes, I stick to the 
rules. Which I get ordered, now about the therapy, sort of… yes. I do what I should and not…. Faithful 
to therapy, like this. Xxx. If you now get medication to calm down, if you… have a fit. Then I would say, 
fidelity to therapy is really if you just take it at the right moment.” (P6). Others related it to physical 
therapy because in Swiss German the term ‘therapy’ [Therapie] theoretically stands for various kinds 
of therapy, but is colloquially often used for physical therapy. Some patients had no idea of the 
meaning of the term ‘fidelity to therapy’. Two patients remembered that they had a talk with their 
health-care professionals about adherence, but the majority thought this was self-evident and that 
they did not need further explanations. All 11 patients declared that medication adherence was very 
important for them and emphasized their willingness to be adherent. As reasons they indicated that it 
made sense to follow the physician’s directions, that they would benefit from the therapy and that 
they would suffer from medical consequences if they were non-adherent. One patient even stated that 
pharmacotherapy was existential for her. All patients who feared medical consequences of non-
adherence had a history of an adverse medical event (e.g., heart attack) or suffered from a medical 
condition, which they had to keep under strict control (e.g., diabetes mellitus, epilepsy). “I know it [the 
medication] holds off a lot, when you had two heart attacks, then you know what it means to take 
medication. Then you really take it [the medication].” (P9). “Well, what do I want? There is nothing else 
for it. It only benefits me, if I take it, right? I don’t want to sit in the hospital again.” (P8). Statements 
about adherence matched Groups A and B defined in the Safety’s section. Patients from Group A were 
more liberal and reported that they were fine with a margin for time of medication intake. Patients 
from Group B were anxious about leaving out one tablet or taking one dose too late since they were 
sure to sense immediate consequences. “If I did not take them, I would feel it. So, I would have to go 
soon, most likely…, so maybe the second day at most [after missing a tablet], I would already have to 
go to the physician and say: ‘I don’t feel well anymore’. So yea, I would feel it.“ (P10). Three patients 
believed that they would forget medication intake if they had to prepare the medication themselves 
out of the regular packaging, if the multidrug punch card was stored at a hidden place, or if there were 
more dosing times. Most patients who admitted that they forgot medication intake with their prior 
medication management system also forgot intake with the use of the multidrug punch cards, but 
much less than before. The visualization of the doses would reveal their omission and allow them to 
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make up the intake. One patient had problems remembering the short-term therapy that she was 
managing besides the multidrug punch cards. Three patients were absolutely sure that they never 
forgot medication intake. Strategies to remember medication included defining an eye-catching place 
of storage for four patients, setting an alarm for two patients and embedding medication taking into a 
ritual or daily routine for four patients. All four patients who had defined a special place of storage 
reported always seeing it and therefore remembering medication intake. Patients who had the 
medication intake embedded in their daily routine told that they did not have to remember medication 
taking as a separate action, it was more like an automatism within their normal activities. They also 
did not need to control the multidrug punch cards to ensure timely intake. „It is, it’s like automatic, 
right? When I’m sitting, having my breakfast at the table, then I just do it and then it’s done. And then 
I put it [the medication] into the plate and the matter is settled.” (P5). “I always take all of them. I 
always take them how I have to, I don’t have to control it.” (P9). For most patients control of intake 
was an additional step of safety. “But here [with the multidrug punch card] you have control after all! 
Here you have it, you are sure that you took the right thing [medication].” (P11). „I see it at first sight. 
I had it, I took it, I know it.” (P2). 
Discussion 
We combined quantitative and qualitative methods in an explanatory way to investigate the profile of 
multidrug punch card users in-depth, and the influence of the dose-dispensing aid on their adherence. 
Our primary care patient using multidrug punch cards reports high level of satisfaction with the 
multidrug punch cards, few handling difficulties, and high medication safety. She/he declares currently 
highest medication adherence and improved adherence compared to her/his prior medication 
management. Our results support the assumption that unintentionally non-adherent patients 
represent a target population for dose dispensing aids 62,145 and highlight some key variables which 
health-care professionals may assess while recommending multidrug punch cards to patients with 
polypharmacy. 
The typical independent primary care patient accepting to use multidrug punch cards is over 70 years 
old, has a low education grade, is retired, lives alone, favors tidiness, rituals and daily routines and is 
unable or reluctant to leave home. She/he trusts the health-care professionals, is a regular customer 
of the same community pharmacy, is motivated to conduct a healthy life and has a feeling of high 
necessity for medication. The association of adherence with the necessity for medication intake is well-
known and has been used as an integral part of the ‘believes about medicines questionnaire’, an 
instrument to assess adherence 53.  
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Our patients much preferred the multidrug punch cards to their prior medication management and 
reported improved adherence of even +37% after the initiation of the device. Significantly increased 
adherence was also demonstrated by five out of six randomized controlled trials investigating the use 
of multidrug punch cards in primary care patients 49,159,160,176,211. Additionally, in two of these studies 
49,160 cardiovascular patients with polypharmacy achieved significantly improved clinical outcomes 
(e.g., blood pressure, LDL cholesterol). Thus, major improvement of adherence and of associated 
outcomes by the use of multidrug punch cards are likely.  
In our study, patients claimed their perfectly adherent behavior to be motivated by a personal 
experience of benefit if they adhered to the physician’s orders or by a fear of medical consequences if 
they did not. These findings correspond to the role of patients’ experiences denoted as crucial for 
clinical safety and effectiveness 262. Trust towards the pharmacy emerged also as a reason for high 
adherence, since the participants expressing trust towards health-care professionals most explicitly, 
were most accurate with their medication plan. This attitude is characterized as the ‘passive 
medication user’, representing one out of three different types of medication intake-behavior 263. We 
thus suggest that the population of ‘passive medication users’ could be a target group for the use of 
multidrug punch cards. If we add that high fidelity to the pharmacy is associated with increased 
medication adherence and decreased adverse drug reactions 162, we can suppose that multiple key 
variables at different levels permit to reach a perfect medication intake behavior (trust in the 
institution/health-care professionals; perceived benefits of the management system; fear of negative 
consequences) (Figure 2).  
Although multidrug punch cards do not feature an explicit reminder function, its storage at a strategic 
visible place helped the patients to remember medication intake. In particular, it allowed immediate 
visual control of the intakes, the performed ones as well as the forgotten ones. An advanced strategy 
seems the integration of the medication intake into daily routine to become an ‘automatism’; the 
patients even did not have to think about medication intake. Habits and routines have long been 
described to be beneficial for general adherence 57,264 as well as for dose-dispensing aids 255. As a 
consequence, recommending multidrug punch cards should include an assessment of the patients’ 
daily habits and routines. 
Reasons for recommendation of multidrug punch cards and major advantages assessed in our study 
e.g., facilitation of medication therapy and improvement of adherence, mostly coincided with results 
of two qualitative studies on primary care patients using different types of dose-dispensing aids (e.g. 
pillboxes, multidrug punch cards, etc.) 32,255. 
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Absence of medication information – due to the dispensing of multidrug punch cards without package 
inserts – was of minor importance in the quantitative interviews. The in-depth exploration of the 
qualitative interviews confirmed that the patients were satisfied with a minimum of medication 
information. Only two patients requested written or oral medication information from the pharmacy. 
These findings might appear controversial, since a lack of medication information has been related to 
a reduction of knowledge resulting in a dangerous loss of skills and autonomy of the patient 32,152,153. 
Inversely, good medication knowledge was suggested to reduce inappropriate medication 
administration, adverse events and non-adherence, and hence to increase medication safety 108,265-267. 
However, these investigations were not performed within a population using multidrug punch cards. 
Since their use spares the handling of regular packaged medication, a different type of knowledge 
seems needed by those patients than the information contained in package inserts. Our assumptions 
are strengthened by a recent study showing that patients over 65 years with dose-dispensing aids were 
significantly more adherent (n=119) but less knowledgeable than patients who managed their 
medication by themselves (n=96) 154. Finally, since multidrug punch cards per se reduce potential errors 
of administration to a minimum, a relation to medication knowledge is unlikely. 
Handling problems (e.g., difficulty in removing medication, confusing inscriptions when to take the 
medication, etc.) were claimed to constitute a major reason for reduced medication safety with dose-
dispensing aids 32,146,151. Consequently, the small number of handling problems in the quantitative 
interviews was surprising. However, the qualitative interviews confirmed the first findings and 
revealed a major contribution of multidrug punch cards to the patients’ feeling of medication safety. 
The clear design of the multidrug punch cards assured its safe use. Hence, for most patients instruction 
was dispensable.  
For practice, our study implies that medication management and non-adherence should be addressed 
actively through health-care professionals. The profiling enables selecting the right patients, provides 
arguments for recommendation and points out relevant issues for advancement of dose-dispensing 
service. Initially, trust between the patient and the health-care professional has to be established and 
patients’ experiences and habits should be included into adherence counselling. While recommending 
multidrug punch cards, pharmacists should emphasize the facilitation of medication management and 
the increased medication safety. Based on our results, other strategies to advance dose-dispensing 
service and increase safety might be considered e.g., regular medication review of the packaged 
medication by a pharmacist 150, giving instruction on multidrug punch cards if necessary (anticipation 
of handling difficulties, integration into life-style, reminder strategies), inclusion of short term 
medication into the packaging, detailed instruction of separate medication, and regular contact 
between pharmacy and patient. 
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Strengths and limitations 
The strength of this study was the deeper explanation of ambiguous quantitative data through 
qualitative interviews. To our knowledge, this is the first study with a mixed methods approach in the 
field of dose-dispensing aids and their impact on medication adherence.  
Our study results are limited through several points. First, our study sample is small. On one hand, this 
is due to the effective small number of primary care patients, who are using multidrug punch cards 
without external help. In Switzerland, multidrug punch cards were originally intended for the supply 
of nursing homes. Only in the last few years, they were recommended to primary care patients. 
Further, the primary care patients selected by the pharmacists as multidrug punch card users really 
were the target group for this type of adherence aid (cognitive or psychological barrier, home care, 
language barrier), but turned out to be inadequate for our study. On the other hand, about half of the 
adequate patients refused study participation. Telephone interviews constituted a major barrier for 
recruitment. Conducting interviews at home or at the pharmacy were more acceptable. Second, the 
high level of satisfaction may reflect a selection bias. We can assume that patients unsatisfied with the 
multidrug punch cards might not have been willing to consent for interviews, especially if invited by 
the provider of the unsatisfactory device. Further, the recruiting pharmacist may have approached 
satisfied users among her/his patients to take part in the study. The problem-free handling of the 
multidrug punch cards that we observed might be the result of a further selection bias, since we 
excluded cognitively impaired patients who are known to experience difficulties with the handling of 
any medication packaging 207,259. Additionally, because our participants had to use the punch cards at 
least three months for inclusion, initially encountered difficulties may have been solved already. Third, 
reporting and interviewer biases may have interfered with study results. Since there were no 
differences observed by location of interview, the conduction of the interviews at the pharmacy does 
not seem to have influenced the patients’ answers. Fourth, adherence was measured through patient 
self-report which has been described not to be fully reliable and often overestimated 268. However, the 
conformity with similar studies 49,154 endorses our results. Fifth, this study represents the views of 
patients solely using multidrug punch cards and cannot be generalized to patients using other dose-
dispensing aids. 
Outlook 
Future research should aim at developing studies with larger populations to enable generalization. The 
development of an assessment tool for non-adherent patients to provide targeted interventions 
should be a priority. Clarification of the impact of multidrug punch cards on patient-oriented outcomes 
should be aspired. Younger patients with complex medication regimen should be interviewed about 
their preferences to clarify the benefit of multidrug punch cards for additional populations. 
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Conclusions 
Characteristics of primary care patients using multidrug punch cards include age over 70 years, low 
education grade, living alone, appreciation for tidiness and daily routine, trust in health-care 
professionals, fidelity to pharmacy and motivation for a healthy lifestyle and medication adherence. 
The patients are satisfied with the multidrug punch cards, feel safe, mostly have no handling problems 
and adhere perfectly to their treatment. Multidrug punch cards constitute a simplification for their 
lives, offer a clear overview of hygienically packaged medication, a reminder function and a possibility 
for adherence monitoring. Key variables for initiating multidrug punch card use and for medication 
adherence are trust in health-care professionals and patients’ experiences. This mixed methods study 
attenuates previous concerns about disadvantages of multidrug punch cards. Hence, health-care 
professionals should actively recommend them for primary care patients with polypharmacy and poor 
adherence. 
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Abstract 
Background: Medication self-management is often impaired in patients with polypharmacy, especially 
after hospital discharge, leading to medication errors and non-adherence. Non-adherence is 
widespread in the primary care population and impairs clinical conditions, quality of life, and 
healthcare costs. Multidrug punch cards are suggested to enhance adherence by optimization of 
medication self-management. In Switzerland, multidrug punch cards have been integrated in practice 
of community pharmacies since 2002. Multidrug punch cards can be equipped with POlypharmacy 
Electronic Monitoring System (POEMS), a novel technique for electronic measurement of adherence 
to polypharmacy. 
Objective: We aimed at investigating the effectiveness of a pharmaceutical care intervention including 
electronic multidrug punch cards and regular feedback on electronic dosing histories, to improve 
adherence to polypharmacy and patient-relevant outcomes in primary care patients after hospital 
discharge. Herein, we report of the results and experiences of a pilot study.  
Methods: During 10 months in 2013, patients on an internal medicine’s ward at the University Hospital 
Basel were screened, recruited, and assessed at bedside. All patients received medication counseling 
and an individualized medication plan prior to hospital discharge. Patients randomized to the 
intervention group received their oral solid medication packaged in electronic multidrug punch cards 
and regular feedback on their electronic dosing histories by a study pharmacist. Patients allocated to 
the control group received usual care. Follow-up visits were carried out at the study pharmacy at three, 
six, and twelve months after hospital discharge. Primary outcomes were ‘time to hospital readmission 
and major adjustment of drug therapy’ and adherence according to medication possession ratio (MPR). 
The evaluation of the pilot study was based on Donabedian’s evaluation model of quality of care. 
Results: Of 958 screened patients, 10 consented to participate. One patient accepted the intervention 
and nine patients were allocated to the control group. The median age of the control patients was 67 
years, 5/9 were male, and their baseline median self-reported adherence was maximal. The 
intervention patient was male, 65 years old, and reported a maximal taking adherence and moderate 
timing adherence. Over the whole study duration, there was no unplanned hospital readmission. One 
major adjustment of drug therapy occurred in the intervention patient, which could not be linked to 
impaired adherence. The mean MPR of the control and the intervention group was 1.01 and 1.18, 
respectively. Patient satisfaction was high and no harm related to the intervention was registered. 
The evaluation showed adequate feasibility of the study design, but a lack in quality and efficiency. Key 
points for these shortcomings were, e.g., the high exclusion rate, the inadequate time management, 
the induction of a potential bias by medication counseling during the follow-up assessments. 
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Conclusions: Because of a lack in efficiency and quality of the pilot study, only ten patients could be 
recruited and only one patient accepted the intervention. Over the whole study duration there was no 
unplanned hospital readmission and one major adjustment of drug therapy in the intervention patient. 
However, the intervention patient maintained perfect adherence and was clinically stable over the 
whole study year. In the control group, adherence was at a maximum according to self-report and 
medication possession ratio (MPR). The evaluation revealed major inadequate points, whose 
improvement might enable the successful study performance. 
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Introduction 
Physical and cognitive impairments of primary care patients pose a barrier for safe and effective 
medication self-management 35,207,256, i.e., the patient’s ability to self-administrate her/his medication 
31, leading to adverse drug events, non-adherence, and related hospitalizations 12,107-109. Elderly 
patients with polypharmacy for chronic diseases and who are newly discharged from hospital are often 
prescribed polypharmacy, which puts them at highest risk for such adverse health outcomes 29,257. 
Adherence was defined as ‘the extent to which a person’s behavior – taking medication, following a 
diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care 
provider’ 37. Typical adherence rates for oral prescription medications are approximately 50-76%. Non-
adherence impairs clinical outcomes 65,90, resulting in increased risk of hospital admission 12,105,269. As 
consequences of the adverse health outcomes, quality of life decreases 110,112,113 and healthcare costs 
rise 117,124. Non-adherence behavior can be categorized into two groups: 1. unintentional non-
adherence is when the patients are prevented from correctly executing their treatment plan by 
physical or cognitive barriers; and 2. intentional non-adherence is when the patients actively decide 
not to take medication according to treatment plan. Various authors suggest that dose-dispensing aids 
may represent a simple method to help unintentionally non-adherent patients to optimize their 
management of polypharmacy 65,145,146 62.  
Dose-dispensing aids usually consist of a certain number of compartments containing oral solid 
medication for specific dosing times and conform to the requirements to be simple, easy to implement, 
and inexpensive 143. Recent literature reviews confirmed a positive effect on adherence and clinical 
outcomes 147,155,258. However, the evidence support for the use of dose-dispensing aids remains weak 
because of poor methodological and reporting quality. Further research gaps encompassed economic 
and humanistic outcomes, safety issues, long-term, disease-unspecific, and generalizable clinical 
outcomes, and clinical effects on multimorbid populations with polypharmacy. More robust replicable 
studies were claimed to strengthen the evidence. 
Multidrug punch cards are disposable frame cards containing 28 plastic cavities for four dosing times 
per day and are filled by community pharmacies or manufacturers with all oral solid medication of an 
individual medication regimen. A specific software assists the production by archiving patient data, 
documenting prescriptions, verifying the medication filled through barcode scanning, and by 
composing data from the database to a label that is fixed on the card 157. The label comprises data of 
the pharmacy, the patient, and the packaged medication (Figure 1). In Switzerland health insurances 
reimburse this dose-dispensing service (i.e., the repackaging of solid oral medication into dose-
dispensing aids by a health care provider) with 21.60 CHF per week with a prescription of ≥ 3 different 
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medication per week, (according to the collective agreement LOA IV 158). Preliminary studies showed 
that the dose-dispensing service with multidrug punch cards integrated well in daily practice at the 
community pharmacies in Switzerland, but that they were mainly produced for patients in nursing 
homes 270. Primary care patients using multidrug punch cards in daily life were very satisfied with them, 
asserting that they constituted a simplification for their lives and increased their safety 271. Pharmacists 
and patients estimated improved adherence with the use of multidrug punch cards 270,271. 
 
 
Figure 1. Multidrug punch card, front side (left): 28 plastic cavities with visible packaged medication and 
labelling with patient and pharmacy information. Back side (right): 28 cavities sealed with foil and marked with 
indication of dosing time (morning, lunch, evening, night; Monday-Friday); the adhesive medication plan labels 
brand name, dose, administration number, dosing frequency, size, color, imprint, batch number, and expiration 
date of each packaged drug. 
 
Electronic measurement of adherence is considered nearest to gold standard 272 and is obtained by 
Medication Event Monitoring System (MEMS®)73 or POlypharmacy Electronic Monitoring System 
(POEMS) 273. POEMS consists of an adhesive film with conductive properties that can be fixed at the 
back of a multidrug punch card. It registers date, time, and position of the cavity where drug was 
removed. Recorded signals are transferred to a database 273. Whereas MEMS® is limited to monitoring 
of adherence to one single lead drug, POEMS can be attached to multidrug punch cards enabling the 
monitoring of adherence to polypharmacy. Many long-term studies on adherence enhancing 
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interventions with MEMS® and feedback on electronic dosing histories reported significant 
improvement on adherence 274-278 and one meta-analysis attributed a large effect to the same 
intervention 136.  
In summary, a service to enhance adherence in primary care patients that is simple, economic, and 
accepted is represented by multidrug punch card service, which is already implemented into daily 
practice in Swiss community pharmacies. However, multidrug punch cards were not commonly 
distributed to primary care patients. We propose that this adherence aid could be provided to any 
patient with polypharmacy, independently of age or condition, to result in improved medication 
adherence and thus yield clinical, humanistic, and economic benefits. Our study was the first in the 
attempt to electronically monitor adherence to polypharmacy, which might substantially add to the 
knowledge about adherence behavior in this complex situation. 
Aims and approach 
We aimed at investigating the effectiveness of a pharmaceutical care intervention comprising the 
packaging of all oral, solid medication into electronic multidrug punch cards and regular individual 
feedback on electronic dosing history, to improve adherence to polypharmacy and to reduce time to 
hospital readmission and major adjustment of medication therapy in primary care patients after 
hospital discharge. 
We approached this aim by conducting a pilot study to evaluate and to optimize the feasibility, 
efficiency, and quality of the study. We report herein of the results and experiences of the pilot study 
(Part C1.1) and of the evaluation (Part C1.2). 
 
Methods 
C1.1 Pilot Study 
The study was designed as a 12-months prospective randomized controlled trial performed at the 
University Hospital Basel and the Notfallapotheke Basel (study pharmacy) (Figure 2). The trial was 
performed in line with legal regulations (HMG, VKlin 279) and the International Conference on 
Harmonization (ICH) guidelines 280. The responsible ethic board approved the study protocol. The 
report of the pilot study is structured following the Consolidated Standards of Reporting Trials 
(CONSORT) statement 281.  
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Figure 2: Trial design. T, time; UHBS, University Hospital Basel. 
 
Setting and participants 
We recruited eligible patients from an internal medicine’s ward at the University Hospital Basel. The 
screening for eligible patients was carried out in two steps. In a first screening, the electronic case 
notes from the hospital database (ISMed) of all patients on the ward were screened according to in- 
and exclusion criteria (Table 1). Included patients of the first screening were assigned a consecutive 
study number. Additional criteria for eligibility were checked in a second screening on the ward with 
paper case notes. A study pharmacist recruited the included patients from the second screening on 
the ward. After informed consent was obtained, the patients were randomized and baseline data were 
assessed at bedside. All patients, irrespective of group allocation, met a study pharmacist for a 
discharge counseling on all prescribed medications. The counseling was performed by following 
standardized information sheets, derived from the official drug information 282, with information on 
indication, long-term benefit, adverse effects and correct use. These elements were described to be 
preferred by patients 143,283. An example of a standardized information sheet is given in the 
supplementary material. At the completion of the counseling, a personalized medication plan was 
handed out to the patients (supplementary material). Uncertainties raising during the counseling 
session were clarified with the responsible physician before the leave of the patient. The patient’s 
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community pharmacy and general physician (GP) were informed by fax about the patient’s 
participation in the study. The hospitalization during which a patient was recruited will herein be called 
‘index hospitalization’. 
 
Table 1. Inclusion and exclusion criteria. 
Inclusion criteria 
Age > 18 years of age 
Literate in German 
Capable to give informed consent 
Self-management of medication 
(Re-)Fill medication at a community pharmacy 
Prescription of ≥ 4 different oral solid drugs at discharge 
Swiss health insurance 
Acceptance of the electronic multidrug punch card use 
Exclusion criteria 
Pregnancy 
Physical impairment (visual or dexterity; as diagnosis or evaluated as such by the responsible nurse) 
Cognitive impairment (as diagnosis or evaluated as such by the responsible nurse) 
Transplantation 
Prescription of vitamin K antagonist at discharge 
Non-packable medication (e.g. > 2 non-solid/non-oral medications, > 4 dosing times per day) 
Transfer to another institution at discharge (e.g. nursing home, rehabilitation center) 
Use of a multidrug punch card or a single dose-dispensing aid (e.g. pouch blister) before hospital admission 
Prohibition of the access to patient records of the community pharmacy / general physician 
 
Three important changes were made to the methods after trial commencement: 
1. The length and wording of the script for recruiting was shortened and simplified. 
2. To augment efficiency of recruiting, the study steps of the hospital phase were adjusted. The 
extensive screening process was abandoned and the study pharmacist was integrated on 
regular weekly ward rounds with the physicians, including one to two thirds of the patients of 
the ward. Eligibility criteria were checked on the spot by consulting paper case notes, 
physicians, and nurses and in conversations with the patients directly (Figure 3). This change 
was indicated by the study evaluation and carried out in May 2013.  
3. The non-acceptance of multidrug punch cards was frequent. To include an adequate number 
of patients for descriptive analysis, patients were offered to take part in the study in the 
control group if they rejected the intervention. The randomization process was abandoned in 
June 2013. 
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Figure 3: Study steps of the hospital phase, before (above) and after adjustment (bottom). Legend: Green box = 
location; blue box = study action; clear box with blue frame: study action specific for intervention group; clear 
box with yellow frame: study action specific for control group. CRF Hosp T-1, case report form hospital T-1, with 
assessment of a: electronic patient records, b: paper case note data, c: patient interview and questionnaire 
quality of life; IC, informed consent form; QoL, quality of life   
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Intervention 
Intervention patients received their oral solid medication packaged in individualized electronic 
multidrug punch cards (Figure 4) continually from discharge until the end of the study. The multidrug 
punch cards were prepared at the study pharmacy by a pharmacist and reviewed by a second 
pharmacist. POEMS was affixed and activated on the completed multidrug punch card. The production 
took place under the conditions of Good Manufacturing Practice 284, following a standard operation 
procedure. At first provision, a study pharmacist instructed the patient in the use of the multidrug 
punch card and of the medication not included into the device. The capability of the patient to remove 
medication from a multidrug punch card was tested with a demo. Exchange of the multidrug punch 
cards took place at the study pharmacy in weekly or multiple weekly intervals. Multidrug punch cards 
and additional medication (if requested) were handed out by a pharmacist. In regular intervals, the 
study pharmacist conducted feedback sessions on adherence behavior with charted electronic dosing 
histories (Figure 4), using elements of motivational interviewing, e.g. active listening, reflective 
listening, affirmation, and summarization to help the patient express his concerns about the behavioral 
change, enhance his personal motivation, set goals and arrive at a change of plan 285. 
 
 
Figure 4. Electronic multidrug punch cards with affixed POlypharmacy Electronic Monitoring System (POEMS) 
on the backside and charted electronic dosing history over one week with a four-times daily intake (from left to 
right). 
 
Control conditions 
Patients allocated to the control group received their medication in commercial medication packaging 
and usual care at the community pharmacy of their own choice. Usual care in Swiss community 
pharmacies comprises management of patient records; validation of prescription; dispensing of the 
requested medication on prescription and over-the-counter (OTC); providing the most economic 
generic; interaction check; check of risk factors and contra indications; calling the physician for further 
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information if needed; check for abuse; counseling on dose, dose frequency, medication 
administration, duration of medication therapy, storage, and potential adverse reactions 158. 
Pharmacies also offer medication review (polymedication check, intermediate medication review 
according to the Pharmaceutical Care Network Europe 286) and dose-dispensing service, which are 
reimbursed by the health insurance. Patients were free to use self-filled medication management aids 
(e.g., pillboxes), however, dose-dispensing service was not allowed during the study. The patients were 
advised to always refill their medication at the same community pharmacy to allow retrieval of 
complete pharmacy claims for adherence measurement. 
Follow-up 
All patients were contacted by phone call within the first two weeks after discharge and before the 
next patient contact for a consolidation phone call analog to the ‘New Medicines Service’ (NMS), 
developed for community pharmacies in 2011 in the UK 287. The aim of the phone call was to ensure 
initiation of medication therapy prescribed at discharge and correct self-management of the 
medication and the multidrug punch card. Follow-up visits took place at three, six, and twelve months 
after hospital discharge at the study pharmacy. A study pharmacist performed one interview on the 
topics of pharmacy visits, GP visits, hospital readmission, medication therapy change, intake of OTC 
medication, medication management, medication management aids, and adverse drug reactions. The 
patients filled questionnaires for self-report of adherence and quality of life assessment. Community 
pharmacies were contacted after every follow-up visit to transmit medication claim records of the 
patients. At 12 months, one additional questionnaire assessed patient satisfaction and the GP was 
contacted by fax to transmit laboratory data of the patients. At the last visit, the future management 
of the medication was discussed and polymedication checks were offered to all patients to evaluate 
their need for dose-dispensing service by multidrug punch card. 
At each follow-up meeting, patients were invited to ask questions about their medication and at 
request, counseling on indication, benefits, use, and adverse reactions was given analog to the 
discharge counseling. The experience of adverse drug events (i.e., any injury related to the use of a 
drug, even if the causality of this relationship is not proven 288) was asked actively. If unexpected 
adverse events occurred at another time during the study, patients were able to contact the trial 
investigators via a hotline number. All reports were treated like any adverse drug event reported in 
the community pharmacy. According to severity of the symptoms, the study pharmacist counseled the 
patient about adverse drug event management, advised to discuss the problem with the GP at the next 
visit, referred the patient to the GP immediately, or phoned the GP for feedback. Every adverse drug 
event report, hotline contact, and further inquiry with the GP, community pharmacy, a relative, or the 
study physician was systematically documented  
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Outcomes 
The primary outcomes were: 
1.1 Composite clinical outcome of time to hospital readmission and time to major adjustment of 
drug therapy 
1.2 Adherence according to Medication Possession Ratio (MPR)  
Time to hospital readmission was calculated as the number of days from the day of discharge until the 
day of first unplanned readmission to any hospital. Time to major adjustment of drug therapy was the 
number of days from the day of discharge until the day of major adjustment of therapy. Major 
adjustment of drug therapy was defined as an at least two fold increase in drug dose and/or a 
prescription of a new drug in the same ATC code class. Events were assessed through patient self-
report at every follow-up visit. Major adjustment of drug therapy was verified by pharmacy records. 
MPR was calculated according to pharmacy claims within the 12 months of study duration as the 
number of the days’ supply obtained over multiple intervals, divided by the duration of the observation 
period 82. The observation period was defined as the time between first and last supply for every 
medication separately, under the assumption that there was no stock available at the first supply. The 
number of days’ supply was the sum of all supplies of the observation period minus the last supply 
divided by the amount of intake per 24 hours. We included all medications into the calculation that 
were prescribed over the whole study duration, had a fixed dosing unit (e.g., oral solid forms, inhalers), 
were prescribed for continuous use (i.e., not upon demand), were refilled at least twice, and with dose 
and dosing frequency, which were known and remained unchanged over the observation period.  
The secondary endpoints comprised: 
2.1 Adherence according to 
2.1.1 Self report: Morisky Medication Adherence Scale (MMAS) score of 0-8, with a maximal score 
of 8, indicating perfect adherence 67; visual analogue scales (VAS) of taking and timing 
adherence ranging from 0: no tablets taken / no tablets taken at the right time, to 100%: all 
tablets taken / all tablets taken at the right time; elements of the ‘Believes about Medicines 
Questionnaire’ (BMQ). 
2.1.2 POlypharmacy Electronic Monitoring System: Taking adherence as percentage of taken doses 
in relation of prescribed doses; timing adherence as average of all recorded intake times 
according to the prescribed dosing times; correct dosing intervals as percentage of doses taken 
within 25% of time interval between the prescribed doses. 
2.2 Clinical outcomes included the single measurements of time to hospital readmission and time to 
major adjustment of drug therapy. 
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2.3 Humanistic outcomes 
2.3.1 Quality of life according to the short form 12 v. 2 (SF 12 v. 2): score of 30-70, with a score of 
70 indicating best physical/mental health, 289.  
2.3.2 Satisfaction with the medication management system and the pilot study: questionnaire 
containing 37 closed-ended questions with 4-point Lickert-scale answers and seven open 
ended questions.  
Self-reported adherence and quality of life were assessed at baseline and at every follow-up visit. 
POEMS data were read out continually at every exchange of the electronic multidrug punch cards. The 
questionnaire for patient satisfaction was administered once at 12 months. 
Additional data assessed at baseline included demographic factors, such as diagnoses, prescribed 
medication at admission and discharge, over-the-counter (OTC) medication, marital status, living 
situation, education level, employment status, dexterity, health status before index hospitalization, 
hospital admissions in the three months before the index hospitalization, frequency of GP and 
community pharmacy visits, prior experiences with adverse events, and financial constraints 
concerning medication refill. Independency in daily activities was assessed with the Barthel index 
questionnaire (score of 0-100 with maximal score of 100 indicating total independency) was filled by 
the investigator with the help of the responsible nurse for the status of the patient at discharge. 
Laboratory data, e.g., glycosylated hemoglobin (HbA1C), were assessed at discharge from hospital 
records and at 12 months from the GP’s patient records, if available. 
Sample size and randomization 
Data of the composite endpoint ‘time to hospital readmission and time to major adjustment of drug 
therapy’ with the intervention of electronic multidrug punch card were not available. Based on studies 
examining a tele-monitoring intervention 290, with elderly patients 291, and with myocardial infarction 
survivors 292,293, we assumed a mean time to hospital readmission + to major adjustment of drug 
therapy of 200 days for the control group and 240 days for the intervention group (+ 20%). With an 
assumed standard deviation of 80 days in both groups and a sample size of 150 patients, the resulting 
power is 86.5% (calculated by a web-tool 294). A sample size of 150 patients (75 patients per group) 
was considered sufficient, since a larger sample size would facilitate to reach statistical significance but 
diminish clinical relevance. The same sample size was also proposed as a conclusion of a review 
analyzing 78 randomized controlled trials on effectiveness of adherence interventions 126. A total of 
200 patients were planned to be recruited to account for attrition, dropouts, and loss to follow up. For 
the pilot study, a sample size of 20 patients was determined. Recruited patients were allocated 
randomly 1:1 into intervention and control groups. Random numbers up to the intended sample size 
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of 20 (for the pilot study) were generated by a web-tool 295. A research assistant not involved in the 
study, packed the allocation information for every patient separately in sequentially numbered 
envelopes. The envelopes were kept in a closed drawer until the assignment. Two study pharmacists 
recruited eligible patients and assigned them to the study groups after informed consent was obtained, 
by opening the envelope with the subsequent number. Due to the nature of the intervention, blinding 
was not aspired. 
Statistics 
Due to the small patient sample size recruited during the pilot study, descriptive statistical methods 
were applied by SPSS v. 20 (IBM, Armonk, New York, USA) and MS Excel 2013 (Microsoft Corporation, 
Redmond, WA, USA). In the following paragraph, the originally planned analysis is described. 
Primary outcome measures will be compared between groups. Secondary outcome measures will be 
compared between groups and between baseline and follow-up measures. Differences in binary data 
will be calculated by χ2-test. The student t-test will be used for normally distributed and the Man-
Whitney-U-test for non-parametric means. In order to measure strength of the relationship between 
the primary endpoint and the group allocation and to test the impact of possible covariate factors, a 
multiple logistic regression model will be calculated. A p-value of ≤ 0.05 will be considered statistically 
significant. The analysis will be performed as an intention to treat analysis. 
C1.2 Study evaluation 
The evaluation was developed according to the ‘Planning-Evaluation-Cycle 20’, composed of the steps 
Formulation of evaluation question; Conceptualization; Evaluation design; Evaluation analysis of; 
Utilization of results in management or decision-making 296.  
Formulation of evaluation question 
The evaluation had the aim to optimize the feasibility, efficiency, and quality of the study. 
Conceptualization 
The evaluation was based on Donabedian’s evaluation model of the quality of care 297. According to 
this model, services are performed in given structures, following defined processes and finally 
generate an outcome of measurable quality. ‘Structure’ describes the properties of an environment in 
which care is performed, including organizational structure, material, and human resources. The 
category ‘process’ describes what effectively is practiced. The ‘outcome’ shows the effects of care on 
the health of the patients, i.e., improvement of the patient’s knowledge, beneficial changes in 
behavior, and satisfaction. These three parts of quality are directly related to each other, therefore 
good structure and processes lead to good outcomes. During the evaluation, key elements of 
structures, processes, and outcomes are measured by indicators. These indicators are suitable 
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numbers, facts, or parameters, which should be easy to assess in practice and need to be valid, reliable, 
and sensitive for assessment 298.  
These definitions were translated to the pilot study. The desired outcomes in this case were feasibility, 
efficiency, and quality of the study. Important elements of the pilot study were allocated to the groups 
of structure and process. For each group, one evaluation method catalogue was developed, containing 
concrete evaluation questions. At least one indicator and measurement method was defined for every 
question, indicating answers in scales (e.g. measurement of time), in categories (e.g. Lickert-scales, 
yes/no), or descriptions and judgment in words (e.g. to open-ended questions). Measurement 
methods included observation, a questionnaire, and analysis of study databases. Assessments were 
performed once for structural elements or repetitive over a defined period for process elements. 
Evaluation Design 
The observation focused on the processes in the hospital, such as the first and second screening, 
recruitment and discharge, and on structural elements like handling of documents and communication 
at the University Hospital Basel. Assessment forms with predefined questions according to the study 
steps were developed. Continuous assessments were measured at five time points. 
The perspective of the study team was assessed by a questionnaire based on the questions of the 
evaluation method catalogues. The questionnaire referred to the whole study duration and comprised 
the topics a. work within the study team; b. work at the University Hospital Basel and at the study 
pharmacy; c. work with the documents. Answers were indicated as binary (yes/no) and as four-point 
Likert scales. Answers could be specified in open comment fields. The same questionnaire was 
provided to the whole study team with the instruction only to answer the questions concerning their 
tasks at a short introduction during the study meeting. 
Analysis of the databases of both screenings, recruitment, and baseline assessment, containing 
patients’ data from the beginning of the study (21.01.2013) to the 30.04.2013, were on the following 
topics: 
 Fluctuation of patients at the hospital according to electronic database (ISMed) 
 The ratio of included and excluded patients after the first screening, the second screening, 
and after the recruitment 
 The reasons for exclusion in the first screening, the second screening, and at the recruitment 
 The reasons for rejection of study participation 
 Number of multiple assessments 
The evaluation was started simultaneously to the commencement of the pilot study. 
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Analysis 
The results of the observation, questionnaires, and database analysis were calculated quantitatively 
with MS Excel 2007 for Windows (Microsoft Corporation, Redmond, WA, USA). Based on these results, 
the evaluator answered the questions of the evaluation catalogues and judged the study elements as 
'adequate / improvement unnecessary’, ‘optimizable / minor improvements recommended’, and 
‘inadequate / major improvements necessary’.  
The evaluation of the hospital phase was systematically carried out by a master student in Pharmacy 
during the first period of the pilot study (21.01.2013-30.04.2013) using the above described methods. 
The evaluation of the primary care phase was conducted by the study coordinator at the termination 
of the pilot study, based on experiences and analysis of study databases. 
Results 
C1.1 Pilot study 
The pilot study was performed from the 21st of January to the 30th of September 2013. 
Participants 
Of a total of 958 screened patients, 10 (1.0%) consented to participate in the study. The numbers of 
the screened and recruited patients and the numbers and reasons for exclusion, lost-to-follow-up, and 
drop-out are depicted in Figures 5 and 6. One patient assigned to the intervention group rejected 
participation upon discharge but agreed to be included in the control group and therefore was 
reassigned.  
Recruitment 
Recruitment started at 21st of January and ended at the abandonment of the pilot study on 30th of 
September with an interruption from the 25th of March to the 12th of April because of a case of death 
in the nursing team of the ward. During the flu season, the ward chosen for the recruitment served as 
pooling ward of patients with infectious isolation and thus was not accessible for recruitment. 
Therefore, we attempted to change the recruitment ward. However, the change of the ward was not 
possible, because the head of the ward did not accept recruiting staff due to understaffing of the 
nurses. For this reason, 58 of the screened patients on this ward (6.2) were lost to follow-up (Figure 
5). Of the 80 visited patients, 10 (12.5%) consented to participate in the study (Figure 6). Reasons for 
rejection of study participation are shown in Figure 7. 
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Figure 5: Flow chart of the screening phase of the pilot study with numbers and reasons for exclusion 
and lost to follow-up. Eighty patients were included for recruitment. GP, general physician. 
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Figure 6: Flow chart of the recruitment of the pilot study with numbers and reasons of exclusion and 
numbers of patients recruited, allocated and analyzed. GP, general physician. 
 
 
Figure 7: Reasons for rejection of study participation (n=45). MDPC, multidrug punch card. GP, general 
physician. 
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Baseline data 
Baseline data of the recruited patients are displayed in Table 2. All patients were fully independent in 
daily management according to the Barthel index (score of 100) 299, except for the patient with the 
fracture (patient ID 2; score of 90). Their health status in the two weeks before index hospitalization 
was very good (n=2), good (n=6), and moderate (n=2). One patient from the control group had had a 
hospital admission within the three months before the index hospitalization. In the year prior to the 
index hospitalization, four patients had visited the GP 1-2 times and six patients 3-6 times. Three 
patients did not visit a community pharmacy during the previous year, five visited it 3-6 times, and one 
patient went to the pharmacy 1-3 times per month. Two patients reported prior experiences with 
adverse drug events and one patient had thought once of not refilling a medication because of financial 
constraints. Correspondingly, the intervention patient had had no hospitalization in the three months 
before index hospitalization and reported two planned GP visits, three to six community pharmacy 
visits, and no experience of and averse drug reaction in the year prior to the index hospitalization.  
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Table 2. Baseline data of the recruited patients. 
* The patient did not use prescribed long-term medications before index hospitalization. 
Appl. sci., applied sciences; MMAS, Morisky Medication Adherence Scale; QoL, quality of life; TaA, taking adherence; TiA, timing adherence; VAS, visual analogue scale. 
Patient 
ID 
Age 
[years] 
Sex Living 
situation 
Education 
level 
Employ-
ment status 
Cause for index 
hospitalization  
Adherence 
MMAS 
Adherence 
VAS 
QoL 
physical/me
ntal score 
No. of drugs 
at hospital 
admission 
No. of drugs 
at hospital 
discharge 
Control patients   
1 75 F With 
partner 
Appren-
ticeship 
Retired  Hypertensive heart 
disease 
2.5 TaA: 90% 
TiA: 90% 
40 / 51 5 7 
2 63 M With 
partner 
University 
(PhD) 
Employed Fracture of lumbar 
spine and pelvis 
6 TaA: 96% 
TiA: 90% 
58 / 58 3 10 
3 67 F With 
partner 
University 
of appl sci 
Retired Glioblastoma  8 TaA: 100% 
TiA: 100% 
40 / 59 6 6 
4 68 F Alone Business 
school 
Retired Pain in upper 
abdomen 
8 TaA: 100% 
TiA: 100% 
56 / 62 3 4 
5 80 F With 
partner 
University 
(PhD) 
Retired Ischemic 
cerebrovascular insult  
8 TaA: 100% 
TiA: 100% 
56 / 54 4 8 
6 53 M With 
partner 
High 
school 
Employed (N)STEMI / 
Myocardial infarction  
n.a.* n.a.* 50 / 61 0 5 
7 76 M With 
partner 
Mandat-
ory school 
Retired Unspecified arthritis  8 TaA: 100% 
TiA: 100% 
56 / 50 8 10 
8 35 M With 
partner 
Appren-
ticeship 
Employed Hematemesis 5.5 TaA: 50% 
TiA: 70% 
54 / 45 1 6 
9 57 M With 
partner 
University 
of appl sci 
Employed Ischemic 
cerebrovascular insult 
8 TaA: 100% 
TiA: 100% 
58 / 52 6 7 
Median 
(range) 
/ Sum 
67 
(35-80) 
F: 4 
M: 5 
With 
partner: 8 
Alone: 1 
n.a. Retired: 5 
Employed: 4 
n.a. 8 
(2.5-8) 
TaA: 100% 
(50-100%) 
TiA: 100% 
(70-100%) 
56 (40-58) / 
54 (45-62) 
4 
(0-8) 
7 
(4-10) 
Intervention patient   
10 64 M Alone University 
of applied 
science 
Retired Staphylococcus 
aureus sepsis 
8 TaA: 100% 
TiA: 50% 
46/42 7 10 
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Outcomes and estimation 
The number analyzed for the control group was n=8, 7, and 6 for follow-up at three, six months, twelve 
months, respectively. The number analyzed for the intervention group was n=1.  
At the phone follow-up, nine of ten patients could be reached and all reported that they could start with 
the treatment as prescribed at discharge. Seven of nine patients had had a control visit at the GP’s and for 
five patients this had resulted in a change of their medication regimen. All patients felt confident in the 
administration of their medication. The phone call was performed at a median of 14 days after discharge 
(range: 4-26 days) with a median duration of 12.5 minutes (range: 7-34 minutes). 
Six of the nine control patients and the intervention patient completed the study. One control patient 
forgot one appointment for follow-up assessment, which was postponed. Otherwise, the patients kept all 
appointments at the study pharmacy. All control patients self-managed their medication, except for one, 
who had the help of his wife. Two patients of the control group had home delivery by mail order pharmacy 
and four received their medication at the community pharmacy. The follow-up visits at three, six, and 
twelve months took place at a median of 98 days (range: 89-109 days), 188.5 days (171-216 days), and 368 
days (365-379 days), respectively, and lasted a median of 19.5 minutes (12 minutes – 1 hour). 
Over the whole study period, no patient experienced an unplanned hospital readmission. The intervention 
patient had one major adjustment of drug therapy, i.e., an augmentation of bisoprolol 2.5mg twice daily 
to 5mg twice daily, 79 days after hospital discharge. The medication possession ratio (MPR) could be 
calculated for five of six patients in the control group for a median of four medications (range 1-5). For one 
patient (patient ID 2), most medications changed during the study period and for the remaining two 
medications he had too few pharmacy claims (<2) to be included into MPR calculation. The overall MPR of 
the control group was 1.01 ± 0.10. For the intervention patient, the MPR could be calculated over six 
medications. Some of the claims had shorter observation periods than others because the patient provided 
his stock medication for inclusion into the multidrug punch card. The overall MPR of the intervention 
patient was 1.18 ± 0.11. The MPRs per groups, patient, and medication are listed in Table 3. 
Adherence measures according to patient self-report, quality of life, clinical outcomes, and the changes of 
the patient’s medications during the study period are displayed in Table 4. Results from the ‘Believes of 
Medicines Questionnaire’ (BMQ) showed that the patients were rather ambivalent in medication use, in 
that they acknowledged the necessity but were worried about the consequences of medication use. 
Detailed answers to BMQ questions and the trends over time are given in Annex A4.7. Results from the 
electronic measurement of adherence by POEMS are reported separately in a case report (page 148). 
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Table 3. Medication possession ratio (MPR) per medication, per patient and per treatment group. 
SD, standard deviation. 
Patient 
ID 
Medication included in calculation Observation 
period [days] 
MPR  Mean MPR / 
patient 
SD 
Control patients (n=5) 
1 Rivaroxaban 312 0.94 0.94 n.a. 
4 Aspirin® 282 1.04   
Candesartan / hydrochlorothiazid 282 1.04 1.04 0 
5 Alendronate 315 1.07   
Aspirin® 189 1.04   
Atorvastatin 279 0.72   
Vitamin B complex 248 1.11 0.99 ± 0.18 
6 Aspirin® 302 0.97   
Atorvastatin 302 0.66   
Bisoprolol 302 0.99   
Lisinopril 302 0.99   
Ticagrelor 302 0.93 0.91 ± 0.14 
7 Aspirin® 169 1.16   
Atorvastatin 321 0.93   
Pantoprazol 244 1.23   
Ramipril 321 1.25   
Tizanidin 246 1.22 1.16 ± 0.13 
Overall MPR of the control group 1.01 ± 0.10 
Intervention patient 
10 Aspirin® 375 1.12   
Atorvastatin 328 1.31   
Clopidogrel 328 1.28   
CoAprovel 178 1.10   
Metfin 341 1.23   
Pantoprazol 232 1.03 1.18 ± 0.11 
 
 
.
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Table 4. Adherence, clinical and humanistic outcomes and medication therapy changes over the study period. 
Hc, healthcare; MMAS, Morisky Medication Adherence Scale; n.a., not applicable; OTC, over-the-counter; pack., packable; pat, patient; QoL, quality of life; SF12 v.2, short form 12 version 2; T0, T3, 
T6, T12, time points of discharge and follow-up visits at three, six, and twelve months. 
 Control patients Intervention patient 
Assessments 
For control patients values are given as median (range) 
T0 
(n=9) 
T3 
(n=8) 
T6 
(n=7) 
T12 
(n=6) 
T0 T3 T6 T12 
Adherence MMAS, 8  
(2.5-8) 
7 
(4.75-8) 
7 
(6.75-8) 
8 
(5-8) 
8 8 8 8 
VAS taking adherence 100% 
(50-100%) 
100%  
(98-100) 
100%  
(96-100%) 
99.5%  
(94-100%) 
100% 65% 95% 95% 
VAS timing adherence 100%  
(70-100%) 
100%  
(95-100%) 
100%  
(80-100%) 
95%  
(90-100%) 
50% 75% 95% 85% 
Humanistic 
outcomes 
(QoL) 
SF12 v.2 physical scale 56 
(40-59) 
47 
(33-60) 
54 
(44-59) 
55 
(33-58) 
46 39 42 48 
SF12 v,2 mental scale 54 
(45-63) 
53 
(44-58) 
57 
(40-60) 
56 
(44-63) 
42 62 61 58 
Clinical 
Outcomes 
Major therapy adjustment n.a. 0 0 0 n.a. 1 0 0 
Unplanned hospital readmissions n.a. 0 0 0 n.a. 0 0 0 
Unplanned visits at any hc facility n.a. 0 0 0 n.a. 0 0 0 
Planned GP visits per patient n.a. 2 (1-6) 2 (1-4) 3 (1-5) n.a. 4 3 2 
Pharmacy visits per patient n.a. 3 (1-7) 2 (0-4) 2 (0-4) n.a. 9 4 6 
Glycosylated hemoglobin ( control pat n=1) 6% n.a. n.a. 5.8% 8% n.a. n.a. 7% 
Blood pressure [mmHg] ( control pat n=5) 141/76  
(123/75-
154/92) 
n.a. n.a. 131/80 
(125/64-
142/91) 
183/93   193/88 
Medication 
changes 
Number of medications per patient 7 
(4-10) 
6.5 
(3-10) 
7 
(3-11) 
5 
(3-12) 
10 9 9 9 
Number of patients with medication changes n.a. 6 6 4 n.a. 2 0 0 
Number of medications started per patient n.a. 0 
(0-3) 
1 
(0-3) 
0 
(0-1) 
n.a. 0 0 0 
Number of medications stopped per patient n.a. 0.5 
(0-4) 
0 
(0-1) 
0 
(0-2) 
n.a. 1 0 0 
Number of medications changed per patient n.a. 1 
(0-3) 
0 
(0-2) 
0.5 
(0-4) 
n.a. 1 0 0 
Number of 
medication by dosage 
form at discharge per 
patient 
Oral, pack. 5 (4-9) n.a. n.a. n.a. 8 n.a. n.a. n.a. 
Oral, non-pack 0 (0-1) n.a. n.a. n.a. 0 n.a. n.a. n.a. 
Parenteral 0 (0-1) n.a. n.a. n.a. 2 n.a. n.a. n.a. 
Inhaler 0 (0-2) n.a. n.a. n.a. 0 n.a. n.a. n.a. 
Skin patch 0 (0-2) n.a. n.a. n.a. 0 n.a. n.a. n.a. 
Number of OTC medications 1.5 (0-6) 1.5 (0-7) 2 (0-5) 3 (0-6) 0 0 0 0 
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All control patients had one or several strategies to remind medication intake encompassing self-filled 
multicompartment adherence aids (n=4), visual reminders, storage of medication at a strategic place, 
connection with a daily routine, and integration in daily life. All patients were very satisfied with their 
strategies of medication management. There was no remarkable difference between control patients, 
who had their own systems for medication management and the intervention patient, who had the 
multidrug punch card. The control patients were confident that the system helped them with the 
correct use of their medication (Figure 8). The satisfaction of the intervention patient with the 
multidrug punch cards is shown in Figure 9. The patient reported initial handling difficulties because 
of strong resistance of drug removal from the cavities that were fully loaded (e.g., morning cavities, 
which contained eight medications). These problems resolved with time. 
 
 
Figure 8: Satisfaction of the control patients with their medication management system (n=6). 
 
 
Figure 9: Satisfaction of the intervention patient with the multidrug punch card. 
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At the end of the study, patient 6 of the control group wished to start multidrug punch card service. 
Patient 1 bought a pillbox, which she filled on her own. All other patients preferred to continue with 
their previous systems. The intervention patient requested to continue the multidrug punch card 
service. 
Harms 
During the whole study, there was no emergency call on the hotline. The intervention patient reported 
initial handling difficulties with the multidrug punch card, which resolved with time. There was never 
a danger of failure of medication intake because of the multidrug punch cards. Five of all ten patients 
stated adverse drug events at one or more follow-up visits, which are specified in Table 5. 
 
Table 5. Adverse drug events (ADE) reported during the study, action taken, and outcomes. 
ADE, adverse drug event; ADR, adverse drug reaction GP, general physician; T0, T3, T6, T12, time points of discharge and 
follow-up visits at three, six, and twelve months. 
Patient 
ID 
Time of ADE 
report 
Nature of ADE / suspected 
medication 
Action taken Outcome (assessed at 
the next follow-up visit) 
1 Consolidation 
phone call 
(1) Myopathy/atorvastatin 
(2) Gastro-intestinal 
problems, loss of appetite, 
obstipation, vertigo 
(1) Atorvastatin was stopped 
by the GP prior to the phone 
call. 
(2) Counseling about ADE 
management. 
Symptoms improved 
Follow-up T6 Obstipation / amlodipine Counseling about ADE 
management 
Symptoms persisted, 
follow-up at the next 
visit 
Follow-up T12 Loss of appetite, obstipation, 
loss of hair / antihypertensive 
medication 
Counseling about ADE 
management 
No follow-up 
2 Follow-up T3 Edema on lower leg, low body 
temperature / amlodipine 
None - patient reported 
handling by the GP 
No follow-up 
5 Consolidation 
phone call 
Increased tiredness Related to rehabilitation 
phase after hospitalization 
No follow-up 
Follow-up T6 Bad smell in mouth, 
hypersalvation / atorvastatin 
None - patient reported 
handling by GP 
No follow-up 
6 Follow-up T3 Increased tiredness / 
bisoprolol 
None - patient reported 
handling by the GP 
Follow-up at the next 
study pharmacy visit 
Follow-up T6 Increased tiredness / 
bisoprolol 
None - patient reported 
handling by the GP 
Follow-up at the next 
study pharmacy visit 
Follow-up T12 Increased tiredness / 
bisoprolol 
None - patient reported 
handling by the GP 
No follow-up 
9 Consolidation 
phone call 
Bleeds rapidly after marginal 
injuries, blood smells metallic, 
dry cough / ramipril 
Advise to discuss the ADE with 
the GP at the next visit 
(substitution of ramipril) 
Symptoms persisted, 
follow-up at the next 
study pharmacy visit 
Follow-up T6 Dry cough / ramipril Advise to discuss the ADE with 
the GP at the next visit 
(substitution of ramipril) 
Ramipril was stopped at 
T6 and substituted 
through valsartan / 
hydrochlorothiazide 
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C1.2 Study evaluation 
Hospital phase 
The evaluation catalogues of the structure and process elements of the pilot study contained a total 
of 158 questions with corresponding indicators and measurement methods (supplementary material). 
Single and continuous observations were performed in eleven halve days distributed over twelve 
working days between 15.04.-30.04.2013. The questionnaire was filled by all four study team 
members. The databases used for evaluation analysis contained data from 376 patients in the first and 
197 patients in second screening during the predefined time period.  
Structure evaluation 
Considering the fixed times of the ward (e.g. for ward rounds, meals, visiting) and the investigators’ 
experiences, the best time to go on the ward was between 10.00-12.00 a.m. for the second screening 
and after 3.00 p.m. for recruitment. The walking distances between the different study locations took 
less than 7 minutes. The response to calls of the hotline was tested five times, of which one was 
answered, one was called back, and three were not registered.  
Access to electronic and paper case notes was always possible, although paper case notes were not 
always traceable. An average of 5.8 ± 3.5 new patients (range: 1-15) were screened per day in the 
electronic hospital database. The average stay of a patient at the hospital was 7.4 ± 5.9 days (range: 1-
30). The number of days between entry of a patient and his / her assessment at the first screening took 
3.2 ± 2.5 days (range: 0-13). The observation showed that the electronic hospital database was not 
always up to date and that there were discrepancies of the patient numbers (±1), which resolved within 
one to two days. 
Figure 10 charts the flow of the first and second screening during the evaluation period. Major 
exclusion reasons were domicile, vitamin K antagonist, and dementia in the first screening, and < 4 
solid oral drugs, transfer to another institution, and non-packable drugs in the second screening. At 
the first screening 58.8% of all screened patients were included and at the second screening 49.2% of 
all patients available for the second screening were included for recruiting. The category ‘transfer to 
other institution’ comprised the transfer to another ward, nursing home, rehabilitation center, 
psychiatry, and women's house. In the first and second screening, 23 and 2 patients were assessed 
multiple times, respectively (exclusion reason ‘multiple inclusion’). The reasons for loss to follow-up 
because of discharge were non-availability of the patient during hospitalization (e.g., because of acute 
clinical condition, medical investigation etc.; 13, 34.2%), absence of the study team (12, 31.6%), too 
short hospital stay (9, 23.7%), and weekend discharge (4, 10.5%). 
Of 34 patients included for recruitment, 11 were excluded during the recruiting because of transfer to 
other institution (4, 8.8%), receiving medication from physician or rejection to change the pharmacy 
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(3, 8.8%), discharge (3, 8.8%), and < 4 oral solid medications (1, 2.9%). Twenty-three patients rejected 
the study participation because of several reasons (Figure 11). At recruitment, 12.5% of the visited 
patients were included and consented to participate. Overall, 1 of 94 patients from the first screening 
was enrolled. There were no drop-outs during the evaluation of the hospital phase of the pilot study. 
 
Figure 10: Flow chart of the patients in the first and second screening during the evaluation phase with the 
numbers and reasons for exclusion and loss of follow-up. Thirty-four patients were included for recruitment 
(this was an intermediate result of the master thesis and may not be in total accordance with the final adjusted 
analysis displayed in Part C1.1, Chapter ‘Participants’). GP, general physician. 
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Figure 11: Reasons for rejection of study participation (n=23; this was an intermediate result of the master 
thesis and may not be in total accordance with the final adjusted analysis displayed in Part C1.1, Chapter 
‘Participants’). 
 
All documents containing sensitive patient data were kept in a separately locked drawer. The study 
team members rated the place for document storage as inadequate because of inconvenience of 
access and the lack of clear arrangement in the drawer. The effort to print new documents was judged 
as low, the items in the case report forms (CRFs) well understandable, and the layout of the CRFs well 
designed. The structure of the CRFs, applicability and understandability of the predefined questions 
for the patients were considered as rather good. During observation, the patients asked no questions 
indicating trouble with the wording.  
Within the study team, the role was unclear for one, and the tasks not clearly defined for another team 
member. Some tasks handed over by the study coordinator were not or only partly manageable 
because of time or skill requirements. The Standard Operating Procedures (SOP) for the study 
distributed at the first study team meeting were known by three of four study team members and two 
persons adhered to them. The information flow was generally judged as too low and a regular updating 
by e-mail was desired. However, team members agreed that there were adequate possibilities for 
feedback to and support by the study coordinator. The study team rated the working atmosphere and 
communication as good at all study locations.  
A summary of the structure evaluation of the hospital phase is given in Table 7 at the end of section 
‘Process evaluation’. 
Process evaluation 
The time measurements of the single study steps and per patient in-, exclusion, and assessment are 
shown in Table 6. ‘Open patient’ means that the patient has not decided about study participation to 
132:  PROJECT C1 | Electronic multidrug punch cards to improve clinical and humanistic outcomes in patients after hospital discharge Results 
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
that moment. Predefined process schemes were available for the recruitment and the discharge 
counseling. The schemes were adhered to and uniformity of processes was mostly kept. The time 
needed by the patients to decide about the participation was 2.0 ± 2.9 days (n=5, range 0-7 days). 
 
Table 6. Time expenditure of study steps and per patient. 
CRF, case report form; min, minutes; n.a., not applicable; no., number; SD, standard deviation; T0, time point of discharge 
Step of the study 1. Screening  2. Screening  Recruitment  Discharge  
Time expenditures and numbers of patients screened and assessed per day 
No. of investigators observed (no. of 
observations) 
2 (11) 2 (8) 2 (6) 1 (1) 
Mean duration per day ± SD [min], (range) 42.7 ± 28.6 63.3 ± 25.0 36.8 ± 30.7 48.9 
Mean no. of patients assessed per day ± SD 6.5 ± 4.9 10.5 ± 3.7 1.60 ± 0.55 1 
Mean no. of included patients per day ± SD 3.6 ± 2.5 2.5 ± 1.1 0.2 ± 0.5 n.a. 
Mean no. of excluded patients per day ± SD 2.6 ± 2.7 3.0 ± 1.5 0.6 ± 0.6 n.a. 
Mean no. of open patients per day ± SD 0.3 ± 0.5 5.0 ± 1.9 0.8 ± 0.8 n.a. 
Time expenditures by patient screening and assessment 
No. of investigators observed (no. of 
observations) 
2 (45) 2 (27) 2 (7) 1 (1) 
Mean time expenditure 
of screening and 
assessment  
± SD [min] 
per included patient 5.4 ± 2.0 4.6 ± 1.0 47.5 48.9 
per excluded patient 0.7 ± 0.0 1.8 ± 2.0 3.8 ± 2.0 n.a. 
per open patient  0.4 2.1 ± 2.0 9.4 ± 5.7 n.a. 
 
At the second screening, a patient initially excluded for a criterion of which a change during 
hospitalization was potentially realistic (e.g., > 4 oral solid medications) and allowed the subsequent 
inclusion of the patient, was followed-up until discharge. At the moment of change of the criterion, 
the patient was included to be recruited. Of 10 initially excluded patients followed-up during the 
observation period, nine were definitively excluded and one patient was still followed-up at the end 
of the observation phase. The mean time for these follow-ups was 5.9 ± 4.4 days. The initial reasons 
for exclusion and the reasons for stopping the follow-up are illustrated in Figure 12.  
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Figure 12: Reasons for initially excluded and followed-up patients (n=10) and reasons for stopping the follow-
up (n=9). One patient was still followed-up at the end of the observation phase. 
 
For data entry, a preset MS Access database and a corresponding data dictionary were available. The 
filling of the database was manageable in adequate time (8.9 ± 3.2 for all data from screening to 
recruitment).  
The communication within the study team was reported to be optimizable. The communication of the 
study team with employees of the hospital pharmacy, the study pharmacy, and the hospital ward was 
rated as good. The observations confirmed these statements. Availability of information from nurses 
and physicians was good.  
A summary of the process evaluation of the hospital phase is given in Table 7. 
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Table 7. Summary table of the hospital phase evaluation. The dots indicate the judgment of the evaluator based on the 
results of the measurements according to the evaluation catalogue performed during the study. Green dots indicate 
adequate process / improvement unnecessary; orange dots indicate optimizable process / minor improvements 
recommended; red dots indicate inadequate process / major improvements necessary. The feasibility of the structure was 
not evaluated herein. 
N.e., not evaluated. 
Study 
step  
1. Scree-
ning 
2. Scree-
ning 
Recruit-
ment 
Disch-
arge 
Hospital Docum-
ents 
Study 
team 
Patients Software 
Structure  
Quality 
        
n.e. 
Efficiency 
        
n.e. 
Procedure 
Feasibility 
      
n.e. 
  
Quality 
       
n.e. 
 
Efficiency 
         
 
Primary care phase and patient satisfaction 
The rest of the evaluation catalogue was answered by the study coordinator’s experiences and by 
analysis of the study databases, and was mainly qualitative. The following paragraph lists, a summary 
of the inadequate points of study structure and process.  
Inadequate points of the study structure: 
 Follow-up visits: 
o Problematic understandability of SF12 v.2 and patient satisfaction questionnaires  
 Study patients: a drop-out rate of 33% is not acceptable 
 Community pharmacies: 
o Complaint from the regional pharmacy association about neglect of informing 
o Complaint from a community pharmacy because of client theft and subsequent 
implication to stop cooperation (transmission of patient records) 
 Study pharmacy:  
o Non-transferable key to the study pharmacy complicated the organization 
o Missing coordination with the study pharmacy team led to a collision of appointments 
(team event, follow-up visit) 
 Multidrug punch card / POEMS 
o We used prototype POEMS films, with which we experienced technical difficulties: false 
positives because of interference with other chips, false positives and early recordings 
because of injured circuitries before the actual removal or without removal, complete loss 
of data of 11 multidrug punch cards and nine additional days because of technical failure. 
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o Non-availability of RFID-chips resulting in a delay of recruitment and therefore in a loss to 
follow-up (discharge), and in increased effort for the intervention patient (more frequent 
visits). 
Major inadequate points of the study procedure: 
 Questionnaires: Conduction as interviews because of reluctance or inability of patients to fill out 
questionnaires. 
 Multidrug punch cards 
o  High time expenditure for production for four weeks (1.5-2h). 
o Difficulty in removing medications from the electronic multidrug punch card by the 
intervention patient if the cavities were fully loaded.  
 
The summary of the structure and process evaluation of the primary care phase is illustrated in Table 8. 
 
Table 8. Summary table of the primary care phase evaluation. The dots indicate the judgment of the evaluator according 
to the evaluation catalogue, based on the experiences of the study coordinator and database analysis. Green dots indicate 
adequate process / improvement unnecessary; orange dots indicate optimizable process / minor improvements 
recommended; red dots indicate inadequate process / major improvements necessary. 
Comm. pharm., community pharmacies; Cons., consolidation; MDPC, multidrug punch card; n.e., not evaluated; POEMS, 
POlypharmacy Electronic Monitoring System 
Study step  Cons. 
phone 
call 
Follow-up 
visits 
Study 
patients 
Comm. 
pharm. 
Study 
pharmacy 
MDPC / 
POEMS 
Resources Outcomes 
Structure 
Feasibility 
 
n.e. 
      
Quality 
  
n.e. 
 
n.e. 
 
n.e. 
 
Efficiency 
 
n.e. 
      
Procedure 
Feasibility 
 
n.e. 
 
n.e. n.e. n.e. n.e. n.e. 
Quality 
   
n.e. 
  
n.e. n.e. 
Efficiency 
   
n.e. n.e. 
 
n.e. n.e. 
 
Patient perspective 
Patient satisfaction with the study elements was high (Figure 13). 
In summary, the few and moderate criticisms concerned the high number of questions of the baseline 
assessment at the hospital, the information about the study, the structure and volume of discharge 
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counseling, the atmosphere in the study center. The intervention patient criticized the lack of financial 
compensation. 
Detailed results of satisfaction about hospital phase and discharge counseling, consolidation phone 
call, and follow-up are illustrated in Figures 14, 15, and 16. 
 
 
Figure 13: Overall satisfaction of all study patients with the study structures and processes (n=7). 
 
 
Figure 14: Patient satisfaction with the hospital phase and discharge counseling (n=7). 
 
 
Figure 15: Patient satisfaction with the consolidation phone call (n=7). 
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Figure 16: Patient satisfaction with the follow-up visits (n=7). 
Discussion 
Summary 
This pilot study showed adequate feasibility of the study design, but a lack in efficiency and quality. 
Accordingly, only ten patients could be recruited and only one patient accepted the intervention. Over 
the whole study duration there was no unplanned hospital readmission and one major adjustment of 
drug therapy in the intervention patient. However, the intervention patient maintained perfect 
adherence, and was clinically stable over the whole study year. In the control group, adherence was at 
a maximum according to self-report and medication possession ratio (MPR) and quality of life was 
adequate. Major inadequate points of the study procedure and structure concerned the high exclusion 
and rejection rates, the inadequate time management, the vague task assignment and poor 
communication within the study team, insufficient communication with the community pharmacies, 
the induction of a potential bias by medication counseling at the follow-up assessments, and technical 
difficulties with the POEMS prototypes. The evaluation of the pilot study pointed out important 
barriers for successful study performance and hence proved beneficial. 
C1.1 Pilot study 
The intent of this study was to show the effectiveness of electronic multidrug punch cards and 
feedback on electronic dosing history on adherence and patient-relevant outcomes, independently 
from clinical condition and age. The results of such a study would be representative for the general 
population and are highly demanded 62,142,155. With the small study sample, this question could not be 
answered.  
Overall, the patients participating in the study showed maximal adherence throughout the study 
period and implied ambivalent and affirmative attitudes towards medication intake. The adherence 
results of the control group lie over values reported for comparable patient groups 29,300. Of course, 
the results of our small study sample cannot be representative. In addition, patients engaging in a 
study investigating adherence might be interested in health and thus motivated to be adherent. 
Adherence of patients participating in a study is known to be higher than in real-life 91. Further, a 
reporting bias might be assumed, which occurs when the patients try to anticipate the preferred 
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answer 252. We performed a discharge counseling with all patients to exclude the interference of 
variable medication knowledge with our outcomes 108,265-267. However, the discharge counseling itself 
could have had an influence on the outcome parameters of the control patients, as this was shown by 
previous work 301. Additionally, we actively discussed medication changes at the follow-up meetings 
with all patients. Under these circumstances, the control patients probably had an unintended 
intervention and cannot be compared to patients having usual care from the community pharmacy.  
Another source for falsification is the insufficient reliability of patient self-report 268. However, the high 
values of self-reported adherence were supported by high MPR values in our study. For all control 
patients the mean MPR was between 0.91 and 1.16. Such MPR values have been reported favorable 
for health outcomes in various diseases 78,79. The oversupply, indicated by an MPR of over 1, occurred 
frequently and is comprehensible for adherent patients because they refill their medication before the 
use of the last tablet resulting in supply overlaps. However, this also means that the assumption 
defined for this calculation, i.e., that the patients were out of medication stock at the first supply, has 
to be doubted and therefore MPR could be underestimated. On the other hand, we did not account 
for supply gaps and allowed the retrospective filling of these gaps, which of course overestimates 
adherence. Further information is lost by the exclusion of patients with fewer than two pharmacy 
claims. For these patients, non-persistence has to be assumed. Finally, the calculation of a mean MPR 
per patient balances high and low values and hides non-adherence to single medications. In our 
sample, there were MPR values below 0.9 for some medications. Above all, it is noticeable that MPR 
values for statins were especially low and that this trend occurred in all patients with prescribed 
statins. Such trends have also been observed in other studies 87,104. For patients with polypharmacy, a 
new method to calculate adherence has been proposed recently, which accounts for the shortcomings 
discussed above, e.g. retrospective filling of gaps 82. In the intervention patient, the MPR symbolizes 
the supplies that registered by the study pharmacist for the multidrug punch card production and does 
not represent the actual refill of the patient. However, indirectly it implies that the patient collected 
all multidrug punch cards for a continuous supply. 
There was no unplanned readmission to the hospital during one year after the index hospitalization. 
This could indicate either that all patients were clinically stable due to optimal adherence, or that the 
observation period for this kind of outcome in that particular population was too short. Available 
literature rather supports the first assumption 99,105,292,293, however, the small sample size limits such 
considerations. One major adjustment of therapy occurred 79 days after discharge in the intervention 
patient (doubling of the bisoprolol dose). Treatment intensification has been associated with poor 
adherence 95. The intervention patient suffered from uncontrollable blood pressure, which persisted 
during index hospitalization and over the whole study period. All other treatments remained 
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unchanged and adherence was high according to all measurement methods. We therefore do not 
assume treatment failure as a result of non-adherence. In the control group, a considerable number 
of treatment changes occurred too. Nevertheless, there was no major therapy adjustment indicating 
treatment intensification.  
Quality of life yielded good results representing average values related to the US population (indicated 
by the SF12 tool 289). The initial drop of the physical component at the three-month follow-up might 
reflect the reason or consequence of the index hospitalization. All control patients had a 
multicompartment adherence aid and / or a strategy remembering the intake of their medication, 
which might further explain the good adherence results. The fact that most of them had had the 
medication and the management system before index hospitalization, made them well used to it and 
medication was integrated in their daily life, which was shown to be beneficial for adherence 57,264. 
Most patients were very satisfied with their own medication management system. One patient 
indicated handling problems and limitations by her system and reported low adherence rates, 
indicating that the system did not sufficiently support her. Accordingly, this patient requested a dose-
dispensing aid that she could fill by herself at the end of the study. Only one patient of the control 
group was interested in adopting a multidrug punch card at the end of the study. He was the youngest 
of all patients in the trial and was hospitalized because of a myocardial infarction without taking any 
medications before that time point. He had the lowest adherence rate of all control patients according 
to MPR and suboptimal adherence according to self-report. This could point out that young patients 
completely integrated in work life receiving multiple newly prescribed medications after a major 
clinical event could be a target group for multidrug punch cards. This assumption is supported by a 
qualitative study reporting that younger patients with busy lives encounter similar medication self-
management troubles as elderly patients, e.g., forgetting medication intake 255. The other patients 
either had compelling strategies for medication management (e.g., one patient kept a log sheet with 
a self-made medication plan and all medication changes including therapy goals and blood pressure 
monitoring), rejected the use of multidrug punch cards, or had a reduced number of prescribed 
medications the end of the study not requiring support for medication management. 
Our intervention patient was perfectly adherent according to all adherence measures and clinically 
stable during the whole study period. The feedback sessions helped him to grow more confident in 
medication self-management and in adherence reporting. The gain of quality of life might have to do 
with the stable clinical condition. We suggest that the sustained pharmaceutical care by the multidrug 
punch card and the repetitive feedback sessions supported the maintenance of the patient’s adherent 
behavior. Increased adherence was reported by five of six studies with multidrug punch cards 
49,159,160,176,211, two of them showing improved clinical outcomes49,160. These results strengthen our 
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assumptions. Initial handling difficulties resolved quickly and the patient reported to be very satisfied 
with the multidrug punch card use. He wished to continue the service after completion of the study. 
Due to the easy application and the good acceptance, we suggest POEMS to constitute an instrument 
for further applications e.g., for diagnosis of therapy resistance, to detect non-adherence or white coat 
adherence and to improve pharmaco-vigilance (by allowing the timely association of drug-drug 
interactions and adverse effects). The use within adherence-enhancing programs allows the detection 
of specific adherence behavior, feedback thereon and tailoring of specific interventions according to 
the detected behavior. Feedback with electronic dosing history of MEMS® and tailored adherence 
support were claimed to be most effective in adherence support 126,136. Therefore, we suggest similar 
success with POEMS for adherence to polypharmacy.  
C1.2 Evaluation 
This part of the report extensively discusses the shortcomings that led to the abandonment of the pilot 
study, exploring reasons and proposing solutions for a more successful future approach. 
At the study planning, the hospital phase was expected to be the most critical phase due to anticipated 
communication difficulties with the ward staff, problems of access to the case notes and loss to follow-
up due to missed discharge. However, feasibility proved very well in the hospital phase and information 
was readily available on request. Apart from this, the unprompted information flow from the ward to 
the study team about discharge proceedings did not work well. We instructed the ward staff to inform 
the study team about the discharge of the study patients by hotline call. This was highlighted during 
two staff meetings (to physicians, to nurses) and described in a leaflet posted in the physicians’ and 
nurses’ room, and in the case notes of every participating patient. However, we received one hotline 
call during the whole study period. Consequently, discharge proceedings were actively pursued by the 
study team.  
In the follow-up phase, feasibility was worse, with weak points including problematic communication 
with community pharmacies of the region, technical difficulties with the electronic monitoring 
technology and the reluctance of the patients to fill the questionnaires.  
The communication with the community pharmacies of the region was difficult. Some of them felt 
competed against, because the intervention patients (10 were intended for the pilot study and 100 for 
the main study) would have received their medication from the study pharmacy instead from their 
usual community pharmacy. This could have resulted in loss of costumers for the community 
pharmacies in the region. This fact was inadequately communicated to the regional professional 
pharmacy association, which inquired for clarification after the commencement of the study. The 
individual information of the community pharmacies by fax at the point of discharge of a study patient 
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belonging to their client base was deemed insufficient. Therefore, projects of this kind and dimension 
might be worth to be introduced at a regional association meeting, addressing challenges and conflicts 
of interest. Additionally, the possibility of collaboration could be checked, for example for dispensing 
of the prepared multidrug punch cards to the intervention patients. In fact, the reluctance to change 
the usual community pharmacy led to many rejections of the study participation. A closer collaboration 
might be beneficial for both sites. Most patients were reluctant and one patient was unable to fill 
questionnaires by their own, which were consequently performed as interviews. This could result in 
an observer bias where the anticipated answers are filled without confirmation of the patient. 
Therefore, the suitability of the instruments has to be checked meticulously for suitability for the 
anticipated study population. 
The efficiency in the hospital phase was majorly flawed, resulting in a recruiting rate of 1%. Inadequate 
points included the high exclusion rate, the time management during the whole hospital phase, the 
vague task assignment to the study team members, and the poor communication in the study team. 
The average hospital stay of 7.4 days minus 3.2 days lost due to the out-of-date electronic database 
minus 2.0 days for the patients to decide over study participation left two days for two screenings, 
recruitment, baseline assessment, and discharge management. To screen ten new patients and include 
two of them in the time-intensive second screening usually lasted one hour. In this screening step the, 
first baseline assessment from paper case notes was included, which was inefficient considering the 
large rejection rate. Additionally the follow-up of initially excluded patients cost unnecessary time, 
because all of them were excluded eventually. Due to these time management problems, patients 
were lost to follow-up because of discharge.  
The exclusion rate was exceptionally high and mainly due to domicile and prescription of a vitamin K 
antagonist in the first screening. We anticipated the first exclusion criteria to be limiting because the 
recruitments’ setting was a competence center and university hospital congregating patients from all 
over Switzerland and from abroad. The ethics approval was restricted to the patients in the region and 
the reduced mobility of the multimorbid patients was limiting for the inclusion of patients living further 
away. In the second screening, the main reasons for exclusion were ‘< 4 oral medications’ and ‘transfer 
to another institution’. The high frequency of the first exclusion reason was unexpected due to the 
assumption that the patients on the ward of the internal medicine were mainly multimorbid requiring 
five or more medications. However, there were also acute patients, who had no underlying chronic 
conditions, e.g., patients with severe infections and patients with stationary oncologic treatment. 
These patients had no additional long-term medications. The multimorbid and old patients and the 
patients, who were admitted for severe clinical events, e.g., stroke, myocardial infarction, mostly had 
over four prescribed medications, but were often transmitted to a rehabilitation center or to a nursing 
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home, which precluded their participation. The main reasons for rejection reflected the characteristics 
of the screened population, namely acute and/or severe illness and therefore physically or 
psychologically not able to engage in a study or, apart from the hospitalization reason, vital and 
independent, preferring to self-manage their medication. Here came to light, that the use of dose-
dispensing aids was somehow stigmatizing and not acceptable for all patients. A predominant 
statement was that they were not so old or dement as to require such an aid. It was investigated before 
that the patients accepting multidrug punch cards had to be picked by special characteristics, e.g. 
retired, living alone, low education grade, preference for daily routines 271. The experiences of the 
hospital phase with its high exclusion and rejection rate showed that the location chosen for 
recruitment did not accommodate this target group.  
The number of lost-to-follow-ups was kept within reasonable limits and was mainly due to a shortage 
of the study team. ‘Exclusion from the ward round’ was due to the processes of the ward and the 
limited availability of the study team members. The ward accommodated 35 patients with three 
responsible physicians. Regular ward rounds took place from 9-11 a.m. in parallel, with each physician 
visiting approximately 10 patients. Most of the time, only one study team member was available and 
attended the ward round of one physician, automatically excluding approximately two thirds of the 
patients. The shortage of the study team resulted out of unclear definition of the study team members’ 
tasks and roles, from high timely demand (e.g., one discharge counseling with preparation and post 
processing lasted approximately 4-6 hours), the lack of communication within the study team, and a 
lack of briefing for the task. Although an SOP was available, it was not used as intended, and tasks and 
roles were not clear for all study team members. This indicated that the formation and continuous 
information for the study team is of major importance for study efficiency 302. Organization of time 
coverage by the study team for the whole study duration should be initiated with defining one 
responsible investigator and one investigator on picket for each day of the week. The study coordinator 
additionally being the main investigator seems to be inadequate, also from the perspective of 
methodological quality (e.g., observer bias). A kick-off meeting, followed by individual briefing and 
regular information update might be valuable. Additionally regular study team meetings should discuss 
uncertainties, difficult situations and problems with the study protocol. This would strengthen the 
feeling of belonging to the team, make the study team members confident and efficient in their work, 
facilitates the precise definition and delegation of tasks, relieve timely constraints, and make study 
procedures more efficient. 
The efficiency of the primary care phase contained also problematic but mainly optimizable points. 
The accessibility of all study team members to the study pharmacy and exchange of event dates at the 
pharmacy (team meetings, follow-up visits) can promote efficient working steps. The production of 
143:  PROJECT C1 | Electronic multidrug punch cards to improve clinical and humanistic outcomes in patients after hospital discharge Discussion 
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
multidrug punch cards for a four-week supply of one patient took a considerable amount of time and 
involved two study team members. Except for the double check of the multidrug punch card content, 
this work could also be completed by a pharmacy technician, relieving the study team. Instructions 
were available from an SOP. The material for the POEMS, namely the RFID chips were scarce and did 
sometimes prevent recruitment of more intervention patients. Additionally the intervention patient 
could not at all times be provided with the number of multidrug punch cards according to his wishes 
to reduce refill frequency.  
The quality of the hospital phase was mostly evaluated to be inadequate. These shortcomings were 
mostly technical in nature and could be improved by small changes. For example the emergency 
hotline did not work properly, which was corrected immediately. Confusion with and availability of the 
CRFs induced the rethinking about having all-in-one electronic forms. 
In the primary care phase, the quality was mostly optimizable. One point concerned the 
understandability of the questionnaires. It seems important to test them preliminary with real patients 
instead of students or team members, which was the common practice. It seems questionable if the 
study follow-up visits should be performed by a pharmacist and if it is suitable to discuss medication 
changes actively. This could lead to a bias. Almost all patients indicated that their medication 
management at home improved because of the follow-up visits, which indicates a bias and undermines 
the effect of the intervention. There were some drawbacks of the prototype POEMS films limiting the 
results of the electronic adherence measurement. First, the electronic film was sensitive to handling 
resulting in false positive results and preventing the analysis of timing adherence. Second, there were 
interferences with other signals, but these could be detected and deleted. Third, due to deficiency of 
the film or the chip, data of 11 multidrug punch cards was lost. Nevertheless, the data obtained from 
the electronic monitoring was valuable for analysis and for the patient. Improvement of the 
functionality and specificity of the technology should be attempted to yield reliable and continuous 
data. 
Finally, there were processes and structures that worked remarkably well. Especially the work on the 
ward was agreeable and the atmosphere was friendly and open. Information was provided without 
hesitation or delay. This could be due to the reason that the ward was well organized, that they were 
used to ongoing studies and that they were informed prior to study commencement. Also the 
Notfallapotheke Basel was found to be a suitable place as a study center. Collaboration with the teams 
of all locations went very well. Additionally the satisfaction of the patient with the study was high. The 
discharge counseling and the medication plan were much appreciated by the patients, however, it 
seemed that the information of the counseling should be as short as possible and more tailored to the 
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patient’s needs 283.The financial compensation of an intervention patient could be reconsidered 
because of substantial additional expenses.  
The evaluation of the hospital phase led to several changes (connection of first and second screening; 
allocation to the control group at non-acceptance of the intervention). These changes slowed down 
the study process, and hence the tasks were better manageable by the study team and the time 
management improved. The screening was limited to one hour a week and to one to two thirds of the 
patients of the ward. The rotation from one third to the other enabled to see new patient at every 
ward round. The physicians and nurses accepted the participation in the ward rounds. Although one 
to two thirds of the patients were excluded by this proceeding, the recruitment success did not 
decrease but improved marginally (four patients in four months before and six patients in four months 
after the changes). However, the majority of the patients had still to be excluded and the recruiting 
rate was still inadequate. For this reason, the pilot study was abandoned for revision of the study 
design. Overall, the parallel conduction of the evaluation proved beneficial and indicated key points 
for amelioration. 
Limitations 
The study sample was too small to draw conclusions. Further, there were limitations of the outcomes 
measures, namely reliability of self-report, calculation method of MPR, and functionality of the POEMS 
prototypes. The discharge counseling and the active discussion on medication change at the follow-up 
visits could have influenced the good adherence outcomes of the control patients. Inversely, a 
selection bias could have included patients in the study who were basically adherent, indicated by the 
high baseline adherence. Due to the slow progress of the study, some points of the evaluation could 
only be studied insufficiently and precluded a fully systematic approach. Analysis based partly on 
subjective judgment of the master student or the study coordinator. Although this limits the results, 
several inadequate points could be detected, which impeded feasibility, efficiency and quality and 
which should be improved for a resumption of the study. 
Challenges 
In summary, the major challenges of the pilot study were: 
 High exclusion and rejection rate 
 Coordination of and communication within the study team 
 Communication with the community pharmacies of the region / regional pharmacy association 
 Organization and coordination of the study within the real-life setting 
 Time management 
 Limited availability and functionality of POEMS prototypes 
145:  PROJECT C1 | Electronic multidrug punch cards to improve clinical and humanistic outcomes in patients after hospital discharge Outlook 
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
 Inadequate number and storage of study documents 
 Reluctance of the study patients to fill questionnaires, inadequate understandability of 
questionnaires 
Outlook 
For the revision of the study to yield adequate feasibility, efficiency, and quality, several 
recommendations can be made: 
 A new location for recruitment may provide a population corresponding to the defined inclusion 
criteria and accepting the multidrug punch card use. In our opinion, a rehabilitation center could 
accommodate such patients. A further advantage of the rehabilitation center would be the 
longer stay of the patients, enabling an improved time management. Alternatively, patients 
could be recruited at the community pharmacy. 
 A pre-assessment of the adherence pattern of eligible patients might be considered to select the 
target population for the multidrug punch card intervention. 
 Physicians on the ward may be involved in recruitment. The patients’ medication self-
management at home could be easily determined during the ward round and at detection of 
problematic polypharmacy, the physician could refer a patient to discharge counseling, where 
the suitability and acceptance of study participation could be checked. For this purpose, a tool to 
check patients at risk could be helpful. 
 The regional professional pharmacy association could be involved at an early time in study 
conceptualization to clarify conflicts of interest and to identify possibilities for collaboration. 
 Organization and formation of the study team has to start early, including the clear definition of 
roles and tasks, maintenance of a study calendar and time coverage (ideally through a 
responsible investigator and a picket investigator per day), and regular information, e.g., kick-off 
meeting, briefing, regular follow-up meetings, update e-mails. 
 The separation of the study coordinator and the main investigator has to be considered to 
minimize observation bias, enable blinding of the investigator, and the enable the study 
coordinator to more adequately fulfill coordinating tasks. 
 For calculation of adherence to polypharmacy out of pharmacy claims, Daily Polypharmacy 
Possession Rate (DPPR) seems more appropriate than MPR. 
 Functionality, sensitivity and specificity of POEMS have to be improved in the next generation. 
Annex 
 A4.1 Final board decision of the Ethikkommission Beider Basel for the Medication Blister Study 
 A4.2 Case report form hospital screening, assessment and recruiting (CRF T-1) 
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 A4.3 Example of a case report form for a follow-up visit (at three month) 
 A4.4 Questionnaire Adherence 
 A4.5 Short form 12 version 2 (quality of life questionnaire) 
 A4.6 Patient satisfaction questionnaire 
 A4.7 Analysis of the Believes about Medicines Questionnaire (BMQ) 
Supplementary material (available on CD-R or on request) 
 Administrative material 
 Case report forms 
 Questionnaires 
 Data dictionaries 
 Material used at discharge counseling 
 Information material for co-workers 
 Standard Operation Procedures 
 Evaluation method catalogues and assessment forms 
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Summary 
We report of the first polypharmacy adherence monitoring over 371 days, integrated in a 
pharmaceutical care service (counselling, electronic multidrug punch cards, feedback on recent 
electronic records) for a 65-year old male diabetic patient after hospital discharge. The initial 4-times 
daily regimen with 15 daily pills changed after 79 days into a 2-times daily regimen with 9 daily pills for 
the next 292 days. The patient removed all medication from the multidrug punch cards (taking 
adherence 100%) and had 96.9% correct dosing intervals (timing adherence). The 57 evening doses 
showed the least variation in intake times at 17h 45min ± 8min. Over the observation year, the patient 
was clinically stable. The patient was very satisfied with the multidrug punch card use and the 
feedbacks on electronic records. In conclusion, long-term monitoring of polypharmacy was associated 
with the benefit of successful disease management. 
Keywords: Healthcare improvement and patient safety, medical management, medical education. 
Background  
According to its latest definition, "Pharmaceutical Care is the pharmacist's contribution to the care of 
individuals in order to optimize medicines use and improve health outcomes" 39. Thus, medication 
adherence, i.e., the extent of a patient following the recommendations by a health-care professional, 
represents a central concern in pharmacy practice. With typical adherence rates for oral prescription 
medication of approximately 50-76% 37,90, non-adherence has been designated as one of the largest 
health care problems in society 37,65,143, since it impairs clinical outcomes and quality of life, and 
generates costs 83,103,105,113,269. Polypharmacy, i.e. the use of multiple drugs administered to the same 
patient 14, has been described as a factor strongly related to non-adherence 13,303. However, 
polypharmacy has become common because of e.g. clinical practice relying on multidrug 
combinations, increased rates of comorbidities and the aging population. In this context, dose-
dispensing aids such as multidrug punch cards are suggested to improve adherence to polypharmacy 
and clinical outcomes 62,146,258.  
Electronic monitoring is considered nearest to gold standard in adherence measurement 272. Several 
studies used a pill bottle with a computer chip equipped cap that records each opening of the bottle. 
Because of the design of this pill bottle, one lead drug can be monitored at one time 274-278. The recent 
development of printed electric circuitries and RFID technology made it possible to monitor 
polypharmacy by using a paper film and a chip collecting real time data (Confrérie Clinique S.A., 
Lausanne, Switzerland) affixed on the back of a multidrug punch card 273. The POlypharmacy Electronic 
Monitoring System (POEMS) records date, time, and location of medication removal of the whole 
therapy regimen.  
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We report of the first polypharmacy adherence monitoring over 12 months, integrated in a 
pharmaceutical care service for a diabetic patient after hospital discharge. The patient was recruited 
within a pilot study to prove feasibility of a pharmaceutical care service with electronic adherence 
monitoring (ClinTrials.gov Identifier: NCT01759095). 
Case presentation  
We report of a 65-year old male patient who was hospitalized for a sepsis by Staphylococcus aureus at 
a large Swiss university hospital from January 28th to February 18th 2013. His actual diagnoses 
included late onset autoimmune diabetes in the adult (HbA1C: 8%, 30.01.2013) with manifest 
complications (diabetic foot with chronic osteomyelitis, non-proliferative retinopathy, 
polyneuropathy), coronary heart disease with double stenting during the actual hospitalisation (LDL: 
2.83 mmol/l, 01.02.2013; TG: 1.82 mmol/l, 01.02.2013), and a beginning heart failure (LVEF 40%, blood 
pressure: 183/93 mmHg, 18.02.2013). Signs of a beginning dementia were reported but not further 
investigated. He was retired, lived independently and alone in a middle-sized city, and self-managed 
his medication by the use of a weekly pillbox. In January 2013, he was newly prescribed basal insulin 
by the general physician (GP) in addition to rapid-acting insulin that had been initiated years before. 
Amputation of digits I and II on the left foot had occurred after emergency hospitalisation in October 
2010. He had no allergies and was a current smoker (30 pack years). At discharge, the patient was 
prescribed ten different medications representing 15 pills in a 4-times daily regimen (Table 1). 
Medication reconciliation, i.e. the comparison of pharmacotherapy before and after hospitalisation, 
showed that three medications were newly introduced, one dosing frequency was reduced, one 
strength was augmented, and intake times changed from 2-times daily to 4-times daily. 
Investigations 
Adherence to polypharmacy was measured by POlypharmacy Electronic Monitoring System (POEMS) 
affixed on a disposable weekly multidrug frame card with 28 unit-of-use doses spread over 7x4 plastic 
cavities, filled by the community pharmacist with all oral solid medication. 
Treatment  
During hospitalisation, a clinical pharmacist recommended to refer the patient to a pharmaceutical 
care service consisting of individualized counselling (knowledge of medication), packaging of solid oral 
medication into multidrug punch cards (facilitation of polypharmacy management), and electronic 
adherence monitoring (measurement-guided medication management). Insulin management did not 
require further instruction. The responsible physician approved the recommendation and the patient 
provided written informed consent. 
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Two days prior to discharge, the pharmacist counselled the patient on indication, long-term benefit, 
adverse effects, and correct use of all discharge medication using standardized information sheets. The 
sheets were handed out instead of official package inserts upon the patient’s request. The pharmacist 
instructed the use of the multidrug punch card and tested the patient’s dexterity to remove tablets.  
At discharge, the patient was provided with one multidrug punch card equipped with POEMS, 
containing all prescribed oral solid medication for one week and his medication plan (Table 1, Figure 1). 
 
Table 1: Medication plan handed out to the patient at hospital discharge.  
HTC, hydrochlorothiazide; n.p., no picture available.  
Medication plan for [patient name] *[year of birth] 
    
 
 
Physician        Date dd.mm.yyyy    
Ward        Visum      
         
Hotline: xxx xxx xx 
xx 
Medication   Dosage     Picture Indication Note 
Name   Dose morning noon evening night       
Irbesartan / htc 300/12.5 mg 1       
 
Blood pressure   
Aspirine® 100mg 1       
 
Blood thinning Before meal 
Atorvastatin 40mg     1   
 
Blood fat   
Pantoprazol 40mg 1       
 
Gastric acid   
Bisoprolol 2.5mg 1   1   n.p.  Blood pressure   
Clopidogrel 75mg 1       
 
Blood thinning   
Metformin 1000mg 1   1     Sugar   
Clindamycin 300mg 2 2   2 
 
Infection Stop on 07.05.13 
                  
Insulin Lisprum              Sugar According to scheme 
Insulin Glargine              Sugar According to scheme 
                 
 
 
Figure 1: Electronic multidrug punch card front (left) and back with affixed POlypharmacy Electronic Monitoring 
System (POEMS; right). 
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Five days after discharge, the patient was called to consolidate the safe and correct management of 
the electronic multidrug punch card. Exchange of empty multidrug punch cards for new filled ones 
occurred every 2-4 weeks at a predefined community pharmacy. The electronic records of the previous 
week were discussed following a protocol for measurement-guided medication management 
(MGMM) 272 and using elements of motivational interviewing 285 like open-ended questions, reflective 
listening, affirmative style, enhancement of personal motivation, setting goals and obtainment of a 
change of plan.  
Outcome and follow-up 
The monitoring period lasted from February 18th 2013 (discharge day) until February 23rd 2014 and 
covered 371 days. In total, 54 multidrug punch cards with 899 unit-of-use doses were handed out. All 
returned multidrug punch cards were empty (taking adherence by pill count of 100%). Eleven 
multidrug punch cards (20.4%) and 9 random days were not readable (technical failure), and 17 event 
times were not recorded, leading to lost data for 218 doses (24.2%). The patient removed 8 pocket 
doses in anticipation of intakes away from home, which were excluded from the calculation. The 
summary of adherence statistics was derived from 673 electronic records. 
The first 79 days of treatment comprised 4-times daily intakes (QID) due to antibiotic treatment until 
7th May 2013, and covered 21.3% of the observation period. On May 8th 2013, the GP augmented 
bisoprolol from 2.5mg to 5mg twice daily without influence on the number of pills or the intake times. 
The next 292 days comprised twice-daily intakes (BID). A total of 278 doses were retrieved in the 
morning (QID: 63, BID: 215) in average at 7h 34min ± 55min (QID: 7h 24min ± 27min, BID: 7h 36min ± 
1h 1min). The antibiotics assigned to be taken at noon (63 doses) and at night (65 doses) were taken 
in average at 12h 22min ± 2h 6min and at 21h 44min ± 44min, respectively. A total of 267 doses were 
retrieved in the evening (QID: 57, BID: 210) in average at 17h 39min ± 1h 1min (QID: 17h 45min ± 8min, 
BID: 17h 37min ± 1h 14min). The electronic records over the whole year are displayed in Figure 2. 
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Figure 2: Electronic records over the one-year monitoring period. 
 
A dosing interval was defined as correct if the time between doses was within 25% of the prescribed 
dosing interval, i.e., ± 3h for a 12-hour period (BID) and ± 1.5h for a 6-hour period (QID). Overall 96.9% 
of the dosing intervals were correct. All morning and evening doses of the QID regimen were taken in 
the grace period of 1.5 hrs, while 10/63 doses at noon and 4/65 doses at night were taken earlier or 
later, representing 5.4% of all QID doses. Of the BID regimen, 2/215 doses in the morning and 5/210 
doses in the evening were taken outside the grace period of 3 hrs, representing 1.6% of all BID doses. 
The patient kept all 17 planed appointments for multidrug punch card exchange and feedback sessions. 
He went on vacations thrice for several weeks. During the 9 feedback sessions conducted regularly 
every 1-2 months, the patient confirmed the safe and correct use of the punch card. He was very 
satisfied with his electronic records and emphasized his efforts for a highly regular taking and timing 
adherence. He reported a strong integration of the process of medication taking into his daily routine, 
i.e. coupled to mealtimes and insulin injection. 
During the 12 months of monitoring, the patient had no readmission to hospital and no emergency 
visit. Laboratory values remained stable (LDL: 2.9 mmol/l, 29.01.2014; TG: 2.2 mmol/l, 29.01.2014; 
blood pressure: 193/88, 31.01.2014). HbA1C decreased to 7% (31.01.2014). 
The patient was satisfied with the intervention and declared a feeling of increased medication safety 
owing to the multidrug punch card use. The electronic records used during the feedback sessions 
helped the patient to gain confidence in medication management and to maintain perfect regularity 
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of the intakes. The electronic monitoring did not bother him. At the beginning, the removal of the 
medication out of the multidrug punch card caused him trouble because the back layer was hard to 
push through. However, he got used to it quickly, reported no more problems and wished to keep the 
punch cards after end of monitoring. 
Discussion  
We found 3 close case reports in literature. First, a 79-year old Japanese female with type 2 diabetes 
and mild cognitive impairment took all medication 3-times daily from a sounding and light flashing 
electronic device 304. After 6 months, adherence by pill count was one missed dose per week (95%) and 
HbA1C decreased from 8.0 to 7.1%, demonstrating the efficacy of the electronic reminder device. 
Second, a 17-year old female treated for Fanconi Anaemia with 8 drugs daily had an estimated 
adherence of 25% 305. She received 35 motivational interviewing sessions over 17 months. Adherence 
to the lead medication levothyroxine measured by electronic pill bottle showed a significant 
improvement up to 82%, demonstrating the efficacy of motivational interviewing. Third, a 65-year old 
Swiss male with epilepsy and suspected abuse of sleeping pills was monitored with electronic 
multidrug punch cards over 3 weeks 76. Inadequate medication intake behaviour could be corrected 
with feedback sessions. 
Our case with pharmaceutical care service including electronic monitoring of adherence to 
polypharmacy and regular feedback on electronic records was successful to maintain perfect 
adherence and clinical stability during one year. A glycosylated haemoglobin (HbA1C) level of 7% was 
reached during the one-year monitoring period and represents the target level recommended by the 
American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) 
for elderly comorbid patients 306. The lowering of the HbA1C by 1% is known to improve micro- and 
macrovascular clinical endpoints significantly and to reduce all-cause mortality by 14% 307. In our case, 
the HbA1C reduction probably followed from the adjustment of insulin therapy one month before 
hospitalisation. However, the impact of multidrug punch cards was demonstrated by a mean HbA1C 
reduction of 0.95% in 36 diabetic patients with oral antidiabetics after 8 months in a randomized 
controlled trial 161. We thus can suppose that for our patient, the multidrug punch card acted as a 
railing and interrelated the oral therapy with the insulin therapy. 
The challenging therapy plan of 4-times daily intake for over a fifth of the observation time and changes 
in daily routine like vacation had no influence on the patient’s adherence. Because frequent dose 
dispensing and interruption in daily life were reported to negatively affect adherence 89,308,309 we 
assume that the multidrug punch card (as practical tool) coupled to the continuous feedback sessions 
(as external motivator) were able to consolidate and maintain perfect adherence. This assumption is 
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supported by a meta-analysis attributing a large effect to the intervention of feedback on electronic 
dosing history 136.  
We acknowledge some limitations. The substantial loss of data due to technical flaws of our first 
generation POEMS is inherent in newly developed technologies. The subsequent generation of 
electronic films will be improved. Electronic monitoring is often criticized to assume rather than prove 
the patient’s actual medication intake. However, we observed that patients usually accept monitoring 
and thus swallow the removed medication 310. Finally, the patient’s being aware of observation is 
supposed to have an impact on the outcomes. However, a recent study showed that the use of an 
electronic device leads to a small, non-significant increase in adherence compared to standard 
packaging 311. In conclusion, this case is to our knowledge the first report of long-term monitoring of 
polypharmacy associated with the benefit of successful disease management. 
Learning points/take home messages 
 The pharmaceutical care intervention – comprising electronic monitoring of adherence to 
polypharmacy and recurrent feedback sessions – maintained optimal adherence and stabilized 
disease management. 
 The patient accepted the electronic monitoring of adherence to polypharmacy over one year and 
was satisfied with the service. He was even willing to continue with this service after study end. 
 Electronic monitoring of polypharmacy was feasible over one year and yielded valuable results. 
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General discussion and conclusions 
In this thesis, we researched the evidence, the present circumstances, and the effectiveness of 
multidrug punch card use in primary care with the aim to support the patient’s medication self-
management for optimization of medication use and thus to reach appropriate polypharmacy. 
 
The World Health Organization and other organs urge the development of effective interventions to 
enhance adherence as a first priority subject. To have an overview of the work done with the focus on 
dose-dispensing aids, PROJECT A1 was designed to review and map the evidence of dose-dispensing aids 
to improve adherence and economic, clinical, and humanist outcomes. Previously published reviews 
with restrictive inclusion criteria were deemed insufficient to have a complete overview 147,155,156. 
Evidence mapping stipulates the use of broader inclusion criteria to give an overview on a whole topic 
area and allows the identification of evidence gaps 168. With the use of this methodology and of a tool 
specifically designed to assess the methodological quality of public health studies with variable study 
designs 163, we were able to include more studies. Further, as health-care professionals rely on both, 
robust evidence and details of the delivered interventions to integrate them into clinical practice, we 
developed a list of additional criteria for completeness of information. Just recently, new guidelines 
were published as an extension to the CONSORT statements, which support this approach 312. 
We found that a substantial amount of research has been done, including 10 randomized controlled 
trials, 19 controlled trials, and 1 cohort study, which involved different dose-dispensing aids in single 
or combined interventions. These devices offered a broad field of application and were mostly studied 
in elderly patients with polypharmacy. Dose-dispensing aids had a significant effect on adherence in 
17 out of 27 studies, using multicompartment adherence aids (6 studies), multidrug punch cards (5 
studies), and unit-of-use packaging (4 studies; 2 without description of device), either as single or as 
an element of a composite intervention. In direct comparison (i.e., in factorial trials), effects tended to 
be larger in composite interventions, which is consistent with the reporting of prior studies 126,155. Ten 
of fifteen studies reporting clinical outcomes showed significant improvements. However, if focusing 
on those with strong methodological quality, studies with significant outcomes in adherence reduced 
to three (in geriatric 177, in chronic mental ill 178, and in cardiovascular patients 49) and studies with 
significant clinical improvements reduced to two (in diabetes mellitus type 2 191 and cardiovascular 
patients 49). At the further application of the list of additional criteria for completeness of information, 
overall only one study with reliable results and a replicable intervention remained 49. Economic and 
humanistic outcomes (as defined by Kozma et al. 174), and safety issues were either missing or 
156:  GENERAL DISCUSSION AND CONCLUSIONS   
 
PhD Thesis Version 02.02.2015 Fabienne Böni 
insufficiently addressed. Further, long-term, disease-unspecific, generalizable clinical outcomes like 
(re-) hospitalization rates were lacking. Clinical effects on multimorbid populations with polypharmacy 
were not evaluated. Twelve of the included studies only measured adherence, and although 
improvement in adherence is generally acknowledged to be associated with improved clinical 
outcomes, it remains widely unclear how much adherence is needed to reach significant health 
benefits for the patient 59,81. In this context, our review detected three studies, which reported a 
significant effect on adherence, but not on clinical outcomes 159,178,182. Ethical standards for adherence 
research urge that adherence is ‘a means to an end’ and should only be measured in connection with 
clinical outcomes to ensure a positive effect on patient-relevant outcomes (i.e. clinical and humanistic 
outcomes) 141. The discussed shortcomings served as a rationale for the development of a randomized 
controlled trial in a later project (PROJECT C1), on the use of a dose-dispensing aid in primary care 
patients with polypharmacy, including measures of adherence, clinical, and humanistic outcomes. 
In the next step of the thesis (B), we explored the status quo in the Swiss primary care setting. On one 
hand, we investigated how and how often community pharmacy staff counsels about adherence 
(PROJECT B1). On the other hand, we studied the integration of multidrug punch card provision in daily 
pharmacy practice and the characteristics, preferences, and experiences of current multidrug punch 
card users in primary care in PROJECT B2 and B3, which will be discussed further down.  
In PROJECT B1, we observed daily practice of counseling by the pharmacy staff in community 
pharmacies. The unique position of the community pharmacy in the healthcare chain, with its easy 
access, regular patient visits, the possibility to monitor medication refill frequency, and the 
pharmacist’s competences, predestines for counseling about adherence. Evidence on successful 
interventions in improving health outcomes and adherence delivered by community pharmacists has 
accumulated 44-50,232-235 with the conclusion that the pharmacists’ cognitive services were beneficial for 
safe and effective medication use 51,52. We found that counseling was provided to half of the patients 
obtaining any medication, and significantly more often to patients receiving medication on 
prescription, a new prescription, and if served by a pharmacist. Our observed counseling rates are in 
line with prior research, reporting limited pharmaceutical care services 218,220,236-240 and predominant 
product-centered counseling 223-225,240. Significantly more patients received explicit adherence 
counseling if served by a pharmacist compared to other staff members. However, on the whole, the 
group of patients receiving this kind of counseling represented only 6.7% of the patients obtaining any 
medication. We defined explicit adherence counseling as a direct, patient-centered and implicit 
adherence counseling as an indirect, product-centered approach. From this perspective, we suggest 
that implicit adherence counseling insufficiently addresses the problem and may at most influence 
unintentional non-adherence. In contrary, explicit adherence counseling directly addresses the 
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problem and can be supposed to facilitate the effective detection, assessment, support, and 
monitoring of intentional and unintentional non-adherence. Literature supports a considerate and 
individualized approach to engage the patients into counseling 243 244 225, which would include the more 
direct, explicit adherence counseling. 
Discordant to the low rate of observed adherence counseling, almost all pharmacists stated to counsel 
about adherence every day and named most of the topics on our predefined list of explicit adherence 
counseling. They were obviously familiar with the topics, though less frequently addressed them 
during the observed patient contacts. Further, the most frequently named topics by the pharmacists 
were implicit. Thus, our observations indicated an implementation problem of research and knowledge 
into daily practice. It seems that changes of structures and processes lagged behind the changing role 
of the pharmacist 42,244,245. Correspondingly, pharmacists named barriers to adherence counseling 
concerning structures (e.g., lack of public acknowledgement of the pharmacist’s competences) and 
procedures (e.g., time constraints). 
Revisiting the numbers of PROJECT B1, we can quantify that out of 1’476 patients receiving medications, 
99 were counseled about adherence topics and only 11 of them specifically on the adherence topic 
‘organization’, i.e. with potential sale of a dose-dispensing aid. PROJECT B2 revealed that only 51 of 
1’743 community pharmacies in Switzerland produced multidrug punch cards in 2011, predominantly 
for patients in nursing homes and only for 269 (14%) primary care patients. Active recommendation of 
multidrug punch card use to primary care patients was performed in 75% of the pharmacies with a 
rather low success rate of 31%. These pharmacies indicated that they targeted a population for the 
service, which seems adequate, namely people with polypharmacy, suspected non-adherence, 
increased age, inability for medication self-management, and at hospital discharge. The dose-
dispensing service fitted well in the community pharmacies’ daily practice with the multidrug punch 
card production being easy and cost-covering and by adding additional values to the pharmacy (e.g., 
the profiling of the pharmacy in advanced pharmaceutical care service or enhanced interdisciplinary 
cooperation). Pharmacies mostly assumed their primary care patients to be very satisfied with the use 
of multidrug punch cards and estimated a very high adherence rate of 93.3% for its users. A qualitative 
study from England also reported a positive attitude of health-care professionals towards dose-
dispensing aids, which they recommended to elderly patients with medication self-management 
problems 32. 
The 269 primary care patients detected to use multidrug punch cards represented the basic target 
group for the subsequent PROJECT B3. We combined quantitative and qualitative interviews in an 
explanatory way to investigate the acceptance, preferences, experiences, and impact on adherence of 
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current multidrug punch card use by primary care patients. We thus responded to a call from prior 
publications, to clarify the characteristics of the primary care patients benefitting most from dose-
dispensing aids and hence to facilitate targeted adherence interventions 32,152,255. We found that an 
independent primary care patient accepting the use of multidrug punch cards is over 70 years old, has 
a low education grade, is retired, lives alone, favors tidiness, rituals, and daily routines, and is unable 
or reluctant to leave home. She/he trusts the health-care professionals, is a regular customer of the 
same community pharmacy, is motivated to conduct a healthy life, and has a feeling of high necessity 
for medication. In consequence, it was not surprising that the patients of our study reported perfect 
adherence. Emerging key variables for their adherent behavior were trust in health-care professionals 
and personal experiences (i.e. either experience of an adverse health outcome in case of non-
adherence, or clinical well-being in case of adherence). Both variables have been reported before to 
be associated with adherent behavior 262,313. Our patients stated an improved adherence of +37% after 
the initiation of multidrug punch card service. In connection with their strong intent for being 
adherent, this indicates that they might have been unintentionally non-adherent prior to multidrug 
punch card use, and thus our results support the assumption that unintentionally non-adherent 
patients might represent a target population for dose-dispensing aids 62,145. The support that multidrug 
punch cards offer to such patients encompasses a reminder function, visual control of intake (i.e. 
adherence self-monitoring), and simplification of daily life. We additionally identified habits and 
routines, which have in fact long been described to be beneficial for adherence 57,255,264, to replace 
reminders because they promoted an ‘automatism’ of medication intake. 
We addressed two major issues of concern about the multidrug punch card use: difficulties with 
handling of multidrug punch cards 32,146,151 and reduction of knowledge about medication 32,152,153. Both 
were reported to constitute a risk of decreased medication safety for patients with dose-dispensing 
aids. This could not be confirmed by our study. In contrary, the patients were very satisfied with the 
handling of the multidrug punch card, highlighting the clear design, which contributed vastly to their 
feeling of medication safety. The majority of the patients did not need or want more information on 
their medication. Although medication knowledge is generally known to improve adherence 108,265-267, 
patients with dose-dispensing service seem to be exempted from this association 154, which could 
result from the minimization of potential administration errors by the packaging. 
Overall, PROJECT B3 proved that a considerable group of patients benefitted from multidrug punch card 
use, initiating our next step: to investigate the effectiveness of multidrug punch cards to improve 
clinical and humanistic outcomes through enhanced adherence. 
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PROJECT C1 was the development and pilot of a randomized controlled trial, which aimed at answering 
this question within a population of various ages and different clinical conditions. To assess the 
feasibility, efficiency, and quality of the study structures and procedures we ran an evaluation in 
parallel to the start of the pilot study. Within nine months, we were able to recruit ten patients from 
the internal medicine’s ward of a university hospital and only one patient accepted the use of a 
multidrug punch card. In the following, the results of these patients and further down the findings 
from the evaluation will be discussed. 
Overall, the patients participating in the study showed maximal adherence rates by self-report and 
medication possession ratio (MPR) through the whole study period, which is not representative for 
comparable patient groups 29,300. Of course, our small sample cannot picture the general situation. 
Other possible explanations are the occurrence of a reporting bias 252, overestimation of adherence 
due to the chosen adherence measurement method of self-report 268 and MPR 82, and higher 
adherence rates in patients participating in a study compared to real-life conditions 91. The discharge 
counseling and the active discussion of medication changes at the follow-up visits could have biased 
the outcomes by supporting adherence 301. The only primary outcome was registered in the 
intervention patient and could not be explained with non-adherence. In the control group, a 
considerable number of treatment changes occurred too, however, no major therapy adjustment. The 
low number of registered primary clinical outcomes indicates either that optimal adherence induced 
clinical stability, or that the observation period was too short. Available literature rather supports the 
first assumption 99,105,292,293, however, the small sample size limits such considerations. Quality of life 
remained relatively stable in both treatment groups. In the control group, almost all patients had had 
polypharmacy before hospital admission and a system or strategy to cope with it. They were very 
satisfied with their own medication self-management system. Feedback from one patient of the 
control group at the end of the study indicated that patients integrated fully in working life might 
represent an alternative target group for multidrug punch card use, which was also reported in a 
previous qualitative study 255. Recruiting pharmacists of PROJECT B3 provided further clues for this 
suggestion by mentioning rejection of study participation because of a busy life-style. This patient 
group was probably missed in the characterization of multidrug punch card users.  
Our intervention patient, whose results were explored in detail in PROJECT C2, was to our knowledge 
the first case of long-term adherence monitoring of polypharmacy integrated in a pharmaceutical care 
service over one year. The patient maintained perfect adherence according to all adherence measures 
and clinical stability through the whole study period. The stability in quality of life and the gain of 
confidence with medication self-management might have been the result of successful disease 
management with the support of the intervention. Similar studies performed with MEMS® devices 
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combined with feedback on electronic dosing histories 274-278 and with multidrug punch cards as 
interventions 49,159,160,176,211 showed improved adherence and clinical outcomes and let us assume 
similar results in a successfully performed randomized controlled trial with electronic multidrug punch 
cards. No harms or adverse events could be associated with the intervention. 
The evaluation showed that the study design was feasible, but lacked in quality and efficiency. The 
University Hospital Basel provided excellent infrastructure and working atmosphere and the 
Notfallapotheke Basel was a suitable place serving as study pharmacy. Collaboration with the teams 
of all locations exceeded our expectations. Additionally, patient satisfaction with the study was high. 
As opposed to the low acceptability of the multidrug punch cards, the patients much appreciated the 
discharge counseling. 
The efficiency of the pilot study was mostly flawed in the hospital phase leading to the poor recruiting 
rate. Major inadequate points were the high exclusion rate, the inadequate time management, the 
vague task assignment for the study team members, and the poor communication within the study 
team. Similar issues were pointed out as being crucial for the successful conduction of a randomized 
controlled trial 302. Both, the exclusion rate and the rejection rate were high, predominantly because 
of the characteristics and preferences of the eligible patients. The location seemed inadequate for 
recruitment of the target population of multidrug punch cards service as determined in PROJECT B3. A 
tool to assess the characteristics of patients accepting the multidrug punch cards would be helpful in 
the identification of eligible patients. Going even further, adherence could be thought of as a medical 
diagnosis, though this has been discussed controversially 314,315. Under these assumptions, it would 
make sense that patients are treated only, i.e. included only into a corresponding study, if they had an 
indication, similarly to any other clinical condition, e.g. hypertension or diabetes mellitus. Several 
authors highlighted that the inclusion of adherent patients into trials testing the effectiveness of an 
adherence-enhancing intervention might be inefficient and costly, dilute the effect of the intervention, 
and impair the patient-centered approach 62,314,316. These considerations strengthen the approach to 
specifically select non-adherent patients for such studies and require a tool with adequate sensitivity 
and specificity to differentiate between different types of (non-)adherence (e.g. intentional and 
unintentional) 314. Such tools have been developed and proposed for similar research questions 
14,314,317. The classification of interventions according to dimensions and factors of adherence (e.g., 
health system, condition-related, patient-related) could additionally facilitate the attribution of proper 
interventions for specific patterns of non-adherence. Translated to our study, the application of such 
a tool would be beneficial because intentionally non-adherent patients will not change their adherence 
behavior with the intervention of a multidrug punch card and thus diminish the intervention’s effect. 
All these thoughts congregate in the approach of tailored adherence-enhancing interventions 
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according to the patients’ needs and necessities, which have been deemed most promising 37,62,142. In 
fact, tailored adherence interventions per se should exclude adherent patients from adherence-
enhancing interventions. 
The poor quality of the study in the hospital phase resulted from the low quality of available data, 
complexity of the case report forms, and technical difficulties with the hotline. All of these 
shortcomings could be adjusted easily. For the primary care phase, the cooperation with the 
community pharmacies of the region has to be reconsidered by effective communication and by 
involving them more into the study proceedings. The induction of a potential bias by the assignment 
of a pharmacist for the follow-up assessments has to be assumed and eliminated. We used prototypes 
of the POEMS technology disclosing technical flaws, which have to be solved for a subsequent 
generation in order to yield continuous, reliable results of electronic adherence measurement. 
The evaluation of the hospital phase led to several changes, which improved time management and 
efficiency, hence the parallel conduction of the evaluation proved beneficial. Further change of study 
elements are necessary to yield an adequate recruitment rate and to improve the quality of the study 
structures and procedures. 
Major challenges during this thesis were: 
 Finding an adequate method to appropriately perform a comprehensive literature review 
 Development and validation of questionnaires for different target groups, i.e. patients and health-
care professionals 
 Motivating community pharmacists for patient recruitment 
 Performing telephone interviews with elderly patients 
 Becoming familiar with qualitative research methods and integrating them in the frame of a mixed 
methods study 
 Development, preparation, conduction, and analysis of a randomized controlled trial 
 Organization and coordination of a randomized clinical trial in a real-life setting with multiple 
locations and collaborators 
 Recruiting an adequate number of patients for a randomized controlled trial 
Limitations 
The overall limitation of this thesis was the constant low recruitment rate. In PROJECT B3, we relied on 
the cooperation of the community pharmacies, who were not always that motivated due to time 
constraints. However, the initial small number of primary care patients using multidrug punch cards 
without external help was already limiting. This results from the fact that in Switzerland multidrug 
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punch cards were originally intended for the supply of nursing homes and recommended only in the 
last few years to primary care patients. We further observed that the community pharmacists targeted 
a narrow group of primary care patients for multidrug punch card provision. This might also have an 
association with the limited adherence counseling provided, which we observed in PROJECT B1. In 
consequence, the omission of addressing adherence topics by the pharmacists could lead to a small 
rate of multidrug punch card recommendation. Further, the patient populations found at the locations 
defined for recruitment did not match our predefined inclusion and exclusion criteria in both, PROJECT 
B3 and C1. The resulting small study populations precluded comparative statistical analysis. Old 
patients have trouble to perform a telephone interview for several reasons, e.g. impaired hearing and 
reduced cognitive capacity. The duration of the qualitative interviews of 45 minutes could have been 
a barrier for younger multimorbid patients with busy life-styles, who could represent an additional 
target group for multidrug punch card provision. Further biases could be assumed to have influenced 
our results, e.g., selection bias, observation bias and Hawthrone effect 252. Our own experience and 
the feedback of the recruiting pharmacists let us assume that the patients most in need for it, decline 
corresponding interventions. 
Within PROJECT B3, we also attempted the collection of the physicians’ opinion about multidrug punch 
cards. However, the response rate to a survey was too low to analyze. Due to the slow progress of the 
pilot study in PROJECT C1, some points could not be studied sufficiently, limiting the results. However, 
identified inadequate points were altered and led to an improvement. Finally, technological 
shortcomings of the POEMS prototypes limited the results of the electronic adherence measurement. 
Steps have to be taken to augment its functionality and specificity for a next generation. However, 
despite the missing data, the electronic measurement of polypharmacy proved feasible and yielded 
valuable results for our research experience and for the intervention patient.  
Our studies are constricted to one region in Switzerland and cannot be generalized to other European 
countries, where the dispensing of dose-dispensing aids occurs more frequently, e.g. the Netherlands 
154. 
Conclusions 
This thesis adds findings on the existing evidence of dose-dispensing aids, on current practice of 
adherence counseling and multidrug punch card service in community pharmacies, on the experiences 
and preferences of multidrug punch card users in primary care, on the impact of the devices on 
adherence of multidrug punch card users, and on experiences of a pilot study with the aim of improving 
adherence and patient-relevant outcomes through electronic multidrug punch card use in primary care 
patients after hospital discharge.  
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The following conclusions could be drawn: 
 Several research gaps exist throughout the literature about dose-dispensing aids (e.g. economic 
and humanistic outcomes), which in combination with poor methodological and reporting quality 
precluded a firm conclusion about the evidence of dose-dispensing aids in improving adherence 
and economic, clinical, and humanistic outcomes. For reviews aiming at giving recommendations 
for clinical practice, the assessment of completeness of information seems inevitable. The 
identification of evidence gaps provided a rationale for future research. 
 Provision of adherence counseling in contemporary practice in Swiss community pharmacies is 
poor and delivered more frequently by pharmacists than by other staff members. Structural and 
procedural barriers hinder pharmacists to adequately deliver explicit adherence counseling (e.g. 
lack of public acknowledgement of the pharmacists’ competences, time mismanagement). 
 Multidrug punch card service by community pharmacies is limited in Switzerland, but well 
integrated in daily practice. Few primary care patients are provided with the service. Pharmacies 
estimate them to be satisfied and to benefit from improved adherence with multidrug punch card 
use. We suggest that many more primary care patients could be approached for multidrug punch 
card use. 
 A specific group of primary care patients reports to benefit from multidrug punch card use, i.e., 
patients of the age of over 70 years, low education grade, living alone, appreciation for tidiness 
and daily routines, trust in health-care professionals, fidelity to pharmacy, and motivation for a 
healthy lifestyle and medication adherence. Multidrug punch cards constitute a simplification for 
the patients’ lives, make them feel safe and promote their adherent behavior. Emerging key 
variables for accepting multidrug punch card use and for perfect medication adherence were trust 
in health-care professionals and the patient’s experiences.  
 A pilot study investigating the effect of electronic multidrug punch cards in primary care patients 
failed in recruitment of an adequate number of patients because of poor efficiency and quality of 
the study structures and procedures. A parallel evaluation enabled the detection of the key points 
for study improvement. Further changes are necessary to yield an adequate recruitment rate and 
study quality. 
 Six patients discharged from the internal medicines’ ward without any further intervention than a 
discharge counseling maintained perfect adherence, stability of clinical condition and quality of 
life over one year.  
 One patient receiving the intervention of the electronic multidrug punch card combined with 
recurrent feedback on his adherence behavior showed maintenance of perfect adherence, stability 
of clinical condition and quality of life, gain in confidence of medication self-management, and 
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satisfaction with the device. No harms could be associated with the use of electronic multidrug 
punch cards. 
 Prototypes of the POlypharmacy Electronic Monitoring System were easy to apply and well 
accepted by the intervention patient. However, drawbacks in the technology’s functionality and 
specificity weakened the quality of our results and have to be addressed in the future development 
of the device. 
Outlook 
According to the conclusions and experiences of this thesis, the recommendations for practice are: 
 In order to empower pharmacists to assume their responsibility in patient-centered counseling, 
structural and procedural barriers have to be overcome by e.g.:  
o Promotion of the pharmacist’s role by public information and advertisement 
o Consideration of new remuneration models for cognitive services for pharmacists 
o Intensification of clinical pharmacy education and training in adherence counseling 
o Reorganization of pharmacy accommodations and staffing. 
 Medication self-management and non-adherence should be addressed actively at patient 
contacts. The patient’s experiences and believes have to be included into counseling, as they can 
have a strong impact on adherence. The embedment of medication taking into daily routine should 
be attempted. Adherence counseling should respect the patient’s preferences and life-style. 
 It must be considered that adherence interventions have the goal of nothing less than a behavior 
change, which is a difficult and private matter. Accordingly, prior to recommending an adherence-
enhancing intervention, trust has to be established between the patient and the provider and the 
patient’s active involvement in decision making seems inevitable for an accepted and successful 
intervention. Fidelity to one community pharmacy should be supported, because this may lead to 
trust towards health-care professionals, which in turn leads to acceptance of interventions and 
improved adherence and medication safety. 
 Multidrug punch cards should be recommended actively to primary care patients with 
polypharmacy with regard to their capabilities, needs, and necessities. While recommending them, 
pharmacists should emphasize the advantages of facilitation of medication self-management and 
increased medication safety reached through multidrug punch card use.  
 In order to ensure continuous care, dose-dispensing service should be embedded in a 
pharmaceutical care framework, involving, e.g.: 
o Giving instruction on multidrug punch cards if necessary (anticipation of handling difficulties, 
integration into life-style, reminder strategies) 
o Detailed instruction of separate medication 
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o Inclusion of short term medication into the packaging 
o Regular medication review of the packaged medication by a pharmacist  
o Regular contact between pharmacy and patient. 
 Tailored interventions for non-adherent patients should be attempted. Steps of tailoring might 
include a. screening to assess the patient’s individual pattern of adherence; b. selection of an 
appropriate intervention out of prepared toolbox of evidence based adherence-enhancing 
interventions in consideration of the patient’s preferences and capacities; and c. monitoring of 
satisfaction, adherence and clinical outcomes.  
 We suggest that POEMS might constitute an instrument for applications in clinical practice, e.g., 
to diagnose therapy resistance, to ‘diagnose’ and characterize non-adherence, and to address 
pharmaco-vigilance questions (by allowing the timely association of drug-drug interactions and 
adverse effects). 
Our recommendations for future research encompass: 
 To identify further patient groups who accept multidrug punch cards and benefit from their use, 
e.g. younger multimorbid patients with busy life-styles. 
 To develop guidelines for the delivery of tailored adherence support, including an assessment tool, 
which enables the detection of adherence patterns. A classification system for adherence-
enhancing interventions analogue to the classification of factors for non-adherence could support 
this approach. 
 Under the assumptions that adherence is an individual behavior influenced by 771 variable, 
interrelating factors 13, it seems inappropriate to investigate mono-interventions without 
stratifying the patients’ individual factors of non-adherence. At the development of clinical trials 
investigating the effectiveness of an adherence-enhancing intervention, the exclusion of adherent 
patients should be reconsidered to enable the estimation of the real, undiluted effect of an 
intervention. 
 A subsequent randomized controlled study on the effectiveness of multidrug punch cards could be 
optimized by  
o A well-instructed, adequately sized study team 
o Sufficient communication between all collaborators 
o Integration into clinical practice (e.g. physicians assisting recruitment at the ward and 
community pharmacies assisting in delivering the intervention) 
o Availability of sufficient, functioning electronic measurement material 
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o Locations enabling the recruitment of an adequate number of the target population (e.g., a 
rehabilitation center, community pharmacies). 
 To develop studies focusing on adherence-enhancing strategies with larger, multimorbid 
populations, measuring patient-relevant outcomes, and use of standardized adherence measures 
to enable comparison and generalization. 
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Figure A1: Answers of the control group to BMQ questions over the study period. T0, at discharge; T3,T6,T12, 
at follow-up at 3,6, and 12 months. 
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Figure A2: Trend of answers to the BMQ questions during the study by the intervention patient. T0, at 
discharge; T3,T6,T12, at follow-up at 3,6, and 12 months. 
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